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Abstract
Human decellularized adipose tissue (DAT) represents a promising extracellular matrix (ECM)
source for the development of biomaterials, with its properties conductive of angiogenesis,
adipogenesis, and scaffold remodelling. This thesis sought to provide new fundamental insight
into the design of ECM-derived bioscaffolds by developing novel modular biomaterials for
soft connective tissue regeneration and by studying the effects of ECM composition on cell
function and fate.
Initial studies explored the effects of ECM composition of pre-assembled bead foams derived
from DAT or commercially-sourced bovine collagen (COL) on human wound edge dermal
fibroblasts (weDFs) sourced from chronic wounds. In vitro testing under conditions simulating
chronic wound stresses and in vivo investigation in a murine subcutaneous implantation model
indicated that weDF survival and angiogenic marker expression were significantly enhanced
in the DAT bead foams as compared to the COL bead foams. These results confirmed DAT as
an ECM source with pro-regenerative properties.
Building from this work, a novel scaffold format comprised of fused networks of ECM-derived
beads was generated through a “cell-assembly” approach using human adipose-derived stromal
cells (ASCs) seeded on DAT beads. The cell-assembled bead foams, stabilized by the synthesis
of new ECM, were structurally robust, easily handled, and contained a high density of viable
ASCs distributed throughout the scaffold. Within a murine subcutaneous implantation model,
the cell-assembled DAT bead foams showed enhanced early cell retention using a non-invasive
in vivo cell tracking approach, along with increased detection of CD31+ endothelial cells within
the implant at day 28, relative to ASC-seeded pre-assembled DAT bead foams. Overall, it was
found that the novel cell-assembled DAT bead foams represented a promising pro-regenerative
cell-delivery system.
The novel cell-assembly methods were extended to produce tissue-specific cell-assembled
bead foams derived from decellularized trabecular bone (DTB) and COL. Preliminary findings
indicated that the DAT and COL scaffold groups provided a highly supportive
microenvironment for adipogenic differentiation in culture. Results also suggested that the
DTB group may have inhibitory effects on ASC adipogenesis. Overall, this work established
ii

that the cell-assembly approach can be used to generate platforms for exploring the effects of
ECM composition on stem cell differentiation.

Keywords
Extracellular matrix; decellularized adipose tissue; collagen; microenvironment; tissue
engineering; adipose-derived stromal cells; fibroblasts; cell delivery; wound healing.
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Summary for Lay Audience
Soft connective tissues have a limited healing capacity following traumatic injuries or when
subjected to chronic disease conditions, such as peripheral vascular disease and chronic
wounds. To drive the repair and regeneration of these tissues, cellular therapies and
biomaterials have both been independently investigated. However, a growing body of evidence
is now showing that approaches combining the use of biomaterials and pro-regenerative cell
populations may augment the efficacy of these new strategies.
Recognizing the need for new regenerative therapies, human decellularized adipose tissue
(DAT) represents a promising source for the development of new biomaterials that can
facilitate the localized delivery of therapeutic cells, such as adipose-derived stromal cells
(ASCs). From this perspective, this thesis aimed to develop novel modular biomaterials for
soft connective tissue regeneration using DAT and ASCs, and to study the effects of ECM
composition within DAT-based biomaterials.
Initial studies explored the effects of ECM composition of “pre-assembled” bead foams on
human wound edge dermal fibroblasts (weDFs) sourced from chronic wounds. Using preassembled bead foams derived from DAT and commercially-sourced bovine collagen (COL),
it was found that the survival and capacity of the weDFs to stimulate blood vessel formation
were significantly enhanced on the DAT bead foams. Building from these findings, a nextgeneration scaffold format was developed through a new cell-assembly approach using DAT
beads seeded with ASCs. The novel “cell-assembled” DAT bead foams were structurally
robust, easily handled, and contained a high density of viable ASCs homogeneously distributed
throughout the biomaterial. Results from animal experiments showed that the new cellassembled bead foams had a greater pro-angiogenic capacity than the previously-established
pre-assembled bead foams, confirming their pro-regenerative potential. Lastly, the effects of
ECM composition in this new biomaterial format were investigated by comparing cellassembled bead foams produced from distinct ECM sources, including DAT, COL, and
decellularized trabecular bone (DTB). Preliminary data suggested the DAT and COL bead
foams promoted ASC differentiation into fat cells, while the DTB bead foams inhibited
differentiation. Overall, the work completed in this thesis supports the rationale that DATiv

derived bioscaffolds are promising pro-regenerative biomaterials and cell delivery platforms
for applications in soft tissue regeneration.
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Chapter 1

1

Literature review

1.1 Roles of cell-instructive bioscaffolds in regenerative
medicine
Regenerative medicine, the branch of biomedical engineering and medicine that aims to
regenerate and restore normal tissue function, holds tremendous therapeutic potential to
treat a wide variety of both acute and chronic diseases [1, 2]. Research in this field aims to
develop therapeutic approaches for the treatment of traumatic injuries and the healing of
chronic conditions, such as peripheral vascular disease, critical limb ischemia and chronic
wounds. Previously, both cellular therapies and biomaterial scaffolds have been
investigated in isolation for these conditions [1, 3]; however, a growing body of evidence
suggests that the combination of these two approaches may augment host tissue
regeneration, compared to either approach alone [2, 4, 5].
For this purpose, a wide range of synthetic, naturally-derived, and composite biomaterials
have been developed as instructive cell-delivery vehicles designed to increase cell survival
and to stimulate pro-regenerative functions, both in vitro and in vivo [5-8]. While the
biochemical and mechanical properties of synthetic polymers can be more easily tuned, it
remains challenging to fully replicate the intricate native tissue microenvironment using
these materials [5-8]. With growing evidence of the critical importance of the extracellular
matrix (ECM) of tissues in directing major cellular processes [9-15], bioscaffolds derived
from the ECM of tissues have emerged as promising cell-instructive culture and delivery
platforms [5, 16]. Consequently, particular attention will be given to the ECM and to ECMderived biomaterials in the current chapter.

1.2 The extracellular matrix
Mammalian cells are subjected to intricate biochemical and biophysical signals through
interactions with the ECM, a complex extracellular network of proteins and
polysaccharides with tissue-specific composition and structure [16]. This complex milieu
plays a pivotal role in mediating cellular phenotypes and functions [16]. Broadly, the ECM
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can be classified into two categories: interstitial matrix and basement membrane [16]. The
interstitial matrix is more abundant and surrounds the cells of all connective tissues, with
the exception of blood [16]. The basement membrane, also known as the basal lamina, is
comprised of flexible 40- to 120-nm thick specialized ECM sheets that separate specialized
compartments within tissues [17]. In connective tissues, basement membranes can be found
surrounding endothelial cells, Schwann cells, and adipocytes [17, 18]. Basement
membranes can also be found separating epithelial tissues from connective tissues, as in
the case of the epidermis and dermis in the skin [17].
Figure 1.1 provides a simplified visual representation of the soft connective tissue
microenvironment, including both the cells and ECM components. These elements will be
further discussed in subsequent sections.

Figure 1.1 The soft-connective tissue microenvironment. Figure built from free of rights
images from the cell biology collection of Servicer medical art (September 2019).
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1.2.1
1.2.1.1

ECM Composition
Collagens

Collagen is the main component of the extracellular matrix and the most abundant protein
present in the body [19]. Collagens play an important structural role within tissues,
contributing to the integrity and tensile strength of the ECM. To date, more than 26
different types of collagen have been identified and can be classified into two main groups:
fibrillar and non-fibrillar collagens. Fibrillar collagens (including type I, II, III, V, and XI
collagens among others) are found within all connective tissues and are generally present
in larger quantities [19, 20]. These collagens are mainly present in the interstitial matrix
and type I collagen is its most ubiquitous member [16]. Type V collagen, another fibrillar
collagen, interacts with other collagens of the interstitial matrix conferring structural
integrity to soft connective tissues, such as the skin and subcutaneous adipose tissue [21].
In contrast, non-fibrillar collagens (type IV, VI, VIII, IX, X, and XII among others) are
present in smaller quantities and play important roles in bridging and connecting elements
of the fibrillar collagen network, in addition to being major components of basement
membranes [19, 20]. More specifically, the network-forming collagen type IV assembles
into a mesh-like structure that forms the main template for the basement membrane. The
microfibrils of type VI collagen, another collagen found in the basement membrane of
several tissues including skeletal muscle and adipose tissue, localize close to cells and helps
stabilizing their membranes [22].
In addition to their structural roles, collagens are bioactive molecules that are able to
interact with cell surfaces directly through integrin-binding interactions [19, 20]. For
example, type I collagen was shown to modulate the response of dermal fibroblasts to
mitogenic factors, as shown through increased human dermal fibroblast proliferation and
migration when the cells were cultured on type I collagen coatings as compared to tissue
culture polystyrene (TCPS) controls [23]. Increasing gradients of collagen type I alone
were also shown to promote human dermal fibroblast migration in vitro [23]. Genetic
diseases and murine knockout models resulting in collagen deficiencies have shown severe
phenotypes, demonstrating the importance of collagens at the cellular, tissue, and organ
levels. Examples include defects in collagen type III leading to cardiac deformities [24],
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defects in collagen type V leading to impaired wound healing and joint pain [21], and
defects in collagen type VII leading to severe skin blistering [25].

1.2.1.2

Elastic fibers

In addition to the collagen network, which gives connective tissues their tensile strength,
soft connective tissues contain a network of fibrous elastic proteins comprised of elastin
[26]. The role of elastin is to allow tissues to deform following mechanical stimulation and
then return to their original shape. Elastin forms elastic fibers through interaction with
fibrillin-1 [26]. The elastic fiber network is mainly synthesized early in life and tends to
degrade slowly over time. This degradation, paired with the limited capacity for elastic
fiber repair within adult tissues, explains the loss of elasticity often observed with aging,
such as in skin [27].

1.2.1.3

Glycoproteins

Glycoproteins are proteins that contain saccharide chains following post-translational
modifications. They are abundantly found in the ECM, where they play important roles in
cell adhesion and ECM assembly. Well-characterized glycoproteins present in the ECM
include fibronectin and laminins.
Fibronectin is a non-collagenous fibrous glycoprotein abundantly found in the ECM of
most tissues [28]. Comprised of two monomers bound at their end through disulfide bonds,
fibronectin contains several adhesion subunits that allow it to bind to various other proteins
including collagens, fibrin, proteoglycans, and integrins [28]. Interactions between
integrins and fibronectin can modulate multiple cell functions, including adhesion,
migration, proliferation, and in some cases, differentiation [28-30]. Two main forms of
fibronectin exist within the body: plasma and cellular fibronectin [31]. Plasma fibronectin
is produced by hepatocytes in the liver and is soluble in the blood. Upon tissue injury,
plasma fibronectin is incorporated into fibrin clots, where it helps to regulate platelet
activity and mediates hemostasis within the repairing tissue [31]. Cellular fibronectin is
non-soluble and produced in all connective tissues by several cell types, including
fibroblasts, endothelial cells, adipocytes, osteoblasts, and mesenchymal stromal cells
(MSCs) [29, 31]. Cellular fibronectin assembles into a fibril network that is tightly
connected to collagen fibers and tissue resident cells [31, 32].
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Laminins are a family of heteromeric glycoproteins that are major constituents of basement
membranes. Laminin molecules are comprised of three interwoven chains and each
member of the family contains a single α-chain, β-chain, and γ-chain [33]. Laminins
provide cell-anchoring signals, along with strong survival and differentiation cues that are
mediated through integrin binding interactions [33]. As major players of the basement
membrane, laminins can greatly impact cell polarity, proliferation and migration; for
example, laminins were shown to promote endothelial cell migration and proliferation,
even in the presence of pharmacological inhibitors [34]. In addition to laminins, other
important components of basement membranes include collagen type IV, nidogens
(formerly known as entactins), and proteoglycans [18, 33].

1.2.1.4

Proteoglycans and glycosaminoglycans

Proteoglycans

are

a

type

of

specialized

glycoprotein

with

large

sulphated

glycosaminoglycan (GAG) chains [17]. Theses GAGs are linear and unbranched
polysaccharides, typically ~ 80 sugars long and made from disaccharide building blocks
[17]. The most common GAGs are chondroitin sulphate, heparin and heparan sulphate, and
dermatan sulphate [35]. By definition, proteoglycans can have one or more polysaccharide
chain, but at least one of their sugar side chains must be a GAG [17]. The main
proteoglycans expressed in connective tissues are biglycan, decorin, and versican [35, 36].
The unique structure of the GAG bound to the peptide core gives proteoglycans strong
water-binding and gel-like properties [35]. More specifically, the negative charges of the
GAGs attract and trap water molecules within the interstitial space of the tissue [35]. The
highly hydrated nature of the ECM is important for metabolite diffusion and tissue
compression [35]. GAGs can interact directly with growth factors and cytokines through
charge interactions between the negatively-charged GAGs and positively-charged soluble
factors [17, 35]. By binding, stabilizing, and sequestering growth factors and cytokines,
GAGs can act as a reservoir that can become available following tissue injury [35, 36].
Examples of pro-angiogenic molecules that can be sequestered within GAGs include
vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), hepatocyte
growth factor, (HGF), and platelet-derived growth factor (PDGF) [35, 36].
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1.2.1.5

ECM-bound soluble proteins

In addition to the soluble factor-GAG interaction previously described, growth factors,
cytokines, matricellular proteins, enzymes, and other soluble molecules have the ability to
bind to other ECM proteins [35, 36]. Their presence in the matrix is important for tissue
homeostasis and function. For example, VEGF [37], HGF [38], and PDGF [39] were
shown to have specific binding affinity for fibronectin. Follistatin domains found in many
ECM glycoproteins and proteoglycans were also shown to be binding sites for bone
morphogenic proteins (BMPs) and transforming growth factor-β (TGF-β) [36, 40]. TGF-β
itself can be found in latent forms bound to several ECM proteins, with a particular affinity
for latent transforming growth factor-β binding proteins (LTBPs), which in turn bind to
fibrillin and fibronectin [36, 41]. These TGF-β/LTBP complexes act as a readily available
TGF-β reservoir and can release active TGF-β following tissue injury [41].
The matricellular protein family is another class of important ECM-bound soluble proteins.
Matricellular proteins are small, soluble, non-structural proteins that can modulate resident
cell behaviours including ECM secretion and deposition, along with cell proliferation,
migration, and recruitment [42, 43]. Unlike growth factors, which function through
enzyme-linked or G protein-coupled cell surface receptors, matricellular proteins
predominantly interact with cells through integrins [43, 44]. While most matricellular
proteins contain at least one ECM-binding domain (e.g. fibronectin-binding, heparinbinding, etc.), all matricellular proteins have integrin-binding domains [42]. Examples of
matricellular proteins include thrombospondins, tenascins, osteonectin, connective tissue
growth factor (CCN2), galectins, and periostin [43]. Matricellular proteins have been
shown to participate in a number of processes related to tissue repair, which have been
demonstrated through the use of knockout mouse models [43, 44].
Other proteins found in the extracellular space include the matrix metalloproteinase (MMP)
family of enzymes and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs). As
endopeptidases, MMPs have the ability to cleave multiple substrates and are involved in
ECM degradation and remodelling [45]. Most MMP members are secreted in a latent form,
called pro-enzymes or pro-MMPs, which can be activated by cleavage of pro-peptides
blocking the catalytic site of the peptidase domains [45]. MMPs are part of the metzincinsuperfamily of zinc-peptidases, with distinct members associated to either the ECM or
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cytoplasmic membranes. The ECM-associated members include MMP-1, MMP-2, MMP3, and MMP-9, which can all be found in latent forms within the ECM of connective tissues
[46]. The cytoplasmic membrane-associated members are not classically considered as part
of the ECM, and include three main subfamilies: the a disintegrin and metalloproteinases
(ADAMs), the ADAM with thrombospondin motifs (ADAMTSs), and the membrane-type
MMPs (MT-MMPs) subfamilies [45, 47]. The enzymatic activity of these zinc-peptidases
can be inhibited by TIMPs, which are a family of four protease inhibitors (TIMP-1 to
TIMP-4). Due to their ECM remodeling abilities, MMPs and TIMPs play central roles in
tissue development and morphogenesis, along with tissue repair and wound healing [45].

1.2.2
1.2.2.1

ECM signal transduction
Integrin-mediated responses

Cells adhere to the ECM through small transmembrane proteins called integrins. Integrins
are heterodimers made up of one α and one β subunit. The 18 known α and 8 known β
subunits are known to assemble into a total of 24 different integrin heterodimers [48].
Classically seen as adhesion molecules, integrins can bind to ligands including structural
proteins, glycoproteins, proteoglycans, matricellular proteins, and MMPs. The 24 integrin
heterodimers have affinities to a variety of ECM components, and the nature of the
heterodimers dictate the nature of the ligands to which they can bind [48].
It is now acknowledged that integrins function as more than adhesion proteins, and through
their interaction with their surrounding ECM ligands, integrins allow cells to sense their
microenvironment [48]. Depending on the nature of the integrins that are activated,
intricate integrin-mediated signals can be transduced to the interior of cells. Transduction
through these pathways is initiated by integrins at cell adhesion complexes, or focal
adhesion complexes, which are integrin-containing protein complexes localized at the
cytoplasmic membrane [41, 49]. These transmembrane focal adhesion complexes bridge
the ECM to the intracellular space and actin cytoskeleton [41, 49]. Cross-talk between
intracellular domains of integrins and intracellular kinases mediate several intracellular
signalling pathways [41, 49]. For example, integrins regulate the formation of adhesion
complexes through focal adhesion kinase (FAK) and Src-family protein tyrosine kinase
(SFK), as well as cell growth through the mitogen-activated protein kinase (MAPK)
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pathway, cell migration through the PI 3-kinase pathway, and actin cytoskeleton changes
through pathways involving the Ras superfamily of GTPases [49, 50].

1.2.2.2

Transmembrane receptor-mediated responses

Cells can also interact with the extracellular space through a variety of specialized
transmembrane receptors. Usually specific to a family of ligands, some transmembrane
receptors are specialized in binding small soluble molecules, such as cytokines, growth
factors, and hormones, while other transmembrane proteins specialise in direct cell-cell
interactions [51].
Transmembrane receptors that bind to small molecules are classified based on their tertiary
folding structures and are separated into three broad groups: G-protein coupled receptors,
enzyme-linked receptors, and ionotropic receptors [51-53]. The G-protein receptor group
encompasses several receptor superfamilies, including but not limited to: C-X-C motif
chemokine (CXC) receptors; olfactory, taste, and photo sensory receptors; and several
neurotransmitter receptors [51]. The enzyme-linked receptor group also includes two
superfamilies: (i) the receptor tyrosine kinase family, with more than 20 different classes
of receptors that can bind to FGFs, HGF, PDGFs, VEGFs, and angiopoietins, and (ii) the
receptor serine/threonine-specific protein kinase family that interacts with TGFs and BMPs
[52]. Lastly, the ionotropic receptors are a group of ion-channel-associated receptors that
plays important roles in neuron polarization following neurotransmitter binding [53].
Cells also have the ability to interact directly with one another using transmembrane
proteins. Direct cell-cell contacts are very common in tissues with a high cell density, such
as epithelial tissues [54]. In connective tissues however, cells tend to be more sparse and
spread-out than cells within epithelial tissues, reducing direct cell-cell contacts and
increasing paracrine and endocrine signaling [55, 56]. Paracrine and endocrine signaling
rely on small secreted factors to transduce signals between cells, either locally using growth
factors and cytokines (paracrine signaling) or through the vasculature over greater
distances using hormones (endocrine signaling) [55, 56].
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1.2.3
1.2.3.1

Tissue-specific ECM
Adipose ECM

Adipose tissue ECM shares a lot of similarities with that of other soft connective tissues in
the body, such as dermis, tendons and ligaments, fibrous connective tissues and fascias.
Adipose ECM is comprised of a dense network of collagen, enriched with components
associated with peripheral nerves and the vasculature [55, 57]. A unique feature of the
adipose ECM is that the mature cell population, termed adipocytes, are individually
surrounded by basement membranes and further assembled into groups called lobules [58,
59].
It was shown through immunohistochemistry that adipose tissue is an abundant source of
collagen types I through VI (with the exception of type II), with collagens types I and IV
being the most prevalent [60, 61]. In addition to collagens, the ECM of adipose tissue is
rich in fibronectin, laminin, GAGs and proteoglycans such as biglycan and decorin [58,
62]. The presence of basement membrane around the individual adipocytes, comprised of
laminins, collagen type IV, V and VI, is key to maintaining the structure, integrity, and
shape of the tissue [58].
Other proteomic techniques have successfully identified numerous growth factors,
matricellular proteins and other soluble factors sequestered within the complex ECM [55,
62]. These proteins include angiopoietin-like proteins, FGFs, galectins, HGF, and VEGF
[62]. In addition to the soluble factors actively secreted by the resident cells, these
sequestered factors are thought to play roles in mediating adipocyte differentiation,
angiogenesis, and overall adipose tissue homeostasis [55, 63].

1.2.3.2

Bone ECM

Bones are comprised of mineralized tissues, also called osseous tissues, and semi-solid
gelatinous tissues referred to as bone marrow [64]. Osseous tissues are comprised of two
main subtypes of mineralized tissues: (i) cortical bone, which is the compact and dense
exterior of the bone, and (ii) the more porous trabecular bone that is mainly found inside
of long bones and vertebrae. Trabecular bone is comprised of a sponge-like network
interspersed with the soft bone marrow [64, 65].
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The ECM of osseous tissues is made up of approximately 70% inorganic compounds [66,
67]. These inorganic compounds are comprised of a calcium- and phosphate-containing
mineral called hydroxyapatite, which provides the bone with its characteristic hardness that
allows it to resist mechanical loading forces [66, 67]. The other part of the ECM is
comprised of organic material, primarily collagen types I, III, IV, V, and XII, as well as
fibronectin, proteoglycans, and matricellular proteins including osteocalcin (also known as
bone gamma-carboxyglutamic acid-containing protein; BGLAP), osteonectin (also known
as secreted protein acidic and rich in cysteine; SPARC), osteopontin (also known as
secreted phosphoprotein 1; SSP1), and bone sialoproteins [65, 68, 69]. The roles of these
matricellular proteins are to facilitate adhesion between the cells and the inorganic
compounds, and to stabilise the interactions between the organic and inorganic components
of the ECM [70]. Proteomic analyses have also shown the presence of sequestered soluble
factors within the ECM, such as BMPs, insulin-like growth factors (IGFs), LTBP, stromal
cell-derived factor-1 (SDF-1/CXCL12), and TGF-β [62].

1.3 ECM-derived scaffolds
1.3.1

Biomaterials and general considerations

Aiming to promote constructive tissue regeneration, naturally-derived biomaterials are
designed to provide structural and biological cues that can positively regulate proregenerative cellular responses [71].
Two main strategies exist to produce ECM-derived biomaterials: bottom-up or top-down
approaches. Bottom-up approaches start with a basic template of purified ECM
components to produce a homogeneous bioscaffold, to which other components can be
subsequently added to tune the composition and potentially modulate other scaffold
properties [72, 73]. In contrast, top-down approaches apply decellularized tissues as
complex ECM sources to produce bioscaffolds [73-76]. Further described in Section 1.3.3,
decellularization is the process of removing immunogenic components from native tissues
(e.g. cells, intracellular organelles, and DNA), while preserving the structure and
composition of the native ECM as much as possible. Although they represent powerful
tools to systematically probe the effects of various ECM-derived factors on cellular
responses, materials fabricated using bottom-up approaches often fail to recapitulate the
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complexity of the native ECM [73, 77, 78]. Advantages of using decellularized tissues over
purified ECM sources, such as gelatin or purified collagen type I, include enhanced
retention of physical and biochemical properties that are specific to the complex
extracellular microenvironment of the native tissue source [74, 79]. Given that different
tissues have varying functions, physical properties, and biochemical composition, there is
a clear rationale for using a tissue-specific approach when designing biomaterials tailored
for specific applications [71, 74, 79]. For these reasons, decellularized tissues have
emerged as a promising ECM source for the production of ECM-derived bioscaffolds [73,
75, 76].
There are several important design considerations when developing bioscaffolds from
decellularized tissues [80, 81]. First, the final scaffolds must be capable of supporting
relevant cell populations for the target application with high cell viability. For example,
utilization of cytotoxic reagents such as cross-linkers (formaldehyde, paraformaldehyde,
and glutaraldehyde) should be avoided whenever possible, as traces of these reagents in
the scaffolds have been associated with decreased cell growth and viability in vitro and
undesired calcification in vivo [82, 83]. In addition, the biomaterial should allow the
delivery of predictable doses of cells, while ideally promoting long-term retention and
viability, as well as directing the function of the delivered cells in animal models [84].
Second, the ECM architecture and composition should be preserved as much as possible
during the decellularization and fabrication processes [85]. Third, the development of
reproducible and successful therapies is dependent on the ability of the ECM-derived
biomaterials to promote a favourable host response, integrate into the surrounding tissues,
and help to coordinate constructive tissue remodelling and repair following implantation
in vivo [71, 84]. Lastly, the resulting formats of the ECM-derived biomaterials should be
stable and have appropriate mechanical properties for handling and for the targeted
applications [74].

1.3.2

Properties of the ECM that can modulate cell behaviour

The biochemical, structural, and biomechanical properties of the ECM can have a profound
impact on seeded and/or infiltrating cells and can modulate their behavior [71]. In vitro
studies investigating the response of cells seeded on ECM-based coatings have shown the
importance of biochemical composition on cell monolayers. In particular, a study focusing
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on tissue-specific ECM composition from decellularized cardiac tissues demonstrated that
tissue-specific myocardial matrix supported murine cardiac progenitor cell (CPC) survival
under stress in response to H2O2 treatment, when compared to purified type I collagen
coating controls [86]. Another study using high throughput screening approaches
investigated the impact of combined ECM components on the phenotype of induced human
pluripotent stem cells (iPSC)-derived endothelial cells [87]. More specifically, the findings
indicated that two specific ECM combinations: (i) collagen, gelatin, heparan sulfate, and
laminin, and (ii) collagen, fibronectin, gelatin, heparan sulfate, and laminin, significantly
increased the survival of the iPSC-derived endothelial cells under hypoxia (1% O2) and a
reduced serum condition (1% fetal bovine serum; FBS) [87]. Similar high throughput
screening approaches have also demonstrated that ECM composition could improve
hepatocyte function of murine hepatocytes and increase the hepatogenic differentiation of
murine embryonic stem cells [88].
In addition to biochemical composition, physical properties of cell substrates are also
important mediators of cell function. For example, substrate stiffness was shown to mediate
cell fate and differentiation in vitro, using bone marrow-derived MSCs [89, 90]. In this
context, a stiffer matrix was shown to stimulate differentiation towards the chondrogenic
and osteogenic lineages, while softer substrates promoted differentiation towards the
adipogenic lineage [89, 90]. Similar effects of matrix stiffness were noted in dermal
fibroblasts [89, 90]. The intracellular pathways involved in this adipogenic-proliferativeosteogenic balance within MSCs and fibroblasts is briefly detailed in Figure 1.2. Further
studies comparing the role of matrix stiffness also demonstrated that fibroblast
proliferation, stress fiber formation, and fibrotic marker expression is enhanced on stiffer
substrates [89, 90]. In contrast, softer substrates and increased matrix compliance were
associated with increased angiogenic potential [91, 92]. Thus, these observations suggest
the important role of matrix stiffness in governing cell survival, cell function, and cell fate,
illustrating the importance of designing biomaterials with appropriate mechanical
properties for targeted applications.

13

Figure 1.2 Correlation between mechano-transduction, growth, and differentiation in
mesenchymal stromal cells (MSCs) and fibroblasts. The lack of strong focal adhesion
complexes on low-adhesion and tension substrates tends to reduce the activation of focal
adhesion kinase (FAK) within MSCs and fibroblasts, which in turn inhibits mitogenactivated protein kinase (MAPK) and extracellular signal-related kinase (ERK) mediated
cell growth. This cell growth inhibition is associated with limited phosphorylation of the
master adipogenic and osteogenic transcription factors, which keeps them in their active
and inactive states respectively (master adipogenic factor = peroxisome proliferatoractivated receptor-γ (PPARγ); master osteogenic transcription factor = Runt-related
transcription factor 2 (RUNX2)), thereby promoting adipogenesis. At the other end of the
spectrum, high ECM tension and stiffness promotes adhesion, stimulating the formation of
high levels of focal adhesion complexes resulting in strong FAK signaling. Strong FAK
signaling strongly activates the MAPK/ERK pathway, which causes the phosphorylation
of both PPARγ and RUNX2, inactivating the former and activating the latter, to promote
osteogenesis. The presence of a negative feedback loop of ERK, following the strong FAK
activation, allows for limited cell growth. On substrates with intermediate stiffness, FAK
signaling induces the MAPK/ERK pathway, but below the threshold of the negative
feedback loop, which allows for cell growth. Adapted with permission from [89].

1.3.3

Decellularization

As previously mentioned, decellularization is the process of removing cells and their
components from tissues, while minimizing ECM alterations as much as possible [93].
Extraction of cells and other potentially antigenic components is dependent on the intrinsic
nature of the tissue, including its specific physical and biochemical characteristics, and
results in the reduction in immunogenic properties of the decellularized tissue [93]. To
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maximize cell removal, most decellularization protocols utilize a combination of physical,
chemical, and enzymatic treatments, either concomitantly or in succession [93-95]. Each
of these treatments can affect the ultrastructure and biochemical composition of the
resulting decellularized ECM, which in turn has the potential to impact the host response
to the material and the overall ability of decellularized-based biomaterial to mediate desired
cell functions for targeted applications [94].

1.3.3.1

Physical methods for tissue decellularization

Physical processing of the tissue, such as freeze-thaw cycles, pressure, sonication, and
agitation, can be employed to mechanically remove cellular components from native
tissues [93, 95]. Considered one of the most gentle physical methods for tissue
decellularization, freeze-thawing of tissues can help disrupt cell membranes through ice
crystal formation [96]. Mechanical agitation and application of pressure on the tissue are
also widely used methods to facilitate the extraction of cellular components from the ECM,
functioning in part by increasing the exposure of the tissues to the reagents [93, 97].
Excessive physical manipulation can disrupt the ECM structure; however, these methods
can be easily controlled and are often used conjointly with other methods described in the
next sections [93, 98].

1.3.3.2

Chemical methods for tissue decellularization

Chemical methods for decellularizing tissue include the use of hypertonic or hypotonic
solutions, alkaline or acid treatment, polar solvents, and detergents. The use of hypertonic
and hypotonic solutions prepared with chelating agents, such as ethylenediaminetetraacetic
acid (EDTA), is a very common cell-lysing and integrin cofactor sequestering method [93,
99, 100]. Alkaline and acid treatments can facilitate the solubilization of cellular
components by altering the pH of the tissue [101]. Acid treatments are also used to
demineralize hard connective tissues such as bones [102, 103]. Alcohols and other polar
solvents are effective for dissolving and extracting lipids from tissues [104-108]. With their
ability to solubilize cell debris and aid in dissociating DNA from the ECM, detergents are
also widely employed in decellularization protocols [109-111].
The limitations of osmotic cell lysis buffers and divalent ion chelating solutions in
decellularization protocols are attributed to their gentle nature. In particular, these
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treatments must typically be performed in conjunction with other methods as they are not
effective at fully extracting cellular components from the tissues [93]. Adverse effects of
using alkaline and acid treatments for decellularization include the hydrolytic degradation
of biomolecules, such as collagens and GAGs, and the extraction of soluble factors found
within the ECM [112]. Polar solvent extraction can lead to protein dehydration [112] and
matrix stiffening [105], although matrix stiffness was reported to be unchanged in the case
of some tissues, such as adipose tissue [113]. Finally, the use of detergents has been
associated with several adverse effects, including the reported loss of non-structural
proteins including growth factors and GAGs in treatments with non-ionic detergents, as
well as the disruption of structural proteins with the use of ionic detergents [110, 114].
There is also concern about residual detergent remaining within the decellularized tissues,
as this has been associated with cytotoxic effects and impaired cell growth in vitro [85,
115].

1.3.3.3

Enzymatic methods for tissue decellularization

The catalytic activity of certain enzymes can be harnessed in the decellularization of tissues
and organs. Proteases (e.g. trypsin and collagenases), nucleases (e.g. deoxyribonucleases
and ribonucleases; respectively DNases and RNases), and lipases have all been explored
in various decellularization protocols [93]. Proteolytic enzymes such as trypsin can disrupt
integrins, releasing the cells from the ECM, while partially digesting dense ECM to allow
for better penetration and exposure to other reagents [94]. DNase and RNase can
successfully digest residual nucleic acids within the ECM, which helps to prevent adverse
host immunogenic responses following implantation of decellularized tissues [94, 116].
Adverse effects of proteolytic enzymes include over-digesting the ECM leading to the loss
of ECM components and architecture [117]. Enzymes, including proteases and nucleases,
have also been reported to have immunogenic properties themselves, emphasizing the need
for extensive wash procedures following treatments [94, 116].

1.3.4

Decellularized adipose tissue

Human adipose tissue is routinely discarded as surgical waste from cosmetic surgeries,
either as lipoaspirates or resected fat from cosmetic surgeries. Advantages of surgicallydiscarded adipose tissue over other ECM sources include the abundance of adipose tissue
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compared to other soft connective tissues (e.g. dermis) and its human origin. Both resected
adipose tissue and lipoaspirates can be processed into decellularized adipose tissue (DAT)
following published protocols [104, 118-125]. The resulting DAT is comprised of collagen
types I, III, and IV, laminin, fibronectin, vitronectin, elastin, and GAGs, and also contains
other soluble growth factors and matricellular proteins, such as FGF-2, VEGF, and
galectins [62, 104, 118, 119, 124].
The Flynn laboratory has pioneered adipose tissue decellularization, being the first research
group to develop a detergent-free method to produce DAT in 2010 [104]. The 5-day
decellularization protocol uses a combination of physical, chemical, and enzymatic
decellularization methods. Briefly, the approach involves freeze-thaw cell-lysis cycles
combined with washes in a hypotonic solution containing EDTA to enhance cell extraction,
digestion with trypsin-EDTA to disrupt cell-cell interactions, isopropanol extraction of
lipids, and combined DNase-RNase-lipase digestion. Interestingly, the resulting DAT has
biomechanical properties similar to native adipose tissue [113]. The DAT was also shown
to have in vitro cell-instructive (i) “adipo-inductive” and (ii)“adipo-conductive” properties
on tissue-specific human adipose-derived stromal cells (ASCs), which can be respectively
described as (i) promoting adipogenesis in a microenvironment not typically supportive of
adipocyte differentiation and (ii) enhancing adipogenesis under adipogenic differentiation
conditions [14]. In addition, the resulting DAT displayed pro-regenerative properties in
vivo, as demonstrated through its remodelling into healthy host-derived fat following
subcutaneous implantation [14]. This remodelling demonstrated the pro-angiogenic and
pro-adipogenic capacities of the DAT, with the scaffolds promoting the recruitment of host
endothelial cells, macrophages, and adipogenic progenitors [126].
A proteomic study performed by Thomas-Porch et al. in 2018 compared the biochemical
composition of the DAT produced from the Flynn laboratory protocol, along with two other
methods [124], respectively based on the use of detergents [123] or the use of urea and
chloroform treatments [127]. The study findings demonstrated that the Flynn laboratory
approach was the only method amongst the three that could achieve proper delipidation
and nucleic content removal, while maintaining structural integrity of the tissue [124]. The
trypsinization-based mass spectrometry analyses revealed a significant decrease in the
detection of proteins from intracellular, membrane, and blood origins in the Flynn
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laboratory protocol, demonstrating that the two other approaches led to incomplete removal
of cell debris from the tissues [124]. Of note, a multi-enzyme-based digestion approach
using collagenase to deplete collagen in samples prior to mass spectrometry analysis was
developed by Kuljanin et al. (2017) using DAT produced using the Flynn laboratory
protocol [62]. This study directly compared traditional sample preparation methods using
trypsin digestion to a new approach using collagenase digestion to selectively deplete
collagens found in high abundance in the samples. Collagenase digestion increased the
number of proteins identified in the DAT by ~2.2 fold, to a total of 804 identified
proteins[62]. When compared to bovine collagen and human decellularized bone tissue,
this study revealed that DAT was enriched in factors associated with adipogenesis,
including FGFs, CXCL14, and protein Wnt-11; along with factors associated with
angiogenesis, including angiopoietin-like proteins, FGFs, HGF, and VEGF [62].

1.3.5

Processing of decellularized tissues for the fabrication of
bioscaffolds

In addition to being applied in their intact form as three-dimensional (3-D) scaffolds,
decellularized tissues can be further processed into other formats [74]. This strategy allows
for the fabrication of new biomaterials that incorporate the complex ECM composition
within platforms that offer greater flexibility in terms of other scaffold properties, including
enhanced porosity or more tuneable mechanical properties. This processing often starts
with the fragmentation of the intact ECM, which can include methods such as mincing
and/or cryo-milling, followed by homogenization of the ECM into a suspension or a
solution, with or without the use of enzymatic digestion [128-130]. Once an ECM
suspension or solution is obtained, it can either be used directly or mixed with other
compounds to produce naturally-derived or composite bioscaffolds, respectively. Table 1.1
list naturally-derived biomaterials that have been explored using DAT as an ECM source.
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Table 1.1 List of naturally-derived biomaterials fabricated using DAT
Scaffold
format
Hydrogel
Mesh
Crosslinked
DAT
microcarriers
Foams
Bead
foams
Microparticles
Enzymatic
crosslinked
hydrogel
Extrusion
based bioprinted
lattices
Porous
microcarriers
Coatings

DAT processing method
Thermo-sensitive gelation of pepsin digested-DAT
solution following neutralization
Electrospinning of homogenized DAT suspension in
organic solvent
Pepsin-digested DAT was solubilized in a sodium
alginate solution, sprayed into a CaCl2 solution using
an air-jet droplet system, cross-linked using rose
Bengal, glutaraldehyde, or riboflavin, followed by
an alginate extraction step using a sodium citrate
buffer
Lyophilization of α-amylase digested DAT
homogenized into a suspension
Lyophilization of electrosprayed beads inside of a
mould, made from α-amylase digested DAT
homogenized into a suspension
DAT particles were directly resuspended in neutral
buffer following cryo-milling
Thermo-sensitive gelation of pepsin digested-DAT
solution following neutralization, supplemented with
transgluminase for in situ enzymatic cross-linking
Bio-printed lattice of a single-phase hydrogel,
produced by thermo-sensitive gelation of pepsindigested DAT solution following neutralization

Lyophilization of electrosprayed microcarriers,
made from α-amylase digested DAT homogenized
into a suspension
Homogenized α-amylase-DAT and neutralized
pepsin digested-DAT suspensions were coated in
cell culture dish and air-dry.
Note: references labelled with (*) are from the Flynn research group

Solvent for DAT
suspension

Year and
reference

0.1 M hydrochloric
acid (neutralized)
hexaflouro-2propanol or
triflouroacetic acid
0.5 M acetic acid
with sodium alginate

2011
[119]
2012
[131]
2012*
[132]

0.2 M acetic acid
(lyophilized)
0.2 M acetic acid
(lyophilized)

2013*
[14]
2013*
[14]

Saline
0.1 M hydro-chloric
acid (neutralized)

2013
[125]
2014
[133]

0.1 M hydro-chloric
acid (neutralized)

2014
[134]

0.2 M acetic acid
(lyophilized)

2017*
[135]

0.2 M acetic acid
(lyophilized)

2019*
[136]

As seen in Table 1.1, several porous and non-cross-linked DAT bioscaffold formats were
pioneered by the Flynn lab. These formats include the intact DAT itself [104], as well as
an array of other scaffold formats derived from processed DAT, including DAT-derived
microcarriers, foams, and bead foams [14, 132, 135, 136]. The key steps to achieving the
production of these bioscaffolds formats, from the adipose tissue itself to the resulting
materials, are illustrated in Figure 1.3.
Notably, in vivo studies directly comparing the regenerative potential of intact DAT
scaffolds and DAT bead foams after subcutaneous implantation in a Wistar rat model
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showed differences in the host response [14]. While both formats integrated into the host
tissues and remodelled over time, the DAT bead foams induced greater cell infiltration,
noted by the increased presence of blood vessels and inflammatory cell migration at earlier
time points relative to the intact DAT [14]. Adipogenic differentiation was observed in
both groups, with an increased presence in the intact DAT group as compared to the DAT
bead foam group [14]. This study also displayed full integration of the DAT bead foams
within the host tissues after 12 weeks, whereas the intact DAT implants macroscopically
maintained their volume over this time course [14]. These results revealed the intrinsic
potential of the DAT bead foams for therapeutic angiogenesis and the inherent potential of
intact DAT for adipose tissue engineering. It was postulated that the different outcomes
may have been linked to the matrix processing, resulting in more homogeneous and porous
DAT bead foams as compared to more heterogeneous and denser intact DAT scaffolds.
In addition to their pro-angiogenic capacity and potential for host integration, the DAT
bead foams have other advantages over other bioscaffold formats. Based on their modular
nature, the bead foam technology is highly adaptable and allows for the fabrication of
scaffolds with well-defined geometries. The resulting scaffolds have both a microporous
architecture within individual spheres, along with a macroporous architecture of channels
between the spheres [14]. In contrast with some other approaches described in Table 1.1,
the production of the DAT bead foams was designed to exclude the use of any detergents,
cross-linking agents, and synthetic materials, in an attempt to preserve the complex
composition of the adipose ECM and to circumvent cytotoxicity concerns associated with
residual chemicals.
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Figure 1.3 Overview of adipose decellularization and further processing steps for
DAT-derived bioscaffold production. (A) Flow chart highlighting the key stages for the
production of the various DAT scaffold formats. (B) Macroscopic appearance during the
main decellularization and processing steps. (a) Excised adipose, (b) Fresh DAT, (c)
Lyophilized DAT, (d) Lyophilized minced DAT, (e) Homogenized DAT suspension in
acetic acid. (f) Diagram of the electrospraying apparatus used for the production of DAT
microcarriers/beads used to make bead foams. A syringe pump is used to control the flow
rate of the DAT suspension into liquid nitrogen. Scale bars = 1 cm. (C) Representative
macroscopic images of (a) DAT foams, (b) DAT microcarriers, and (c) DAT bead foams.
Scale bars = 2 mm. Modified with permission from a book chapter published by Morissette
Martin et al. in 2018 [130].
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1.4 Angiogenesis and wound healing
All biomaterials invoke an initial inflammatory response following implantation [75]. The
description of the classic host response is generally broken into several stages, beginning
with the traumatic tissue injury during implantation surgeries and continuing throughout
the wound-healing period [75]. This body response following implantation is similar to
physiological wound healing [137]. For these reasons, the phases of normal wound healing
and the mechanisms of angiogenesis elicited following ECM-derived biomaterial
implantation will be described in Sections 1.4.1 and 1.4.2.

1.4.1

Phases of wound healing

Following tissue injury, cascades of complex cellular mechanisms are initiated at the
wound site. These mechanisms are classically grouped into four major overlapping phases:
hemostasis, inflammation, proliferation, and remodeling [138, 139]. The phases of
cutaneous wound healing are illustrated in Figure 1.4.

Figure 1.4 Schematic representation of cutaneous healing processes. (A) Wound crosssectional representation at various time points. (B) Temporal representation of the four
overlapping phases of healing. Modified with permission from a book chapter published
by Morissette Martin et al. in 2016 [140].
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1.4.1.1

Hemostasis

Hemostasis includes a set of cellular and molecular processes to stop bleeding following
wounding. This process is highly regulated by thrombocytes, also known as platelets,
which will start to agglomerate at the site of injury to limit blood loss [138]. In parallel,
enzymatic cascades are initiated by the thrombocytes, which will lead to the polymerization
of plasma soluble fibrinogen into insoluble fibrin at the wounded site. This coagulation
step completes the hemostatic plug, also known as a thrombus. These processes occur
rapidly, on the order of minutes, to limit blood loss [138, 141].

1.4.1.2

Inflammatory phase

The inflammatory phase begins following the release of pro-inflammatory molecules from
the resident cells of the wounded tissues and from the hemostatic plug. Early mediators of
inflammation include interleukins-1, -6 and -8 (IL-1, IL-6 and IL-8), and TGF-β [138, 141].
These factors will stimulate the recruitment of neutrophils, as well as leukocytes
specialized in phagocytosis of foreign particles and bacteria. During the 24-to-48-hour
period when they are present in high abundance in the wound, neutrophils have a strong
pro-inflammatory action [138, 141]. In particular, neutrophils secrete cytokines including
monocyte chemoattractant protein-1 (MCP-1), TNF-α, and IL-1β, concomitantly with
proteases and reactive oxygen species [142]. This assortment of factors initiates the
recruitment and infiltration of circulating monocytes, which then differentiate into
macrophages at the wound site [143].
Macrophages are key effectors involved in a plethora of immune processes, ranging from
phagocytosis, lymphocyte chemo-attraction, antigen presentation to lymphocytes, and
initiation of the proliferative phase [143]. Macrophages can accomplish these various
functions through a process called macrophage polarization, where macrophages specialize
their phenotypes in response to dynamic signals from the microenvironment [143]. Classic
definitions comprise two main subtypes of macrophages: M1 pro-inflammatory
macrophages, specialized in phagocytosis and sustaining a strong pro-inflammatory
response, and M2 pro-regenerative macrophages, specialized in resolving the
inflammatory response and initiating tissue repair [143]. However, it is now understood
that in vivo macrophage polarization is a dynamic continuum, with few cells at both ends
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of the M1/M2 spectrum [143]. The activity of M1-like macrophages is mediated through
the secretion of pro-inflammatory factors, such as TNF-α, IL-1β, and IL-6, while the
activity of the M2-like macrophages is mediated through the secretion of pro-regenerative
and pro-proliferative factors TGF-β, interleukin 4 (IL-4), interleukin-1 receptor antagonist
(IL-1RA), and VEGF, among others [143].

1.4.1.3

Proliferative phase

The proliferative phase is characterized by the migration and proliferation of several cell
types, ultimately resulting in the formation of scar tissue [138, 141]. Depending on the
afflicted tissue and the anatomical localization of the wound, different cell types are
involved; however, three main processes are usually defined within the proliferative phase
of skin healing: re-epithelialisation (keratinocyte migration), granulation tissue formation
(fibroblast and immune cell migration, paired with ECM secretion), and angiogenesis
(migration of endothelial cells to re-vascularize the newly formed granulation tissue,
described in section 1.4.2) [138, 141].
The formation of granulation tissue, the temporary and fast-remodelling connective tissue
secreted at the wounded site, is first initiated by neighboring fibroblasts in response to the
cytokines released by the thrombocytes and neutrophils [144]. The arrival of macrophages
sustains the fibroblast activation through the action of several cytokines, including FGF-2,
EGF, PDGF, and TGF-β, and will induce fibroblast proliferation and migration into the
fibrin-fibronectin provisional matrix formed during hemostasis [144, 145]. Cells within the
granulation tissue start remodelling this matrix through MMP-mediated degradation and
ECM deposition, including the weaker but rapidly-assembled collagen type III, fibronectin,
GAG and proteoglycans, along with small amounts of collagen type I [145].

1.4.1.4

Remodelling phase

The remodelling phase is characterized by both a degradation and deposition of ECM by
myofibroblasts [145]. Originating from different precursor cells, primarily local connective
tissue fibroblasts, along with local pericytes, local and circulating MSCs, myofibroblasts
differentiate in the wound microenvironment through the action of sustained TGF-βmediated signaling and matrix stiffening [146, 147]. Temporal secretion substrate-specific
MMPs and TIMPs by the myofibroblast populations orchestrate ECM degradation [144].
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This degradation is concomitant with ECM deposition of more mature components by the
myofibroblasts, primarily collagen type I, but also other glycoproteins including
matricellular proteins and proteoglycans [43, 144]. In normal non-pathologic wound
healing, myofibroblast numbers will then decrease through apoptosis, with few cells
present in the mature scar tissue [144].

1.4.2

Physiology and mechanisms of angiogenesis

Angiogenesis is a highly regulated physiological process associated with the extension of
the blood vessel network from previously-existing blood vessels and capillaries. Two
different types of angiogenesis can be defined: sprouting angiogenesis (Figure 1.5) and
intussusceptive angiogenesis [148]. While being an important vascular network extension
strategy in the body, intussusception is usually recognized as much less prominent than
sprouting angiogenesis in the context of tissue repair and neo-vascularization of soft
biomaterials [149]. For these reasons, particular attention will be given to sprouting
angiogenesis in this chapter.
Several steps are required to drive the maturation of the endothelial sprouts into functional
vessels and capillaries. The first stage of sprouting angiogenesis is associated with
endothelial cell activation and budding within neighbouring tissues, including wound
granulation tissues and ECM-derived implants (Figure 1.5A). Paracrine growth factor
gradients, such as VEGF, along with EGF, FGF-2, HGF, and IGF, can activate endothelial
cells [150, 151]. Strongly activated endothelial cells then inhibit lateral endothelial cells
through Notch signaling and the sprouting “tip” endothelial cells begin to degrade their
surrounding basement membrane. Neighbouring pericytes also become activated by the
mitogen gradients, which results in a reduction of their cell-cell stabilizing interaction with
the endothelial cells [148].
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Figure 1.5 Schematic representation of sprouting angiogenesis. A) Sprouting is
controlled by the balance between pro-angiogenic and pro-quiescent signals. Strongly
activated endothelial cells start sprouting (in green), whereas other endothelial cells remain
quiescent (in gray). Pericytes (in yellow) modulate their cell-cell interactions with the
endothelial cells. (B) Endothelial cell sprouts are growing and are guided by the growth
factor gradient and surrounding microenvironment. (C) Interactions between tip cells
regulate the fusion of sprouts and vessels. Lumen formation in stalk endothelial cells
involves the fusion of vacuoles and other tube-forming mechanisms. (D) Perfusion of the
vessels with blood promotes maturation processes, including the stabilization of cell
junctions, matrix deposition, and pericyte-endothelial cell interactions. Abbreviations: Cell
division control protein 42 homolog: CDC42, DLL4: delta-like-4 ligand, EC: endothelial
cells, ECM: extracellular matrix, PC: pericytes, PDGF: platelet-derived growth factor, Rasrelated C3 botulinum toxin substrate 1: Rac1, VEGF: vascular endothelial growth factor,
VEGFR: VEGF receptor. Adapted with permission from [148].

The second stage of sprouting angiogenesis, sprout outgrowth and guidance (Figure 1.5B),
is characterized by the invasive phenotype of the endothelial tip cells [148]. More
specifically, activated tip cells show highly proliferative and migratory behavior towards
the gradient of growth factors. In contrast to fibroblasts, this migration occurs sequentially,
with the endothelial cells first aligning with each other to form proto-capillaries [148].
Pericytes are then recruited at the base of the new sprouts through paracrine secretion of
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PDGF by the tip cells. This process ensures sufficient stabilization to support the growing
endothelium [148].
Sprout fusion and lumen formation, the third stage of sprouting angiogenesis, is then selfinitiated by the tip cells when they encounter other sprouts or existing vasculature (Figure
1.5C). To form new vascular connections, tip cells downregulate their invasive motile and
explorative phenotype upon interacting with target endothelial cells. These interactions
with endothelial cells from other sprouts or vessels initiate the assembly of cell-cell
junctions [152]. This step is also characterized by stalk endothelial cell proliferation and
basement membrane formation, stabilizing the base of the proto-capillary. Proto-capillaries
can be converted into tubes in various ways, including pinocytosis and vacuole formation
within the stalk endothelial cells [148]. These processes are dependent on the activity of
small GTPases (Cell division control protein 42 homolog and Ras-related C3 botulinum
toxin substrate 1; CDC42 and RAC1, respectively) and only occur in stalk cells forming
strong integrin-basement membrane adhesions [148].
The proto-capillaries may be called capillaries once they are able to transport blood
following the formation of a lumen, at the end of the fourth stage of the sprouting
angiogenesis process (Figure 1.5D). Following perfusion of the newly formed capillaries,
the presence of shear flow will inhibit endothelial cell proliferation and strengthen
endothelial cell-cell interactions [148]. Mural cells, including pericytes in the case of
capillaries and smooth muscle cells in larger diameter blood vessels, will migrate around
the endothelial cell tubes and initiate stabilizing cell contacts [148]. Secretion of angiostatic
molecules, such as angiopoietin-1, vascular endothelial statin (also known as EGF-like
domain-7; EGFL7), TGF-β, and thrombospondins, also helps to stabilize the capillaries by
inhibiting endothelial cell proliferation and stabilizing cell-cell interactions [150, 153].

1.4.3
1.4.3.1

Pathologies with insufficient angiogenesis
Cutaneous chronic wounds

Also known as skin ulcers, cutaneous chronic wounds are wounds that fail to go through
normal wound healing processes and a large proportion of these wounds never resolve and
will deteriorate over time [154]. These wounds are especially prevalent in the diabetic
population, where 15 to 25% of diabetic patients will develop at least one lower limb ulcer
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in their lifetime [155]. In the context of an aging population, with an estimated population
of 415 million diabetics worldwide in 2015, chronic wounds are expected to steadily
increase [156]. Chronic wound complications include pain, claudication, peripheral
neuropathy, tissue necrosis (gangrene), and amputations in the most severe cases [155].
Indeed, amputations are required in 15 to 27% of non-healing wound cases, when all other
conventional treatments have been unsuccessful [157]. Care associated with wounds and
their complications represents a burden for healthcare systems and is estimated to cost more
than 25 billion dollars annually in the United-States alone [158].
While a variety of effectors have been postulated as possible co-factors that modify the
wound bed to create a microenvironment that is non-permissive for healing, the causes
leading to the chronicity of impaired wound healing are diverse and are currently not well
understood [154]. Possible effectors include insufficient oxygen and nutrient delivery,
improper cellular waste removal, ischemia-reperfusion injuries, along with the
hyperglycemic microenvironment and altered immune cell functions in diabetic patients
[154, 159-162].

1.4.3.2

Peripheral artery disease

Peripheral artery disease (PAD), also known as peripheral vascular disease or lower
extremity arterial disease, is characterized by atherosclerotic lesions in arteries that supply
blood to the limbs, with the lower extremities being the most commonly affected. The
build-up of occlusive atherosclerosis plaques, comprised of fibrous tissue and lipid
deposition in the lumen of blood vessels, reduces blood flow in the extremities [163].
Between 2000 and 2010, the prevalence of PAD increased by 23.5% worldwide, impacting
approximately 202 million people in 2010 [163]. The chronicity of PAD can lead to its
more severe form, critical limb ischemia (CLI), which is associated with a chronic lack of
oxygen delivery in the limbs. CLI is considered as the end stage of PAD and can lead to
complications that are similar to the ones associated with chronic ulcers, ranging from pain
to tissue necrosis, and can often require amputations [164]. PAD is usually diagnosed in
half of all cases of chronic ulcers, and together, PAD and CLI accounts for 2-4% of the
healthcare budgets of industrialised countries [165]. Percutaneous or open surgical
revascularization is considered as the best therapy to eliminate pain and to trigger wound
healing of PAD-associated lesions [164].
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1.4.3.3

Clinical need to promote angiogenesis

Gold standard treatments in the field of chronic wounds include classical wound care
(debridement, moist wound environment, selection of proper wound dressings, etc.),
resolution of infections, offloading of wounded areas when possible, and medication to
reduce the effect of contributing factors (e.g. diabetes, atherosclerosis, or high blood
pressure) [165]. Current clinical treatments for PAD and CLI include medications targeted
to prevent atherosclerotic plaque deposition (including but not limited to anti-low-density
lipoprotein, anti-platelet, and anti-coagulant medications), compression stockings that can
help venous drainage when appropriate, and revascularization surgery to re-establish
proper blood flow when possible [165, 166].
The previously-discussed complications associated with CLI and chronic wounds remain
severe and illustrate the frequent failure of the aforementioned conventional treatment
approaches to enable adequate revascularization and healing. Both CLI and chronic
wounds are highly hypoxic environments characterized by a lack of nutrient and oxygen
diffusion to the affected areas [166, 167]. In this context, pro-angiogenic therapies hold
tremendous potential for the treatment of CLI and chronic wounds [168].

1.4.4

Bioscaffold-derived and cell-derived regeneration strategies

While biomaterials alone have shown some success in promoting wound healing and
therapeutic angiogenesis [169, 170], the clinical efficacy of these approaches is unclear.
The current commercially-available bioscaffolds approved for wound healing applications
are only accredited for limited subset of wound etiologies [170, 171]. Possible reasons for
the mixed success of biomaterials-based approaches are still ambiguous, but recent
findings suggest that poor host cell infiltration and scaffold remodelling caused by low
scaffold porosity may be factors that affect the therapeutic potential of these biomaterials
[172, 173]. Cell therapy-based approaches have also been reported to have some success
in triggering therapeutic angiogenesis, with some ongoing human clinical trials; however,
none of these therapies have been currently approved for clinical use due to the limited
functional effects observed [174]. Postulated reasons for the poor translation of cell-only
approaches from preclinical to clinical studies may include the loss of the injected cell
populations at the ischemic site after treatment, potentially due to cell death in the harsh
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low-nutrient and hypoxic environment of the wounds or to a host immune system response
following injection [174, 175]. Notably, studies investigating combined biomaterial and
cell approaches within biomaterials-based cell-delivery systems have reported increased
treatment efficiency in preclinical models, compared to biomaterials alone or cell alone
controls [126, 176-179].

1.4.5

In vivo preclinical animal models for assessing angiogenesis

Due to the limited opportunities to carry out controlled studies assessing tissue repair
processes in humans, in vivo preclinical models for assessing tissue repair in animals are
frequently performed on rodents (mice and rats), lagomorphs (rabbits), and pigs [180, 181].
Due to lower cost, ease of use, and the availability of small animal facilities, murine models
are often preferred to other animal models [180, 181]. The availability of various transgenic
mouse strains also provides powerful tools to better understand the biological mechanisms
associated with tissue repair. For example, immuno-compromised rodent models are of
great interest for preclinical testing of cell-based products or biomaterials of human origin
[182]. The preclinical animal models used for assessing tissue repair can be classified in
several categories, including cutaneous wound healing models, ischemic models, and
implantation models. Given their broad use in the biomaterials field, this section will focus
will be on the subcutaneous implantation models.
Subcutaneous implantation models in rodents are often used to evaluate host cell
infiltration, immunogenic reactivity, and neo-vascularization of new biomaterials
subjected to in vivo settings. In this model system, the implants are positioned within a
subcutaneous pocket, into which host plasma can infuse if the material is porous [180].
Cells from the host can then migrate and infiltrate the non-vascularized and hypoxic
implants, forming a granulation-like tissue. Depending on the implant material, further
tissue remodelling may occur over time [180]. Additionally, murine subcutaneous
implantation models have been extensively used in the field of adipose tissue engineering
due to the close proximity of the subcutaneous compartment with native adipose tissue.
Several implant locations have been studied, with the dorsum being the most common
implantation site due to the ability to reduce animal numbers by implanting two or four
scaffolds per animal [183]. Surgical techniques include free implantation into a
subcutaneous pocket [14], suturing of implants to secure it in place [184], implantation of
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a pre-fixed material onto a frame [185], and injection of liquid phase materials or particles
[119, 125]. Interestingly, neo-vascularization has been reported in all surgical iterations
[14, 125, 184, 185], which confirms the utilization of the dorsal subcutaneous implantation
as a valid strategy to study angiogenesis and tissue repair mechanisms.

1.5 Mesenchymal cells
1.5.1

Dermal fibroblasts

Dermal fibroblasts are the major resident cells within the dermis, which is the vascularized
skin connective tissue that supports the outermost layer of the skin, the non-vascularized
epidermis. These cells can be found interspersed in the dermal matrix, mostly isolated from
one another. Dermal fibroblasts play constitutive roles in tissue homeostasis and participate
in tissue repair following injuries as detailed in Section 1.4.1.
When subjected to chronic wound microenvironments, the phenotype of dermal fibroblasts
is altered, compared to fibroblasts from non-involved tissues [186-189]. For example,
human wound edge dermal fibroblasts (weDFs) sourced from chronic wound tissues were
shown to express significantly lower levels of pro-fibrotic markers in the presence of TNFa, compared to dermal fibroblasts from non-involved tissues (niDF) [186]. Reduction in
proliferation rates [187, 188] and impaired responses to pro-regenerative growth factors
[189] in weDF were also observed. These phenotypic differences could be partially
explained by epigenetic differences observed in the weDF and niDF populations, denoted
by different genome-wide DNA methylation patterns between the two populations [190].

1.5.2

Mesenchymal stromal cells

Adult MSCs were first identified in the bone marrow by Friedenstein and colleagues in
1976 [191]. It is now known that MSCs can be found in nearly all tissues of the body, with
the three main sources currently identified as bone marrow, adipose tissue, and peripheral
blood [192]. While their name varies from author-to-author, these cells are generally
termed bone marrow-derived mesenchymal stromal cells (BMSCs), adipose-derived
stromal cells (ASCs), and peripheral blood-derived mesenchymal stromal cells (PBMSCs),
respectively. Originating from different tissues, these MSC populations are fibroblastic in
nature and are closely related, playing similar roles in tissue homeostasis through their
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migratory and paracrine abilities during inflammation, tissue injuries and repair [192, 193].
In the context of the current thesis, MSCs from the adipose niche, or ASCs, will be
discussed in detail in the following sections.

1.5.3

Adipose-derived stromal cells

The stromal vascular fraction of adipose tissue is rich in mesenchymal cell types, including
fibroblasts, pericytes, mesenchymal progenitors, preadipocytes, and ASCs [194].
Approximately 2% of the resident stromal cells of adipose tissue are multipotent ASCs
[194]. In single cell clonal experiments, ASCs were shown to have the ability to
differentiate in vitro towards the three classic mesenchymal lineages (e.g. adipogenic,
osteogenic, and chondrogenic) [195-198]. The scientific community has given three main
guidelines to identify cell populations as ASCs. First, the cells must be isolated from
adipose tissue and must be able to adhere to TCPS. Second, their immunophenotype must
be more than 80% positive for CD105, CD90, CD73, CD29, and CD44, concomitant with
less than 2% positive for CD31 and CD45 [199]. Finally, the cells should be able to
differentiate towards the three main mesenchymal lineages (e. g. adipogenic, osteogenic,
and chondrogenic), as demonstrated with a combination of methods. These methods can
include histological staining, gene expression, or enzyme activity assays [199].
While ASCs and MSCs have the ability to differentiate in vitro, a growing body of evidence
suggests that the main mediator of their pro-regenerative effects in vivo is their secretion
of beneficial paracrine factors [191, 200, 201]. Indeed, the ASC secretome was shown to
include numerous factors involved in mediating angiogenic and inflammatory processes,
as highlighted in Table 1.2.

Table 1.2 List of paracrine factors secreted by human ASCs
Soluble factor
angiopoeitin-1
angiopoeitin-2
colony stimulating
factor 1(CSF-1)

Main function in tissue repair processes
Acts as a vascular growth factor participating in endothelial cell-cell
interactions, tube formation, and capillary stability.
Antagonist of angiopoietin-1. Plays important roles in capillary
destabilization required for earlier stages of angiogenesis.
Also known as monocyte colony-stimulating factor (M-CSF). Involved
in macrophage recruitment and polarization into an M1 phenotype.

Reference
[202]
[203]
[201]
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colony stimulating
factor 2 (CSF-2)
CXC ligand 1
(CXCL1)
C-C motif chemokine
22 (CCL22)
C-C motif chemokine
5 (CCL5)
FGF-2
HGF
IGF-1
IL6
IL8
Keratinocyte growth
factor (KGF)
MCP-1
Nerve growth factor
(NGF)
Placental growth
factor (PlGF)
PDGF
Plasminogen
activator inhibitor-1
(PAI-1)
stem cell factor
(SCF)
SDF1/CXCL12
TGF-β
VEGF

Also known as granulocyte-macrophage colony-stimulating factor
(GM-CSF). Involved in neutrophil, eosinophil, monocyte, and
macrophage recruitment.
Cytokine with mitogenic properties on multiple cell types and a potent
neutrophil and monocyte chemoattractant.
Cytokine with chemotactic activity for monocytes, dendritic cells,
natural killer cells and activated T lymphocytes.
Cytokine with chemotactic and activating activity for blood monocytes,
memory T helper cells and eosinophils.
Pleiotropic mitogenic agent involved in several biological processes,
with particularly potent paracrine effects on mesenchymal and
endothelial cells in the context of wound healing.
Pleiotropic mitogenic agent involved in several biological processes,
with particularly potent paracrine effects on epithelial, mesenchymal,
and endothelial cells in the context of wound healing.
Pleiotropic mitogenic agent secreted by the liver with important
endocrine effects. Produced by several cell types during tissue repair,
with important mitogenic activity on dividing cells.
Pro-inflammatory cytokine involved in several inflammatory
processes. Involved in regulating the balance between M1 and M2
macrophage polarization.
Cytokine with mitogenic properties on several cell types and a potent
neutrophil, monocyte, and endothelial cell chemoattractant.
Common mitogenic agent involved in several biological processes,
with particularly potent paracrine effects on epithelial cells.
Cytokine involved in monocyte, T cell, and dendritic cell recruitment.
Mitogenic agent involved in the growth and maintenance of peripheral
neurons. Chemoattractant agent for tip endothelial cells.
Member of the VEGF sub-family. Strong mitogenic and
chemoattractant effects for endothelial cells.
Pleiotropic mitogenic agent involved in several biological processes,
with particularly potent paracrine effects on mesenchymal and
endothelial cells in the context of wound healing.
Principal inhibitor of tissue plasminogen activator and urokinase, and
hence an inhibitor of fibrinolysis. Its enzymatic activity plays proangiogenic roles in the context of wound healing.
Pleiotropic agent associated with several hematopoietic processes.
Plays roles in mast cell regulation in the context of wound healing.
Potent homing factor for circulating stem cells, including endothelial
progenitor cells. Plays roles in inflammation and angiogenesis.
Pleiotropic mitogenic agent regulating cell proliferation, differentiation
and growth. Its expression is strongly associated with pro-fibrotic cell
phenotypes in the context of wound healing.
Strong mitogenic and chemoattractant agent for endothelial cells. Plays
important roles in destabilizing and increasing the permeability of
blood vessels, allowing endothelial cell activation and sprouting.

[201]
[203]
[203]
[203]
[201]
[201]
[204]
[205]
[204]
[204]
[206]
[207]
[175]
[204]
[208]
[203]
[209]
[201]
[201]
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1.5.4
1.5.4.1

ASC-based tissue-engineering strategies and considerations
Therapeutic advantages of using ASCs

The use of ASCs as a pro-regenerative cell population has several advantages as compared
to other MSC populations from other tissues. Inherent advantages of ASCs include their
availability and accessibility through minimally-invasive harvesting methods. ASCs can
be isolated from lipoaspirated adipose tissue under local anesthesia, as compared to the
invasive hipbone aspiration of bone marrow under general anaesthesia required to isolate
BMSCs. In addition, larger quantities of adipose tissue can be extracted from a single
intervention, compared to hipbones aspirates. Moreover, the harvesting yield of ASCs is
greater than for BMSCs [210, 211], with a gram of adipose tissue yielding more stem cells
than a gram of bone marrow, with approximatively 5 x 103 ASCs per gram of adipose tissue
and between 1 x 102 to 1 x 103 BMSCs per gram of bone-marrow [211].
When looking at the presence of 22 surface markers, the immunophenotype of human
ASCs is similar to that of human BMSC and human dermal fibroblasts [212]. However,
recent evidence indicates that ASCs, BMSCs, and fibroblasts show differences in their
secretory profiles. More specifically, ASCs were reported to secrete higher levels of
immunomodulatory factors compared to BMSCs, such as CXCL1, CCL22, CSF-1, and
IL-6 [209]. ASCs were also shown to secrete higher levels of pro-angiogenic factors,
including angiopoietin-1, HGF, and VEGF, and lower levels of pro-inflammatory factors
as compared to dermal fibroblasts, including MCP-1 and CCL5 [203]. These observed
differences may play important roles in mediating tissue regeneration [203, 209]. ASCconditioned media has also been shown to better stimulate endothelial cell proliferation
and tube formation, compared to BMSC- and dermal fibroblast-conditioned media [203,
209].
The delivery of high doses of ASCs was shown to be an important factor for the
development of approaches for therapeutic angiogenesis. Dose-response experiments
demonstrated that injecting higher doses of adult stem cells positively correlated with tissue
repair and reperfusion in a hindlimb ischemia model [175]. Findings of this study showed
that the lowest doses of 1 x 105 ASCs injected intramuscularly induced a modest increase
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in blood reperfusion in hindlimbs compared to saline controls, while the highest tested dose
of 1 x 106 cells stimulated robust reperfusion as compared to lower doses of cells [175].
Similar dose-response results were seen following injection of BMSCs in a hamster heart
failure model, where higher doses correlated with lower cardiac fibrosis [213].

1.5.4.2

MSC preconditioning strategies

While biomaterial-based strategies have shown promise to enhance localized cell retention
and viability, other strategies have been shown to increase MSC resilience and survival
following implantation [214]. Such strategies include in vitro preconditioning prior to
delivery, including hypoxic culture [215, 216], soluble factor treatments [217-219], and
dynamic culture [220, 221].
Hypoxic preconditioning can enhance the therapeutic potential of several MSC
populations, including ASCs [215, 216]. Previous studies have demonstrated that oxygen
tension below 5% increased the secretion of pro-angiogenic soluble factors [215, 216, 222].
Conditioned media from MSC treated in oxygen tension below 5% was also shown to
stimulate endothelial cell tube formation [215, 216, 222]. These effects were shown to be
mediated through the activation of the alpha subunit of the transcription factor hypoxiainducible factor 1 (HIF1α), the master regulator of the hypoxia signalling cascade [222,
223].
Effective preconditioning of MSCs was also demonstrated through the addition of small
soluble mitogenic agents to culture media. Soluble molecules investigated to date include
growth factors such as epithelial growth factor (EGF) [217, 224], basic fibroblast growth
factor (FGF-2) [218, 225], and insulin-like growth factor-1 (IGF-1) [219, 226]. In
particular, it was shown that EGF treatments promoted cell growth, without compromising
stem cell multipotency, and stimulated the secretion of pro-angiogenic molecules including
HGF and VEGF over untreated control groups through the activation of the ERK1/2
signalling pathway [217, 224]. Other studies focusing on FGF-2 preconditioning
demonstrated that FGF-2 could mediate the activation of protein kinase B (PKB; also
known as Akt)/ERK1/2, Smad2, and Stat3 signaling pathways, which resulted in decreased
oxidative stress, cellular senescence and apoptosis, concomitant with increased expression
of α-smooth muscle actin and enhanced secretion of TGF-β and VEGF [218, 225]. Finally,
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IGF-1 treatments were shown to enhance MMP activity, to promote PDGF and VEGF
secretion, and to stimulate cell resistance to hypoxia through apoptosis-resistant
mechanisms through activation of the phosphoinositide 3-kinase (PI3K)/Akt signalling
pathway [219, 226].
Emerging literature has also identified dynamic culture conditions as a potential
preconditioning strategy to modulate the phenotype of MSCs within biomaterial scaffolds.
Several types of 3-D systems have shown promising results, including spinner flasks and
rotating wall vessel bioreactors that increased the adipogenic and osteogenic differentiation
potential of the BMSCs compared to TCPS controls [220], and orbital-shaker culture that
enhanced ECM synthesis and adipogenic differentiation by ASCs [221].

1.6 Objectives and specific aims
The overarching hypothesis for this project is that 3-D DAT-derived bead foams will
promote the retention and paracrine function of seeded cell populations both in vitro and
in vivo, and will enhance the adipogenic differentiation of seeded human ASCs relative to
bead foams fabricated from other ECM sources.
To test this hypothesis, the three specific aims of this thesis are:
1. To investigate the effects of ECM composition within the bead foams on the
survival, pro-fibrotic, and pro-angiogenic function of human weDFs.
2. To establish a new fabrication approach for generating “cell-assembled bead
foams” incorporating a high density of human ASCs and investigate their potential
to support localized cell retention and function for applications in therapeutic
angiogenesis.
3. To explore the role of ECM composition on the lineage-specific differentiation of
human ASCs towards the adipogenic lineage within cell-assembled bead foams
made from DAT, decellularized trabecular bone (DTB), or purified type I collagen.

1.7 Project overview
Recognizing the need for a better understanding of the mechanisms of regeneration
associated with DAT-based biomaterial strategies for tissue repair, the first aim of the
current project (Chapter 2) focused on studying the effects of the biochemical composition
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of modular biomaterials termed bead foams, comprised of porous beads synthesized
exclusively of ECM and assembled into cohesive 3-D networks, on the phenotype of
human weDFs sourced from chronic wound tissues. To compare the effects of ECM
composition, the bead foams were fabricated from human DAT or commercially-sourced
bovine tendon collagen (COL) as a control. Compared to COL bead foams, the structurally
similar but compositionally distinct DAT bead foams were shown to enhance weDF
survival and angiogenic marker expression in vitro, when tested under conditions
simulating stresses within the chronic wound microenvironment, and in vivo within a
subcutaneous athymic mouse model. Taken together, the results demonstrated the
enhanced potential of DAT as a pro-regenerative cell-instructive ECM source on weDF as
compared to COL.
Aiming to overcome limitations associated with the relatively low cell infiltration observed
in the bead foams applied in the first aim, the second aim of the current project (Chapter
3) established new methods to generate novel modular bioscaffolds through a “cellassembly” approach using human ASCs. In vitro, these cell-assembled bead foams
supported human ASC survival and growth. Histological and biochemical characterization
confirmed that there was a high density of ASCs that were well distributed throughout the
scaffolds and showed that the assembly process was mediated by matrix remodeling and
the synthesis of new ECM. Subcutaneous implantation of the cell-assembled scaffolds in
an immune-compromised mouse model showed enhanced ASC retention and neovascularization as compared to the previous bead foam technology, supporting the potential
of this new format for soft tissue regeneration and therapeutic angiogenesis.
The third aim of the current project (Chapter 4) expanded on the new cell-assembly
methods towards establishing a platform technology for exploring the effects of tissuespecific ECM on ASC differentiation. More specifically, the effects of ECM composition
on the adipogenic differentiation of human ASCs were explored using cell-assembled bead
foams fabricated with DAT, COL, and decellularized trabecular bone (DTB). Initial studies
focused on modifying the methods to generate structurally comparable and stable scaffolds
using the 3 distinct ECM sources. Next, pilot studies were performed to compare the
adipogenic response of human ASCs within the various cell-assembled bead foams. The
preliminary data suggested that adipogenic differentiation was enhanced in the cell-
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assembled bead foams fabricated from DAT and COL as compared to DTB, supporting
that the ECM composition within the platforms can modulate ASC differentiation.
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Chapter 2

2

Matrix composition in 3-D collagenous bioscaffolds
modulates the survival and angiogenic phenotype of
human chronic wound dermal fibroblasts

2.1 Co-authorship statement
A version of this chapter was published in Acta Biomaterialia in 2019: “Morissette Martin
P, Grant A, Hamilton DW, Flynn LE (2019). Matrix composition in 3-D collagenous
bioscaffolds modulates the survival and angiogenic phenotype of human chronic wound
dermal fibroblasts. Acta Biomaterialia, 83(2019): 199-210”.
I conceptualized this study in collaboration with Dr. Douglas Hamilton and Dr. Lauren
Flynn. I personally designed and performed all of the experimental studies described in the
Chapter, with support from the remaining authors. More specifically:
•

Dr. Hamilton and his team isolated and banked the human wound edge dermal
fibroblasts used for the study.

•

Dr. Grant is the clinical collaborator that provided the human adipose tissue
samples.

I analyzed all the data in collaboration with Dr. Flynn. I made all the figures and
supplementary content (table and figures). The manuscript was written in collaboration
with Dr. Lauren Flynn.
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2.2

Abstract

There is a substantial need for new strategies to stimulate cutaneous tissue repair in the
treatment of chronic wounds. To address this challenge, our team is developing modular
biomaterials termed “bead foams”, comprised of porous beads synthesized exclusively of
extracellular matrix (ECM) and assembled into a cohesive three-dimensional (3-D)
network. In the current study, bead foams were fabricated from human decellularized
adipose tissue (DAT) or commercially-sourced bovine tendon collagen (COL) to explore
the effects of ECM composition on human wound edge dermal fibroblasts (weDFs)
sourced from chronic wound tissues. The DAT and COL bead foams were shown to be
structurally similar, but compositionally distinct, containing different levels of
glycosaminoglycan content and collagen types IV, V, and VI. In vitro testing under
conditions simulating stresses within the chronic wound microenvironment indicated that
weDF survival and angiogenic marker expression were significantly enhanced in the DAT
bead foams as compared to the COL bead foams. These findings were corroborated through
in vivo assessment in a subcutaneous athymic mouse model. Taken together, the results
demonstrate that weDF survival and paracrine function can be modulated by the matrix
source applied in the design of ECM-derived scaffolds and that the DAT bead foams hold
promise as cell-instructive biological wound dressings.

2.3

INTRODUCTION

The treatment of chronic or non-healing skin wounds, including diabetic, pressure, and
venous ulcers, places a substantial burden on healthcare systems around the globe [154].
Moreover, it is expected that the prevalence of these conditions will continue to rise, given
the increasing frequency of risk factors including diabetes, peripheral vascular disease,
obesity, and the aging of the population [227, 228]. Treating these patients is resource
intensive, with annual costs approaching $25B USD in North America [158, 229].
Responses to current therapies are highly variable and chronic wounds remain a leading
cause of lower limb amputation, which is associated with high rates of mortality [230].
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Although the pathophysiology of chronic skin wounds is not well understood [154],
deleterious effects on healing have been attributed to an imbalance in extracellular matrix
(ECM) turnover [231, 232] and the aberrant expression of bioactive factors including
matricellular proteins, cytokines, and growth factors [43, 233]. Resident and infiltrating
cells are subjected to a complex dysfunctional milieu within the chronic wound, which can
alter their phenotypes and contribute to a pro-inflammatory state that is non-permissive for
healing [43, 234, 235]. From this perspective, complex bioscaffolds incorporating proregenerative ECM components have the potential to disrupt this cycle and shift the balance
in the wound microenvironment to stimulate healthy tissue regeneration [236-238].
Our laboratory has pioneered the development of pro-regenerative bioscaffolds derived
from human fat for applications in soft tissue regeneration and cell delivery [14, 104, 126].
Abundantly discarded as surgical waste, human adipose tissue is an accessible matrix
source that can be extracted through detergent-free decellularization to obtain scaffolds
incorporating a diverse range of structural collagens, matricellular proteins, proteoglycans,
adhesion glycoproteins, growth factors, and cytokines [62]. In addition to using
decellularized adipose tissue (DAT) in its intact form, the ECM can be further processed
to generate alternative scaffold formats with properties tuned to specific applications. In
previous work, methods were established to fabricate novel porous scaffolds termed “DAT
bead foams”, comprised of fused networks of ECM-derived beads that were stable without
the need for chemical crosslinking [14].
While tissue-specific ECM has been postulated to be a mediator of cell function, relatively
few studies to date have focused on systematically comparing the effects of different matrix
sources

on

cellular

function

within

three-dimensional

(3-D)

engineered

microenvironments. The bead foam technology provides a versatile platform for exploring
the influence of ECM composition on the cellular response for applications in wound
healing. Expanding on our previous work, the novel processing methods were adapted to
fabricate bead foams from human DAT and commercially-sourced bovine tendon collagen
(COL). Based on our recent proteomics characterization of these matrix sources [62], it
was postulated that DAT and COL bead foams could be generated that were structurally
similar, but biochemically distinct. The initial studies focused on characterizing the
physical properties and composition of the resultant scaffolds to validate this hypothesis.
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Subsequent analyses probed the response of primary human dermal fibroblasts isolated
from chronic wound tissues on the DAT and COL bead foams both in vitro and in vivo. As
key players involved in multiple processes in wound repair, dermal fibroblasts have the
potential to influence the behaviour of resident and transient wound cells through the
secretion of soluble factors including growth factors, cytokines, and matricellular proteins
[203, 239, 240]. Relative to fibroblasts sourced from healthy tissues, dermal fibroblasts
from chronic wounds have been reported to have altered functionality, including an
impaired response to TNF-α [239], a decreased ability to withstand oxidative stress [241]
and reduced pro-angiogenic functions [242], which may impact their capacity to stimulate
healing [241, 242]. Based on this, our studies focused on exploring whether the ECM
composition in the bead foams could modulate the response of human wound edge dermal
fibroblasts (weDFs) under stresses simulating features of the chronic wound
microenvironment. In vitro testing was performed under serum-free conditions to create a
non-permissive environment for proliferation, as would be expected when healing does not
progress from the inflammatory phase [188]. Further, the media was supplemented with
pathophysiological levels of tumor necrosis factor-α (TNF-α) (1 ng/mL) [243, 244], and
all testing was performed under 2% oxygen tension [166, 167], to simulate the harsh
conditions within human chronic wounds. In vivo testing was conducted using a
subcutaneous implant model in athymic mice to provide a complementary analysis of the
effects of the human cells delivered in the engineered scaffolds within a complex living
system. Using both models, weDF survival and angiogenic function were explored on the
DAT and COL bead foams to assess whether the matrix source could impact the
regenerative potential of the cells.

2.4
2.4.1

Materials and methods
Materials

Unless otherwise stated, all chemicals used were purchased from Sigma Aldrich Canada
Ltd. (Oakville, ON, Canada).

2.4.2

Adipose tissue collection and decellularization

Subcutaneous adipose tissue samples were collected with informed consent from female
patients undergoing elective lipo-reduction surgeries at the London Health Sciences

42

Centre (London, ON, Canada) with human research ethics board approval (REB#
105426). The samples were transported to the lab on ice in sterile phosphate buffered
saline (PBS) with 2% bovine serum albumin (BSA), transferred into a hypotonic cell
lysis buffer (Solution A:10 mM Tris base and 5 mM ethylenediaminetetraacetic acid
(EDTA), pH 8.0), and frozen at -80°C.
After thawing, the adipose tissue was processed with a 3-day detergent-free
decellularization protocol. All decellularization solutions were supplemented with 1%
antibiotic-antimycotic

solution

(Gibco,

Burlington,

ON,

Canada)

and

1%

phenylmethylsulphonyl fluoride (PMSF), with the exception of the enzymatic treatment
steps where the PMSF was excluded. All incubation steps were performed with 3-4 adipose
tissue segments (starting volume ~3 cm x 3 cm x 3 cm) in 100 mL of solution under
agitation at 150 rpm and 37°C. In brief, the freshly-thawed adipose tissue was rinsed in
Solution A and then incubated in fresh Solution A for 2 h. Each tissue segment was then
centrifuged in 30 mL of fresh Solution A at 1500 xg for 30 min, transferred into fresh
Solution A, and incubated for an additional 2 h. After rinsing in fresh Solution A, the
samples were incubated overnight in 0.25% trypsin-0.1% EDTA (Gibco). On the second
day, the samples were incubated twice in fresh absolute isopropanol for 3 h, with gentle
mechanical pressing and centrifugation at 1500 xg for 30 min in 30 mL of fresh isopropanol
between solution changes to promote lipid extraction. The samples were then incubated
overnight in fresh absolute isopropanol. On the third day, the samples were mechanically
compressed and transferred into fresh isopropanol for a final 4 h extraction prior to
rehydration by three 30 min incubations in a rinsing buffer comprised of 8 g/L NaCl, 200
mg/L KCl, 1 g/L Na2HPO4, and 200 mg/L KH2PO4, at pH 8.0 (BioShop Canada Inc,
Burlington, ON, Canada). Finally, the individual DAT segments were mechanically
compressed, rinsed in deionized water, and transferred into 50 mL conical tubes, prior to
freezing at -80°C and lyophilization.

2.4.3

DAT and COL bead fabrication

Lyophilized DAT samples (pooled from 5 donors) or commercially-sourced collagen from
bovine Achilles tendon (Cat# C9879, Sigma) were finely minced and digested with αamylase from Aspergillus oryzae to prepare ECM suspensions (25 mg/mL) following
published methods [14]. To synthesize the individual spherical subunits for the bead foams,
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the DAT and COL suspensions were electrosprayed into liquid nitrogen as previously
described [14], using plastic syringes fitted with 25G butterfly needles (BD Medical,
Mississauga, ON, Canada) positioned 3 cm from the surface of the liquid nitrogen with an
applied voltage of 16-17 kV and infusion at 35 mL/h. Following synthesis, the DAT and
COL beads were collected and transferred into absolute ethanol prior to gradual
rehydration in an ethanol series (100%, 98%, 95%, 90%, 75%, 50%, 25%, and 12.5% (v/v)
diluted with sterile PBS), followed by three washes in sterile PBS.

2.4.4

Characterization of DAT and COL beads

Feret’s diameters of hydrated DAT and COL beads were measured (n = 25-35 beads/trial,
N = 3 trials with different ECM suspensions) under brightfield microscopy using ImageJ.
The mechanical properties of the hydrated DAT and COL beads were assessed using a
CellScale MicroSquisher system (Waterloo, ON, Canada) and the Young's moduli were
calculated using nonlinear least squares curve fitting with a published extended mechanics
model for large elastic deformations of spherical microparticles [245]. In brief, the microscale parallel-plate compression system was equipped with a 203 µm diameter cantilever
attached to a square platen (2 mm x 2 mm), and testing of individual beads was performed
in a PBS bath at 37°C. The beads were compressed to 50% deformation for 3
preconditioning cycles at a strain rate of 0.01 s-1, and then data was collected from 3
consecutive cycles and analyzed (n=6 beads/trial, N=3 trials with different ECM
suspensions).

2.4.5

DAT and COL bead foam fabrication

To fabricate the bead foams, the DAT and COL beads were collected immediately
following electrospraying, allowed to thaw, and gently transferred without excess fluid into
cylindrical moulds (diameter = 8 mm, height = 5 mm), which were frozen at -80°C
overnight and lyophilized. The resultant bead foams were decontaminated and gradually
rehydrated through an ethanol series (100%, 90%, 75%, 50%, 25%, and 12.5% (v/v) diluted
with sterile PBS), followed by three washes in sterile PBS. The rehydrated scaffolds were
stored at 4°C for up to 1 week.
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2.4.6
2.4.6.1

Characterization of the DAT and COL bead foams
Scanning electron microscopy

The ultrastructure of the DAT and COL bead foams was visualized by scanning electron
microscopy (SEM) using published protocols [135]. Briefly, the scaffolds were
lyophilized, coated with osmium, and imaged with a LEO 1530 scanning electron
microscope at an accelerating voltage of 1 kV and working distance of 4 to 5 mm.

2.4.6.2

Porosity measurement

A modified Archimedes’ method [246] was used to estimate the porosity of the bead foams
(n=3 scaffolds/trial, N=5 trials with different ECM suspensions) using isopropanol as the
solvent and assuming the scaffolds were comprised primarily of collagen with a density of
1.343 g/mL [247].

2.4.6.3

Hydroxyproline and dimethylmethylene blue assays

The scaffolds were digested with 60 mU/mL of proteinase K (Promega, Madison, WI,
USA) in Tris-EDTA buffer (200 nM Tris-HCl, 200 nM EDTA, pH 7.5) under agitation at
300 rpm and 65°C for 1 h, followed by a 10 min incubation at 95°C to inactivate the enzyme
(n=3 scaffolds/trial, N=3 trials with different ECM suspensions).
For the hydroxyproline assay, digested samples were hydrolyzed in 12 N hydrochloric acid
at 110°C for 24 h, neutralized with 6 N sodium hydroxide, and filtered using activated
charcoal. Equal volumes of 0.05 N chloramine-T/20% 2-methoxyethanol (20 min
incubation), 3.15 N perchloric acid (5 min incubation) and Ehrlich’s reagent (20 min
incubation at 60°C) were sequentially added to the digested scaffolds (1:80 in deionized
water) inside a 96-well plate. After a 5 min incubation at 4°C and a 20 min incubation at
room temperature, the absorbance was measured at 560 nm using a CLARIOstar®
spectrophotometer (BMG LABTECH Inc., Cary, NC, USA), including a hydroxyproline
standard curve.
For the DMMB assay, 10 µL aliquots of the digested scaffolds were transferred in technical
triplicate into a 96-well plate and 200 µL of a 1.6% solution of DMMB in deionized water
supplemented with 1% ethanol and 0.2% formic acid was added. The absorbance at 525
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nm was recorded using a CLARIOstar® spectrophotometer (BMG LABTECH Inc.),
including a chondroitin sulphate standard curve.

2.4.6.4

Immunohistochemical analysis of ECM constituents in the
DAT and COL bead foams

DAT and COL bead foams (n=2 – 6 scaffolds/trial, N=3 trials with different ECM
suspensions) were fixed for 24 h in 10% formalin, embedded in Tissue-Tek OCT
compound (Sakura Finetek, Torrance, CA, USA), and snap frozen in liquid nitrogen prior
to cryosectioning (7-µm transverse sections). Following fixation in acetone and blocking
(in 10% goat serum in Tris buffered saline; TBS) sections were stained overnight at 4°C
with primary antibodies against collagen type I (dilution 1:100 in TBS with 1% BSA,
ab90395, Abcam, Toronto, ON, Canada), collagen type IV (dilution 1:100, ab6586,
Abcam), collagen type V (dilution 1:300, ab7046, Abcam), collagen type VI (dilution
1:300, ab6588, Abcam), fibronectin (dilution 1:150, ab23750, Abcam), or laminin (dilution
1:200, ab11575, Abcam). Detection was carried out using an anti-rabbit secondary
conjugated to Alexa Fluor 594 (dilution 1:200, ab150080, Abcam) or an anti-mouse
secondary conjugated to Dylight 650 (dilution 1:200, ab96882, Abcam). No primary and
tissue positive controls (Supplementary Fig. 1) were included in all trials. Images were
acquired with a Zeiss Imager M2 microscope (Zeiss Canada, Toronto, ON, Canada). Semiquantitative analysis of the relative expression levels was performed using ImageJ. Results
were reported as a percentage of the positive signal area normalized to the total scaffold
area.

2.4.7

Chronic wound fibroblast isolation, culture and
characterization

Chronic wound tissues were harvested from the amputated lower limbs of patients with
non-healing skin wounds at the London Health Sciences Centre, with human research
ethics board approval (REB# 16245E). Human fibroblasts were isolated from the tissues
following published explant isolation methods [147] and stored in liquid nitrogen at
passage 1 (P1). Primary cell populations from three donors (Supplementary Table 2.1)
were included in the studies.
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All subsequent cell culture was performed in a hypoxic chamber (Whitley H35
Hypoxystation, Don Whitley Scientific Limited, West Yorkshire, UK) with 2% O2 and 5%
CO2 at 37°C. Prior to scaffold seeding, the cells were thawed and expanded to passage 4
(P4) in complete medium comprised of Dulbecco's Modified Eagle's medium (DMEM;
Gibco) supplemented with 10% fetal bovine serum (FBS; cat# 12483020; Gibco), 100
U/mL penicillin and 0.1 mg/mL streptomycin (1% pen-strep; Gibco). Media was changed
every 2-3 days and the cells were passaged at 90% confluence.
Immunophenotyping was performed on P4 fibroblasts using a Guava easyCyte 8HT flow
cytometer (Millipore, Billerica, MA, USA) as described previously [248]. Single marker
staining was performed with monoclonal, fluorochrome-conjugated antibodies from
eBioscience (San Diego, CA, USA), as follows: CD90-FITC, CD-105-PE, CD73-FITC,
CD44-PE-Cy7, CD29-PE, CD34-APC, CD31-PE, CD146-FITC (Supplementary Table
2.2). All samples were stained for 30 min at 4°C and then fixed in 0.5% paraformaldehyde
for 10 min at 4°C. Unstained controls were included in every trial.

2.4.8

DAT and COL bead foam seeding

Prior to seeding, the rehydrated bead foams were incubated overnight in complete medium.
Each DAT or COL bead foam was seeded with 2x105 P4 chronic wound fibroblasts in 20
µL of complete medium. Following 2 h incubation, the complete medium was topped up
to 1.5 mL and the scaffolds were incubated for an additional 24 h (2% O2 and 5% CO2,
37°C).

2.4.8.1

Comparison of seeded DAT and COL bead foams in vitro

For the in vitro assessments, the scaffolds were transferred into serum-free DMEM
supplemented with 1% pen-strep for 24 h (2% O2 and 5% CO2, 37°C), and then cultured
in serum-free DMEM supplemented with 1 ng/mL TNF-α (R&D System Inc.,
Minneapolis, MT, USA) and 1% pen-strep for an additional 1 or 7 days (2% O2 and
5% CO2, 37°C). The media was changed daily, with fresh TNF-α added.
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2.4.9

Analysis of cell distribution

Immunostaining for vimentin (dilution 1:200, ab92547, Abcam) was performed to assess
cell distribution within scaffold cryo-sections at 3 days post-seeding, following similar
methods to Section 2.5.4.

2.4.9.1

Cell abundance and cytotoxicity assays

weDF abundance was measured at 1, 3 and 9 days post-seeding using the Quant-iTTM
PicoGreen® dsDNA kit (Molecular Probes, Burlington, ON, Canada) (n=3 scaffolds/trial,
N=3 trials with different cell donors). The scaffolds were rinsed in PBS, snap frozen, and
stored at -80°. After thawing, the scaffolds were digested using proteinase K as described
in Section 2.6.3, and total double-stranded DNA (dsDNA) was quantified according to the
manufacturer’s instructions. Cell lysates prepared from 2x105 P4 dissociated weDFs were
included in the assay and used to normalize the data to the initial seeding levels. The
conditioned media from the 3 and 9 day samples was also collected and stored at -80°C,
and analyzed using the ToxilightTM non-destructive cytotoxicity assay (Lonza,
Walkersville, MD, USA) according to the manufacturer’s instructions. A standard curve
was prepared using serial dilutions of lysed weDFs, and the results were normalized to the
total dsDNA content in the corresponding sample.

2.4.9.2

Gene expression (RT-qPCR)

At day 9 post-seeding, the DAT and COL bead foams (n=3 scaffolds/trial, N=3 trials with
different cell donors) were finely minced and RNA was extracted in TRIzol® (Thermo
Fisher Scientific, Burlington, ON, Canada) and purified using RNeasy® mini kits (Qiagen,
Valencia, CA, USA). TaqmanTM real-time RT-qPCR was performed using qSCRIPT®
XLT one-step real-time quantitative PCR ToughMix (Quanta Biosciences, Gaithersburg,
MD, USA) following the manufacturer’s instructions. TaqmanTM probes targeted against
the angiogenic markers CXCL12 (Hs03676656_mH), HGF (Hs0030159_m1), and VEGFA
(Hs00900055_m1) were used, with 18S rRNA (4352655) as the housekeeping gene.
Calculations were based on relative standard curves made from serial dilutions of pooled
template mRNA for each probe set. After confirming that amplification efficiencies were
between 90%-110% for all probe sets, Ct values for each of the samples were converted
into mRNA quantities using linear regression, and the technical triplicate values were
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averaged. These quantities were then normalized to the housekeeping gene for each
sample, and reported relative to the COL bead foam group.

2.4.10

In vivo analysis of seeded DAT and COL bead foams

All studies followed the Canadian Council on Animal Care (CCAC) guidelines and were
reviewed and approved by the Animal Care Committee at The University of Western
Ontario (Protocol #2015-049). To facilitate identification of the scaffolds in tissue sections
under fluorescence microscopy, the DAT and COL bead foams (cylindrical moulds;
diameter = 8 mm, height = 5 mm) were pre-labeled prior to cell seeding with an Alexa
Fluor 350 Succinimidyl Ester (A10168, Thermo Fisher Scientific) following the
manufacturer’s instructions. Scaffolds were then seeded with human weDFs and cultured
for 24 h as described in Section 2.8.

2.4.10.1 Analysis of weDF angiogenic factor secretion on DAT and
COL bead foams
To provide a baseline for the in vivo model, angiogenic factor secretion was assessed in the
conditioned media collected 24 h after scaffold seeding (n=3 scaffolds/trial, N=3 trials with
different cell donors) using a Luminex® multiplex assay directed against angiopoietin-1,
CXCL12, HGF, PDGF-BB, and VEGFA, according to the manufacturer’s instructions
(R&D Systems). The samples were analyzed on a Bio-Plex® MAGPIX™ Multiplex
Reader (Bio-Rad, Mississauga, ON), and the levels were normalized to the total dsDNA
content in the corresponding scaffolds measured using the Picogreen® assay.

2.4.10.2 Subcutaneous implantation of DAT and COL bead foams in
an athymic mouse model
Seeded DAT and COL bead foams (n=4-6 scaffolds/trial, N=3 trials with different cell
donors), along with unseeded controls, were implanted subcutaneously in female Crl:NUFoxn1nu mice (nu/nu nude mice; Strain Code 088, Charles River, Wilmington, MA,
U.S.A.) [14]. Briefly, the mice were anesthetised with isoflurane and given subcutaneous
injections of meloxicam (2 mg/kg loading dose; 1 mg/kg follow up dose at 24 h;
Boehhringer Ingelheim, Burlington, ON, Canada) and bupivacaine (2 mg/kg; Hospira,
Saint-Laurent, QC, Canada). Bilateral paraspinal incisions (~1 cm) were made on the dorsa
and subcutaneous pockets were created on each flank, below the panniculus carnosus. Each
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mouse received one DAT and one COL bead foam and the incisions were closed with
surgical staples. The animals were sacrificed by CO2 overdose at 2 weeks post-implantation
and the scaffolds were carefully excised within their surrounding tissues, embedded in
OCT and stored at -20°C.

2.4.10.3 Immunohistochemical analysis of scaffold explants
After acetone fixation and blocking (5% goat serum, 5% BSA, and 0.2% tween diluted in
TBS), immunostaining was performed to identify human cells (antigen: human-specific
Ku80, CST-2180, Cell Signaling Technologies, Danvers, MA, USA) and murine
endothelial cells (antigen: CD31, ab28364, Abcam) on scaffold cryo-sections (7 µm) at 3
different depths. Ku80 staining was performed as described by Allard et al. [249] and
CD31 staining was performed overnight at 4°C (dilution 1:200 in blocking solution,
ab28364, Abcam). A secondary anti-rabbit antibody conjugated to Alexa Fluor 594
(dilution 1:100, ab150080, Abcam) was used for detection and nuclei were counterstained
with PicoGreen Reagent® (dilution 1:600, Thermo Fisher Scientific). The fluorescentlylabeled scaffold cross-sections were imaged using an EVOS FL Cell Imaging System
(Thermo Fisher Scientific). Ku80+ human cells were counted in up to 5 non-overlapping
fields of view within the scaffold region using ImageJ analysis software. CD31 expression
was quantitatively assessed through positive pixel counting within the entire scaffold crosssection using ImageJ, normalized to the total scaffold area. For comparative purposes, the
results were reported as a fold change relative to the unseeded DAT control group.

2.4.11

Statistical Analyses

All data were expressed as the mean ± standard deviation (SD) and analyzed by t-test or
two-way ANOVA with Tukey’s post-hoc comparison of the means. The Kolmogorov–
Smirnov non-parametric test was used to compare the size distribution of the DAT and
COL beads. Statistical analyses were performed using GraphPad Prism 7 (GraphPad, La
Jolla, CA, USA) and differences were considered statistically significant at P<0.05.
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2.5
2.5.1

Results
Beads and bead foams fabricated from DAT and COL are
structurally similar

The DAT and COL beads and bead foams were characterized to confirm that varying the
ECM source did not substantially alter the physical properties of the scaffolds.
Macroscopically, the DAT and COL beads and bead foams (Figure 2.1A) had a similar
appearance, with the COL scaffolds having a whiter colouration consistent with the starting
materials. Analysis of the hydrated bead diameter revealed similar bimodal size
distributions for the electrosprayed DAT and COL beads (Figure 2.1B). The DAT and COL
beads were soft and compressible, showing similar viscoelastic behaviour (Figure 2.1C).
Further, there was no significant difference in the Young’s modulus (DAT = 0.49 ± 0.06
kPa, COL = 0.36 ± 0.09 kPa) between the two formulations (Figure 2.1D). SEM analysis
of the bead foams (Figure 2.1A) revealed that the scaffolds had a similar ultrastructure
comprised of spherical subunits with void spaces between the beads. Both types of
scaffolds were highly porous, with values of 96.7 ± 0.8% and 96.2 ± 0.5% estimated for
the DAT and COL bead foams respectively using a modified Archimedes’ test (Figure
2.1E).
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Figure 2.1: DAT and collagen bead foams are structurally similar. (A) Representative
macroscopic and SEM images of DAT and COL bead foams, showing that both are
comprised of a network of spherical beads with qualitatively similar morphology. (B)
Feret’s diameter of the individual beads used to fabricate the foams (n=25-35 beads/trial,
N=3 trials with different ECM suspensions). There was no significant difference in the size
distributions when analysed with the Kolmogorov-Smirnov test. (C) Representative force
versus deformation curves for individual DAT and collagen beads. Data from 3 cycles are
shown with compression at a strain rate of 0.01 s-1. (D) Young’s modulus of the individual
DAT and collagen beads, with no significant difference measured between the two groups
(n=6 beads/trial, N=3 trials with different ECM suspensions). (E) Porosity of the bead
foams measured with a modified Archimedes’ method, showing that both scaffold groups
had a similar high level of porosity (n=3 bead foams/trial, N=5 trials with different ECM
suspensions).

2.5.2

DAT and COL bead foams are compositionally distinct

Following confirmation that the scaffolds had similar structural properties, the biochemical
composition of the DAT and COL bead foams was assessed. Analysis of total collagen
content with the hydroxyproline assay demonstrated that both types of scaffolds were
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enriched in collagen, with 91.5 ± 4.1 µg and 85.3 ± 8.3 µg of hydroxyproline per mg dry
mass for the DAT and COL bead foams respectively (Figure 2.2A). In contrast, the DMMB
assay revealed that the total sulphated GAG content was significantly higher in the DAT
bead foams, at ~4.5 times the levels observed in the COL bead foams (Figure 2.2B). Semiquantitative immunohistochemical analyses indicated that both scaffold types contained a
similar distribution of collagen type I and fibronectin, with no laminin detected in either
group (Supplementary Figure 2.2). However, the DAT bead foams were shown to contain
higher levels of collagen type IV, V, and VI, distributed throughout the scaffolds with some
regional variability (Figure 2.2C). Taken together with the total collagen content data, the
immunofluorescence staining results suggested that the DAT and COL bead foams
contained similar amounts of collagen, but that the relative abundance and distribution of
collagen subtypes varied between the groups.

2.5.3

weDF cell abundance and survival is enhanced on the DAT
bead foams in vitro

Initial cell culture studies focused on exploring whether the ECM source could mediate the
in vitro survival of human weDFs under stresses simulating features of the chronic wound
microenvironment (Figure 2.3A). Immunostaining for vimentin indicated that there were
qualitatively more weDF on the DAT bead foams at 3 days post-seeding, with a higher cell
density observed in proximity to the seeded scaffold surface in both groups (Figure 2.3B).
While cell abundance was similar on both platforms at 24 h post-seeding, quantification of
total dsDNA supported that there were significantly more cells on the DAT bead foams at
both 3 and 9 days (Figure 2.3C). Measurement of adenylate kinase release via the
ToxilightTM assay further corroborated these findings, indicating there were significantly
higher levels of compromised or dying cells on the COL bead foams at 9 days post-seeding
(Figure 2.3D).
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Figure 2.2: DAT and COL bead foams are biochemically distinct. (A) Quantitative
analysis of total collagen content with the hydroxyproline assay, demonstrating that both
scaffold groups contained similar levels of total collagen (n=3 scaffolds/trial, N=3 trials
with different ECM suspensions). (B) Sulphated glycosaminoglycan (GAG) content
measured with the DMMB assay, showing that the DAT bead foams contained
significantly more sulphated GAG (n=3 scaffolds/trial, N=3 trials with different scaffolds).
(C) Representative immunohistochemical staining for collagen types IV, V, and VI in cryosections of the DAT and COL bead foams. (D) Quantification of relative collagen type IV,
V and VI levels, showing significantly higher levels in the DAT bead foam group (n=2-6
scaffolds/trial, N=3 trials with different ECM suspensions). *** = P<0.001, ** = P<0.01.
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Figure 2.3: weDF cell abundance and survival is enhanced in vitro on the DAT bead
foams as compared to the COL bead foams under conditions simulating stresses in
the chronic wound microenvironment. (A) Overview of the cell culture conditions and
experimental endpoints. A = cell abundance assay; S = secretome analysis; D = cell death
assay; H = histological assessment; G = gene expression analysis. (B) Representative
vimentin immunostaining (red) showing qualitatively enhanced weDF abundance on the
DAT bead foams at 3 days post-seeding. Scaffold autofluorescence shown in green, and
white lines denote the scaffold boundary, with the seeded surface oriented at the top of the
images. Scale bars = 200 µm. (C) Picogreen® dsDNA assay results showing enhanced cell
abundance on the DAT bead foams at 3 and 9 days post-seeding. (D) Quantification of cell
death as measured by the ToxilightTM assay indicating that there were higher levels of
dead/dying cells on the COL bead foams at 9 days post-seeding. (n=3 scaffolds/trial, N=3
cell donors); ** = P<0.01.
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2.5.4

Angiogenic gene expression is enhanced in the weDFs
cultured on the DAT bead foams

RT-qPCR analysis of angiogenic gene expression was performed to probe weDF function
on the DAT and COL bead foams after 9 days of culture in vitro (Figure 2.4) under the
stress-inducing conditions in the current study (Figure 2.3A). VEGFA and HGF expression
levels were significantly higher in the weDFs cultured on the DAT bead foams, with
consistent trends across all cell donors studied (Supplementary Figure 2.3). While the
pooled data indicated that CXCL12 expression was also significantly enhanced in the DAT
bead foam group, this trend only held for 2 of the 3 cell donors, with similar levels of
expression observed on the DAT and COL bead foams for cell donor 1 (Supplementary
Figure 2.3C).

2.5.5

Angiogenic factor secretion is enhanced in the weDFs
cultured on the DAT bead foams prior to implantation

Building from the in vitro findings, the subsequent studies focused on further probing the
effects of bead foam composition on weDF survival and function through testing in an in
vivo model. Prior to implantation, the weDFs were cultured on the DAT or COL bead
foams under hypoxic conditions (2% O2) for 24 h. As previously indicated, quantification
of total dsDNA content indicated there was no significant difference in cell attachment at
24 h between the groups (Figure 2.3B). Screening of the supernatant media revealed that
the weDFs on the DAT bead foams secreted significantly higher levels of VEGFa, HGF,
CXCL12/SDF-1α, angiopoietin-1, and PDGF-BB (Figure 2.5). In contrast to the gene
expression results, CXCL12 protein secretion was enhanced in the DAT bead foam group
for all cell donors. Notably, PDGF-BB was only detected in the DAT bead foams seeded
with cell donors 2 and 3, with no measurable levels observed in the COL bead foam group
for any of the cell donors.

2.5.6

Human weDF abundance is enhanced in vivo in the DAT
bead foams

At two weeks post-implantation in the athymic mouse model, immunohistochemical
analysis of human-specific Ku80 expression [249] identified the weDFs within the seeded
DAT and COL bead foams (Figure 2.6). Similar to the in vitro results, quantification of the
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Ku80+ human cells demonstrated that there were more weDF detected within the DAT
bead foams as compared to the COL bead foams at 14 days post-implantation, suggestive
of enhanced survival.

2.5.7

CD31+ cell recruitment is enhanced in the weDF-seeded
DAT bead foams

Immunohistochemical analysis revealed that there were murine CD31+ cells distributed
heterogeneously at the scaffold-tissue interface in all of the implant groups (Figure 2.7A).
While there were no differences in total cell infiltration between the groups based on
analysis of nuclear staining, endothelial cell density and infiltration appeared to be
qualitatively enhanced in the seeded scaffolds as compared to the unseeded controls
(Supplementary Figure 2.4). Quantitative analysis of the CD31 staining suggested that
early angiogenesis was enhanced in the weDF-seeded DAT bead foams as compared to the
seeded COL bead foams and both unseeded controls (Figure 2.7B).

Figure 2.4: Pro-angiogenic gene expression is enhanced in vitro in weDFs cultured on
DAT bead foams relative to COL bead foams under conditions simulating stresses in
the chronic wound microenvironment. Pooled data from the three cell donors showing
relative mRNA expression levels at 9 days post-seeding of the pro-angiogenic markers (A)
VEGFA, (B) HGF, and (C) CXCL12, with significantly increased expression in the weDFs
cultured on the DAT bead foams. Gene expression levels were normalized to the COL bead
foam group for each cell donor, with 18S as the housekeeping gene. (n=3 scaffolds/trial,
N=3 cell donors); *** = P<0.001, ** = P<0.01, * = P<0.05.
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Figure 2.5: Pro-angiogenic factor secretion is enhanced in weDFs cultured on DAT
bead foams relative to COL bead foams prior to implantation in the in vivo model.
Quantification of secreted proteins in cell culture supernatants at 24 h post-seeding,
normalized to total dsDNA content, showing that weDFs secreted significantly higher
levels of (A) VEGFa, (B) HGF, (C) CXCL12, (D) Ang-1, and (E) PDGF-BB on the DAT
bead foams. (n=3 scaffolds /trial, N=3 cell donors) *** = P<0.001, ** = P<0.01, * =
P<0.05. ND = not detected.
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Figure 2.6: Human weDF abundance is enhanced on the DAT bead foams relative to
the COL bead foams at 14 days after subcutaneous implantation in an athymic mouse
model. (A) Representative human Ku80 immunostaining (red) showing qualitatively
enhanced weDF abundance within the DAT bead foams. Nuclei were counter-stained with
PicoGreen Reagent® (green) and the scaffolds were pre-labeled with an Alexa Fluor 350
succinimidyl ester (blue). Scale bars = 100 µm. (B) Human Ku80+ cell density quantified
using ImageJ showing significantly increased numbers of human cells in the DAT bead
foams. (n=4-6 scaffolds /trial, N=3 cell donors) *** = P<0.001.
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Figure 2.7: CD31+ cell recruitment is enhanced in the DAT bead foams seeded with
human weDFs relative to seeded COL bead foams and unseeded controls at 14 days
after subcutaneous implantation in an athymic mouse model. (A) Representative CD31
immunostaining (red) showing qualitatively enhanced cell infiltration in the seeded DAT
bead foams relative to the seeded COL bead foams at 14 days post-implantation. Nuclei
were counter-stained with PicoGreen Reagent® (green) and the scaffolds were pre-labeled
with an Alexa Fluor 350 succinimidyl ester (blue). White dotted lines denote the scaffold
periphery. Scale bars = 200 µm (left panel) and 100 µm (right panel). (B) Relative CD31+
expression levels, normalized to the unseeded DAT control group, suggesting that early
angiogenesis was enhanced in the seeded DAT bead foams relative to all other groups. **
= P<0.01, * = P<0.05.
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2.6

Discussion

Numerous collagenous wound dressings have been explored for the treatment of chronic
wounds [169, 170]. However, the clinical efficacy of these approaches is unclear and the
existing collagen-based bioengineered products available for skin healing are approved for
only a limited subset of wound etiologies [170, 171, 250]. Possible reasons for the mixed
success of these biological dressings are not well understood, but pre-clinical studies
suggest that poor host cell infiltration and scaffold remodeling may be important factors
limiting the therapeutic potential of these biomaterials [172, 173].
In the present study, human DAT was compared as a complex matrix source for the
production of bioscaffolds to commercially-sourced bovine collagen, similar to the bovine
collagen incorporated in numerous commercially-available skin substitutes including
INTEGRA™, Apligraf ®, PermaDerm™, Matriderm®, and OrCel® [169]. Previously,
DAT bead foams were shown to stimulate regeneration in a subcutaneous implant model
in immunocompetent rats, with increased cell infiltration and more rapid remodelling
relative to intact DAT [14], supporting the selection of this more highly processed
scaffolding format for wound healing applications.
While the bead foam technology was developed using DAT [14], any collagen-rich tissue
could theoretically be applied as a matrix source to generate tissue-specific scaffolds, as
demonstrated in the present study using commercially-available collagen. Advantages of
the bead foams include their modular approach that allows for tunability in the design of
both the spherical subunits and the larger assembled scaffolds. Further, the highly-porous
DAT and COL bead foams were soft and compliant, with the modulus of the individual
beads being within the range reported for normal human skin (0.1 kPa - 10 kPa, as
measured by atomic force microscopy) [251], which may help to promote implant
integration.
The DAT and COL bead foams were stable without synthetic additives or chemical crosslinking, which may be favourable from biocompatibility and bioactivity perspectives [85,
252]. In general, bead foam stability is enhanced when there is greater contact between
adjacent beads, as well as more ECM present within the overall structure. As such, in our
experience it is easier to synthesize larger scaffolds appropriate for clinical applications, as
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compared to smaller constructs for use in pre-clinical studies. While DAT- and collagenbased bioscaffolds are biodegradable and will be remodelled over time, previous studies in
our lab have demonstrated that non-chemically crosslinked DAT microcarriers, foams, and
bead foams can be designed to remain stable for extended periods of time in vitro. In
particular, these platforms have been successfully applied in culture studies with human
adipose-derived stem/stromal cells (ASCs) extending from 14 to 28 days [14, 135]. Under
the conditions in the current study, the DAT and COL bead foams did not macroscopically
contract but remained intact over the 9-day culture period. However, in applying these
platforms, it is important to note that cell types that express high levels of matrix
metalloproteinases (MMPs) may interfere with scaffold integrity over time.
Manipulating ECM-derived scaffolds is challenging, as changes in composition can cause
alterations in the biophysical and biomechanical properties of the constructs [236], and few
studies have systematically investigated the effects of complex ECM composition on cell
function within 3-D engineered microenvironments. Frequently, studies using tissuederived scaffolds lack appropriate 3-D controls to be able to fully interpret the effects of
scaffold composition on the cellular response. Recognizing this limitation, the bead foam
fabrication methods were successfully applied to generate DAT and COL bead foams that
were structurally similar. While the substrates were designed to have comparable initial
properties, it is acknowledged that there may be subtle differences in scaffold architecture
and/or biomechanics, and that the scaffold properties may have changed over time as the
cells interacted with their environment. Regardless, the DAT bead foams reproducibly
enhanced the survival and angiogenic function of the human weDFs relative to bead foams
derived from bovine collagen, suggesting that human adipose tissue may be a promising
cell-instructive matrix source for wound healing applications.
The current findings suggest that the complex ECM composition within the scaffolds
modulated the response of dermal fibroblasts isolated from the chronic wounds of patients
undergoing limb amputation. The xenogeneic sourcing of the bovine COL bead foams may
be a factor impacting the cellular response. However, the ECM is highly conserved
between species [253, 254] and human fibroblasts and keratinocytes have been previously
shown to be responsive to matrices produced from bovine collagen [169, 255]. The higher
levels of sulphated GAGs and collagen types IV, V, and VI in the DAT bead foams may
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be advantageous for wound healing, as these ECM components are known to play
important roles in angiogenesis. More specifically, sulphated GAGs can act as a depot for
pro-angiogenic factors and can modulate endothelial cell attachment and migration directly
through α5 and αV integrin interactions [256]. Endothelial cell recruitment can also be
stimulated through interactions with collagen type IV [257], which has been shown to have
dose-dependent effects on vessel elongation and stabilization [258]. Recent studies have
also identified collagen type VI as an emerging pro-angiogenic factor through its role in
macrophage and endothelial cell recruitment in the context of tumour angiogenesis [22].
Lastly, collagen type V has been positively associated with newly-developing blood
vessels in granulation tissue, as well as wound healing [259].
Fibroblasts sourced from non-healing wounds, such as those used in the present study, have
been reported to have innate impaired functions [241, 242]. To the authors’ knowledge, the
current study is the first to directly compare the effects of ECM composition on the proregenerative phenotype of human weDFs. The findings suggest that weDFs can contribute
to tissue repair through the secretion of pro-angiogenic factors, and that cell survival and
functional capacity can be modulated by the matrix source applied in the design of cellinstructive ECM-derived scaffolds. In terms of complex ECM promoting cell survival
under stress, the in vitro findings are consistent with previous work demonstrating
enhanced survival in response to H2O2 treatment when murine cardiac progenitor cells
(CPCs) were cultured in decellularized myocardial matrix hydrogels as compared to
collagen gel controls [86].
The design of cell-instructive microenvironments that harness the pro-regenerative
paracrine capacity of stromal cell populations is an area of emerging research interest. To
date, the influence of complex ECM composition on cellular secretomes has been more
extensively explored in the context of cancer biology [260, 261]. For example, using a 3D culture model with Matrigel supplemented with collagen type I, Biondani et al. recently
reported that human cancer stem cells secreted lower levels of a range of pro-angiogenic
factors in matrices that contained higher amounts of collagen type I [260]. These findings,
along with the results of the current study, suggest that the incorporation of complex ECM
components within collagenous wound dressings could enhance regeneration by inducing
cells within the wound bed to adopt a more pro-angiogenic phenotype.
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2.7

Conclusions

Relative to the bead foams fabricated from bovine collagen, the survival and proangiogenic capacity of human dermal fibroblasts sourced from chronic wounds were
enhanced on the DAT bead foams both in vitro and in vivo. The assembled data supports
that the complex ECM composition within engineered bioscaffolds can be harnessed to
establish a more pro-regenerative microenvironment for cells involved in the process of
wound repair. Future work could assess the pro-regenerative effects of the scaffolds in preclinical models of impaired wound healing, as well as exploring the DAT bead foams as
cell-instructive platforms for regenerative cell populations, such as mesenchymal
stem/stromal cells (MSCs). Overall, decellularized adipose tissue represents a promising
and clinically-relevant human matrix source for the design of novel pro-angiogenic wound
dressings.
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Chapter 3

3

Modular cell-assembled matrix-derived bead foams as
a pro-angiogenic mesenchymal stromal cell delivery
platform

3.1 Co-authorship statement
The work presented in Chapter 3 forms the basis of a manuscript that is currently in
preparation for submission, entitled: “Modular cell-assembled matrix-derived bead foams
as a pro-angiogenic mesenchymal stromal cell delivery platform”, with the following list
of authors: “Morissette Martin P, Kim KJ, Juignet L, Hamilton AM, Ronald JA, Flynn LE”.
I conceptualized the study in collaboration with Dr. Lauren Flynn. I personally designed
and performed all of the experimental studies described in the Chapter, with support from
the remaining authors. More specifically:
•

Ms. Kellie J. Kim helped with the production of the cell-assembled bead foams for
Figures 3.2, 3.3, and 3.4.

•

Dr. Laura Juignet operated the flow cytometer and performed flow cytometry data
analysis (Figure 3.2D and E).

•

Dr. Amanda Hamilton produced the lentiviral vectors and transduced the cells that
were used for the animal experiments.

•

Dr. John Ronald provided scientific guidance with the lentiviral transduction and
granted access to the in vivo imaging system (IVIS) platform.

I analyzed all the data in collaboration with Dr. Flynn. I made all the figures and
supplementary content (tables and figures). The manuscript was written in collaboration
with Dr. Lauren Flynn.
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3.2 Abstract
There is a need for new approaches for bioscaffold fabrication that enable the localized
delivery of a high density of pro-regenerative cells for applications in soft tissue
regeneration. Towards this goal, novel scaffolds comprised of fused networks of
extracellular matrix (ECM)-derived beads were developed and generated through a “cellassembly” approach using human adipose-derived stromal cells (ASCs) seeded on
spherical decellularized adipose tissue (DAT) beads. Our novel fabrication protocol
successfully produced robust 3-D cell-assembled bead foams that were easy to handle and
contained a high density of viable ASCs. Histological, biochemical and gene expression
assays demonstrated that the cell-assembly process was mediated through the synthesis of
new ECM, including collagen, fibronectin and glycosaminoglycans (GAGs), combined
with enhanced ECM remodelling. Further, the ASCs within the cell-assembled bead foams
were shown to express a variety of pro-angiogenic proteins. In vivo assessment in a
subcutaneous implant model in athymic nude mice was performed to probe ASC retention
and angiogenesis using the new cell-assembled bead foam platform relative to ASCs
seeded on pre-assembled DAT foams. To enable in vivo cell tracking, all scaffolds were
prepared with transduced human ASCs that were engineered to express codon optimized
firefly luciferase (Fluc2) and tdTomato (tdT). Bioluminescence imaging (BLI) results
indicated that there were significantly more viable ASCs present in the cell-assembled bead
foams at 2 days post-implantation, with the enhanced signal in this group diminishing over
time. BLI and histological analysis of the tdT+ cell population within the scaffolds
confirmed that both platforms contained similar levels of ASCs at 28 days postimplantation. Further, the cell-assembled bead foam implants were shown to contain a
higher density of CD31+ cells at 28 days, suggesting that this platform was favorable for
stimulating localized angiogenesis. Overall, the novel cell-assembled DAT bead foams
represent a promising pro-regenerative cell delivery system that supports the localized in
vivo retention of delivered ASCs with pro-angiogenic functionality.
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3.3 INTRODUCTION
There is growing interest in the development of new approaches to stimulate soft tissue
regeneration for applications in plastic and reconstructive surgery, including the restoration
of soft tissue defects caused by post-oncologic resection, trauma, and congenital
abnormalities [74, 84]. While the implantation of pro-regenerative biomaterials may be
sufficient for the treatment of small defects or voids, more complex strategies would likely
be required for stable mid-to-large volume soft tissue augmentation [74, 79]. In particular,
there remains a significant need for new strategies that can help to augment angiogenesis
within engineered tissue replacements, to avoid eventual failure due to the lack of a
supporting vascular network within the implant [74, 79]. From this perspective, cell-based
therapies harnessing the pro-regenerative paracrine functionality of mesenchymal stromal
cells (MSCs) have shown promise in stimulating angiogenesis within implanted
biomaterials [126, 175, 262, 263].
Towards the goal of designing innovative strategies for soft tissue repair, our lab has
pioneered the development of bioscaffolds derived from human decellularized adipose
tissue (DAT) [14, 104, 126, 264]. From a translational perspective, adipose tissue is
abundantly discarded as surgical waste and is a uniquely accessible source of human
extracellular matrix (ECM) that can be decellularized using our detergent-free
decellularization process [104]. The resulting DAT incorporates a diverse range of
biomacromolecules, such as collagens, proteoglycans, glycosaminoglycans, adhesion
glycoproteins, growth factors, cytokines, and matricellular proteins, which may be
favourable for cell survival and angiogenesis [264]. Recent studies from our group and
others have also shown that DAT can be further processed into a variety of bioscaffold
formats, including foams [14, 264], microcarriers [13, 135], coatings [136], hydrogels
[119], meshes [131], and bioinks for 3-D printing applications [134]. These alternative
scaffold formats have properties, such as porosity, stiffness, and architecture, that can be
tuned depending on the target application [13, 14, 119, 131, 134-136, 264].
In previous studies, we developed a DAT “bead foam” platform that was fabricated by
subjecting spherical porous DAT beads combined within a mould to a controlled freezing
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and lyophilization procedure that resulted in fusion of the beads to generate 3-D constructs
stabilized through physical interactions [135, 265]. Using this pre-assembled bead foam
format, DAT was shown to have cell-instructive properties in terms of enhancing the
survival and pro-angiogenic functionality of human dermal fibroblasts isolated from
chronic wounds relative to similar foams derived from purified collagen both in vitro and
in vivo [264]. While the cell-supportive and pro-angiogenic properties of the previous DAT
bead foam technology were promising, a limitation was that the foams tended to be fragile
and could only be seeded and cultured using static approaches, which resulted in limited
cellular infiltration and distribution. Having a core devoid of cells is not ideal for strategies
striving to apply MSCs to promote scaffold integration and implant vascularization [74,
84].
To address these limitations, the overall objective of the current study was to establish new
fabrication techniques to generate robust three-dimensional (3-D) DAT bioscaffolds
containing a high density of viable cells that were well distributed throughout the scaffolds.
More specifically, we sought to harness the innate capacity of human adipose-derived
stromal cells (ASCs) to synthesize and remodel ECM [221, 266] in order to produce novel
“cell-assembled” bead foams. ASCs are a logical cell source for soft tissue regeneration
strategies, given their relative abundance and accessibility [267], as well as their capacity
to promote regeneration through the secretion of pro-angiogenic and immunomodulatory
paracrine factors [201, 203, 209].
To generate the cell-assembled foams, the ASCs were first seeded onto porous DAT beads
under dynamic conditions within a spinner culture system [135]. Following a 24 h cell
attachment period, the seeded beads were then transferred into moulds and cultured for 8
days to promote scaffold assembly. In developing the new fabrication protocols, the effects
of varying the culture conditions were explored, with the goal of improving the handling
properties of the scaffolds, while ensuring the ASCs retained high viability and proangiogenic paracrine functionality. In previous studies with MSCs, preconditioning with
soluble factors including epidermal growth factor (EGF) [224], basic fibroblast growth
factor (FGF-2) [225], and insulin-like growth factor-1 (IGF-1) [226] has been shown to
have positive effects in terms of stimulating cell growth, decreasing apoptosis, and
enhancing the secretion of a variety of factors including pro-angiogenic and pro-fibrotic
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molecules, as well as matrix metalloproteinases (MMPs) that regulate ECM remodelling
[218, 219, 224-226, 268]. In addition, dynamic culture was employed throughout all stages
of the process, as previous literature has identified that dynamic preconditioning can
enhance ECM synthesis by human ASCs [221], and promoting media exchange within the
scaffolds may also help to augment cell viability and paracrine factor production [269].
Following the establishment of the fabrication methods, detailed in vitro characterization
studies were performed with a focus on assessing ASC number, distribution, proliferation,
and viability, as well as probing for pro-angiogenic markers along with ECM synthesis and
remodelling. Subsequently, the capacity of the scaffolds to support viable human ASC
retention in vivo was investigated within a subcutaneous implant model in athymic nude
mice relative to ASCs delivered on our previous pre-assembled DAT bead foam platform.
To enable in vivo cell tracking, the scaffolds were prepared with human ASCs that had
been transduced to constitutively express codon optimized firefly luciferase (Fluc2) and
tdTomato (tdT), a red fluorescent protein [270]. Bioluminescence imaging (BLI) was
performed over 28 days, and the implants were collected within their surrounding tissues
at day 28, for histological analysis of tdTomato+ cell retention and immunohistochemical
staining for CD31 as a marker of angiogenesis within the scaffolds.

3.4 Materials and methods
3.4.1 Decellularization of adipose tissue and DAT bead synthesis
Human subcutaneous adipose tissue was obtained with informed consent from elective
lipo-reduction procedures at the London Health Sciences Centre in London, Canada
(HREB #105426) and transferred within 2 h of collection into a hypotonic cell lysis buffer
(Solution A:10 mM Tris base and 5 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0)
and frozen at -80°C. All decellularization solutions were supplemented with 1% antibioticantimycotic solution (Gibco, Burlington, ON, Canada) and 1% phenylmethylsulphonyl
fluoride (PMSF), with the exception of the enzymatic treatment steps where the PMSF was
excluded. After thawing, the tissues were processed following a published five-day
decellularization protocol [104].
Lyophilized DAT samples from five patients were pooled and finely minced, suspended
into 0.2 M acetic acid, and homogenized (PowerGen Model 125 homogenizer, Fisher
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Scientific, Ottawa, ON, Canada). The homogenized DAT suspension was diluted with
deionized water to obtain a final ECM concentration of 20 mg ECM/mL (dry weight), and
then electrosprayed to synthesize DAT beads following published methods [264]. In brief,
the beads were produced by electrospraying the suspension directly into a Dewar flask
filled with liquid nitrogen with an applied voltage of 16-18 kV, an extrusion speed of
35 mL/h, and the needle positioned 3 cm from the surface of the liquid nitrogen.
Immediately following synthesis, the frozen beads were collected into conical tubes,
lyophilized, and stored under vacuum at room temperature.
Following synthesis, DAT beads were decontaminated and rehydrated through an ethanol
series (100%, 99%, 98%, 95%, 90%, 80%, 70%, 50, 25%, and 12.5% (v/v) diluted with
sterile PBS), followed by three washes in sterile PBS. The rehydrated beads were stored at
4°C before being used in characterization and cell culture studies.

3.4.2 Human ASC isolation, expansion, and characterization
Collected human adipose tissue was processed within 2 h for ASC isolation following
published protocols [12]. Isolated ASCs were cultured on tissue culture polystyrene
(TCPS; Corning, NY, USA) at 37°C, 5% CO2 in proliferation medium comprised of
DMEM:Ham’s F12 (Wisent Bio Products, Montreal, QC) supplemented with 10% fetal
bovine serum (FBS; Wisent Bio Products), 100 U/mL penicillin and 0.1 mg/mL
streptomycin (Wisent Bio Products). Media was changed every 2-3 days. Cells were frozen
at passage 0, stored in liquid nitrogen, and thawed when needed. Primary cell populations
from three donors (Supplementary Table 3.1) were included in the studies.
Immunophenotyping (Supplementary Figure 3.1) was performed on P4 ASCs using a
Guava easyCyte 8HT flow cytometer (Millipore, Billerica, MA, USA) as previously
described [248]. Single marker staining was performed with monoclonal, fluorochromeconjugated antibodies from eBioscience (San Diego, CA, USA), as follows: CD90-FITC,
CD-105-PE, CD73-FITC, CD44-PE-Cy7, CD29-PE, CD34-APC, CD31-PE, CD146FITC. All samples were stained for 30 min at 4°C in 5% FBS diluted in PBS. Unstained
controls were included in every trial.
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3.4.3 Production of cell-assembled DAT bead foams
3.4.3.1 Cell seeding regimen on DAT beads
Rehydrated DAT beads were resuspended in proliferation medium and incubated overnight
at 4°C. The next day, the beads were transferred into 250 mL CELLSPIN® spinner flasks
(INTEGRA Biosciences, AG, Switzerland) with 100 mL of proliferation media. Passage 4
or 5 ASCs were trypsinized and seeded into the spinner flasks at a ratio of 1.25 x 106
cells/mg of DAT beads (wet weight in 100% ethanol). Immediately after the addition of
the cells into the spinner flasks, a 12-h stirring regimen was performed (37°C, 5% CO2)
[135]. In brief, (i) the cultures were stirred for 2 min at 25 rpm, followed by 30 min of
static culture repeated over a period of 3 h, (ii) the cultures were then maintained under
static conditions for 6 h, and (iii) the intermittent stirring conditions described in stage (i)
were repeated for the final 3 h. After the seeding period, the spinner flasks were stirred
continuously at 25 rpm for 12 h.
Cell attachment was assessed by counting the number of unadhered cells in the spinner
flask system at 24 h after seeding. More specifically, the media was collected and
centrifuged to pellet the cells (1200 xg, 5 min), which were counted using a hemocytometer
with a 1:1 ratio of cell suspension with trypan blue. Cell numbers were reported as a
percentage of unadherent cells relative to the initial number of cells inoculated into each
flask (n = 3 replicate samples/cell donor, N = 3 cell donors).

3.4.3.2 Cell assembly of the DAT beads into DAT bead foams
Following cell seeding, ASC-seeded DAT beads were transferred into circular moulds
comprised of 12-well transwell inserts lined with medical-grade silicone rings (inner
diameter: 8 mm; outer diameter: 12 mm; height: 3 mm). Prime-XV® MSC EXPANSION
XSFM Medium (cat#91149, Irvine Scientific, CA, USA), a xenogenic-free chemicallydefined (XFCD) media, was supplemented with 50 µg/mL of L-ascorbic acid 2-phophate
(A2P) to promote ECM deposition [271, 272], as well as 100 U/mL penicillin and 0.1
mg/mL streptomycin. In addition, in one set of samples supplementation of the media with
5 ng/mL of recombinant human EGF, 10 ng/mL of recombinant human FGF-2, and 20
ng/mL of recombinant LONG® R3 human IGF-1 (+GF) was also investigated as a possible
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strategy to enhance cell proliferation and matrix production. All three growth factor stock
solutions were reconstituted with 1 mg/mL of human serum albumin.
For both groups, media was changed every two days with freshly-supplemented A2P. After
three days of static culture, 12-well plates containing the scaffolds were transferred onto
an orbital-shaker for dynamic culturing until harvesting (75 rpm, 37°C, 5% CO2).

3.4.4 Cell viability and abundance on DAT beads and within the cellassembled DAT bead foams
3.4.4.1 Cell viability and distribution analysis using confocal
microscopy
To qualitatively analyse ASC viability and distribution on the surface of the DAT beads,
cell-seeded beads were stained at 24 h after seeding with a Live/Dead® assay kit (Cat. #
L-3224; Life Technologies, Burlington, ON, Canada) and imaged with a Zeiss LSM800
confocal microscope (Zeiss Canada, Toronto, ON, Canada) (N = 3 cell donors).

3.4.4.2 Cell viability analysis using flow cytometry
After 7 days of transwell culture, the cell-assembled DAT bead foams were rinsed in PBS
and incubated in trypsin to dissociate the cells (1 h, 37°C, 75 rpm). The samples were then
neutralized using complete proliferation media, filtered through 100-µm and 40-µm nylon
meshes, pelleted, and rinsed in ice-cold PBS supplemented with 5% FBS. Isolated cells
were then stained for annexin-V and propidium iodide using an Apoptosis Detection Kit I
(cat. # 556547; BD bioscience, Mississauga, ON, Canada) according to the manufacturer’s
instructions, and analyzed using an LSR II/FACSCanto flow cytometer (BD bioscience; n
= 3 scaffolds/cell donor, N = 3 cell donors). Controls included unstained cell-assembled
bead foams, along with propidium iodide and Annexin-V single and double-stained ASCs
cultured on TCPS. In addition, ASCs cultured on TCPS were treated with staurosporine (1
µM staurosporine, 16 hrs, 37°C, 5% CO2) as a positive control for apoptosis.

3.4.4.3 Cell abundance and total double-stranded DNA
content measurements
Cell-assembled bead foam samples were rinsed in PBS, snap frozen, weighed, and
lyophilized. Samples were then digested with 60 mU/mL of proteinase K (Promega,

72

Madison, WI, USA) in Tris-EDTA buffer (200 nM Tris- HCl, 200 nM EDTA, pH 7.5)
under agitation at 500 rpm and 56°C overnight, followed by a 10 min incubation at 95°C
to inactivate the enzyme (n = 3 scaffolds/cell donors, N = 3 cell donors).
To estimate the number of cells incorporated within the bead foams, DNA extraction from
the proteinase K-digested lyophilized samples was performed using a DNeasy® Blood and
Tissue kit (cat# 69504; Qiagen, Valencia, CA, USA) according to the manufacturer’s
instructions. Total double-stranded DNA (dsDNA) was quantified from the columnpurified DNA samples using the Quant-iT™ PicoGreen® dsDNA assay (Molecular
Probes, Burlington, ON, Canada) according to the manufacturer’s instructions, with
analysis using a CLARIOstar® spectrophotometer (BMG LABTECH Inc., Cary, NC,
USA). Cell lysates prepared from ASCs cultured on TCPS were included to generate
standard curves to report the data in terms of cell numbers (n = 3 scaffolds/cell donors, N
= 3 cell donors).

3.4.5 Physical and biochemical characterization of the DAT beads
and DAT bead foams
3.4.5.1 Bead diameter
Hydrated DAT beads were imaged under a light microscope at low magnification. The
Feret’s diameter function on ImageJ (NIH, http://imagej.nih.gov/) was used to measure the
largest diameter of the beads (N= 3 donors, n= 25 to 35 biological replicates per donor).

3.4.5.2 Mechanical Testing
The mechanical properties of individual DAT beads were assessed using a CellScale
MicroTester system (Waterloo, ON, Canada). Testing of individual beads was performed
in a PBS bath at 37°C, using a 203 µm diameter cantilever attached to a square platen
(2 mm x 2 mm), and the beads were compressed to 50% deformation for 3 preconditioning
cycles at a strain rate of 0.01 s-1 (1 cycle = 45 s compression, 1 s hold, 45 s recovery). The
data was collected from 3 consecutive cycles and the Young's moduli were calculated using
nonlinear least squares curve fitting with a published extended mechanics model for large
elastic deformations of spherical microparticles [245] (n=6 beads/batch; N=3 batches from
3 different ECM donors).
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3.4.5.3 Contraction Measurement of Cell-Assembled DAT
Bead Foams
Macroscopic images were acquired after 8 days of transwell culture. Using the inner
diameter of the silicone ring to represent the initial area at day 0, contraction measurements
were performed using ImageJ and were reported as a percentage compared to the initial
day of moulding (n=15-18 replicates per donor, N=3 cell donors).

3.4.5.4 Porosity measurement
Rehydrated DAT beads and DAT bead foams were lyophilized and weighed. After
recording their dry mass, the scaffolds were immersed in 100% isopropanol overnight
under light vacuum with gentle agitation to minimize the formation of air bubbles. Excess
isopropanol was then removed through gentle blotting and the wet mass of the scaffold was
recorded. Porosity was calculated using a modified Archimedes’ method [246].

3.4.5.5 Hydroxyproline and dimethylmethylene blue assays
Total collagen and total sulphated glycosaminoglycan (GAG) contents were quantified
using the hydroxyproline and dimethylmethlylene blue (DMMB) assays respectively.
Unseeded DAT beads, seeded DAT beads, and cell-assembled DAT bead foams were
digested with 60 mAnson units of proteinase K/mL (Promega, Madison, WI, USA) in TrisEDTA buffer (200 nM Tris-HCl, 200 nM EDTA, pH 7.5) under agitation at 500 rpm and
65°C for 2 h. Following digestion, the proteinase K was inactivated by a 10 min incubation
at 95°C. Both DMMB and hydroxyproline assays were run using the same set of digested
samples.
The DMMB assay was performed by mixing 10 µL aliquots of the digested samples and
200 µL of a 1.6% DMMB solution (solvent: 1% ethanol and 0.2% formic acid) into a 96well plate. The absorbance at 525 nm was recorded using a CLARIOstar®
spectrophotometer (BMG LABTECH Inc.) and the GAG concentration was determined by
comparison to a chondroitin sulphate standard curve.
The hydroxyproline assay was performed following further processing of the proteinase Kdigested samples. More specifically, sample aliquots were hydrolyzed (24 h incubation in
12 N hydrochloric acid at 110°C), neutralized (with 6 N sodium hydroxide), diluted (1:80
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with water), and transferred in duplicate into a 96-well plate. Next, 0.05 N chloramineT/20% 2-methoxyethanol solution was added to each well (incubated for 20 min at room
temperature), followed by the addition of 3.15 N percholoric acid (incubated 5 min at room
temperature), and Ehrlich’s reagent (incubated 20 min at 60°C). After the stabilization of
the colour (5 min incubation at 4°C followed by a 20 min incubation at room temperature),
absorbance was measured at 560 nm using a CLARIOstar® spectrophotometer (BMG
LABTECH Inc.). The hydroxyproline content was determined by comparison to a
hydroxyproline standard curve.

3.4.5.6 Zymography
To determine the relative amounts of MMP activity within the experimental groups,
conditioned media from the cell-assembled DAT bead foams was analysed using gelatin
zymography. Media that had been conditioned for 48 h was collected at day 8 and stored
at -80°C. Samples were thawed on ice, diluted in a 1:1 ratio with 4X Laemmli buffer
(without β-mercaptoethanol) and loaded on 7.5% SDS-polyacrylamide gels containing 1
mg/mL gelatin (10 µL of diluted conditioned media per gel well). To allow for protein
size analysis and gel-to-gel normalization, BLUelf Prestained Protein ladder (FroggaBio)
and 10 ng recombinant human MMP-2 standards (Biolegend; cat#554302) activated with
4-aminophenylmercuric acetate (Sigma; Cat#A9563) were loaded on all gels [273]. Media
only controls (incubated 48 hours without scaffolds, 37°C, 5% CO2) were also included.
Following electrophoresis, SDS was removed by incubating the gels in washing buffer
(2.5% Triton X-100, 50 mM Tris HCl, 5 mM CaCl2, 1 µM ZnCl2; two 30 min washes,
100 rpm, room temperature). Gels were then rinsed once in digestion buffer (1% Triton X100, 50 mM Tris HCl, 5 mM CaCl2, 1 µM ZnCl2; 10 min at 37°C) and incubated 24 h at
37°C in fresh digestion buffer. Gels were then stained with Coomassie blue (0.05%
Coomassie blue, 10% acetic acid, 40% methanol, dissolved in water), destained (10%
acetic acid, 40% methanol), imaged, and analyzed for densitometry using ImageJ. Results
were normalized to the MMP-2 standard bands at ~60 kDa.
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3.4.5.7 Immunohistochemical and histological analysis of DAT
bead foams
To distinguish newly-synthesized ECM from the pre-existing DAT beads in the cryosections, DAT beads were pre-labeled with an Alexa Fluor 350 Succinimidyl Ester
(A10168, Thermo Fisher Scientific, Oakville, ON, Canada) following the manufacturer’s
instructions. DAT beads were then seeded in the spinner flask system as described in
section 3.3.1 and cultured as described in section 3.3.3.1 with protection from light
exposure. After 8 days of transwell culture, the DAT bead foams (n = 3 scaffolds/cell
donors, N = 3 cell donors) were rinsed in PBS, embedded in Tissue-Tek OCT compound
(Sakura Finetek, Torrance, CA, USA), and snap frozen in liquid nitrogen prior to cryosectioning (7 µm transverse sections). Following fixation in acetone and blocking in 10%
goat serum in PBS, the sections were stained overnight at 4°C with primary antibodies
against collagen type I (1:200 in 5% goat serum in PBS, ab34710, Abcam, Toronto, ON,
Canada), fibronectin (1:200, ab23750, Abcam), or Ki67 (1:200, ab16667, Abcam).
Detection was carried out using an anti-rabbit secondary conjugated to Alexa Fluor 594
(dilution 1:200, ab150080, Abcam) and Picogreen® reagent to identify cell nuclei (dilution
1:400). No primary controls were included in all trials. Images were acquired with an
EVOS FL Cell Imaging System (Thermo Fisher Scientific, Burlington, ON, Canada). In
order to assess the collagen fiber network within the scaffolds, picrosirius red staining was
also conducted (7 µm cryo-sections), with visualization under circularly polarized light
using a Nikon Optiphot microscope (Nikon, Mississauga, ON, Canada) and an Infinity 23 CCD camera (Lumenera, Ottawa, Canada).

3.4.6 Gene expression analysis measured using RT-qPCR
Total cellular RNA was isolated from the cell-assembled bead foams using PureZOL™
RNA Isolation Reagent (Bio-Rad; cat# 7326880) and the Aurum™ Total RNA Fatty and
Fibrous Tissue Kit (Bio-Rad; cat# 7326870). cDNA was then synthesized from 400 ng of
input RNA using the iScript™ Reverse Transcription Supermix kit (Bio-Rad; Cat. #
1708840) according to the manufacturer's protocol.
Custom-made qPCR arrays (Bio-Rad; PrimePCR™ arrays) were designed to probe for 23
genes gene of interest (see Supplementary Table 3.2 for a list of gene symbols and gene
names), along with the housekeeping genes ribosomal protein S18 (RPS18) and ubiquitin

76

C (UBC). Three cDNA samples from each experimental condition were pooled (3 ng of
cDNA each/well, for a total of 9 ng of pooled cDNA per well) and run in technical
duplicates for all genes. Samples from three cell donors were analyzed independently.
Several technical controls were included in the plate design for each set of pooled samples,
including a gDNA control, a RT control, a positive PCR control, and two RNA quality
controls

(cat#

qHsaCtlD0001004,

qHsaCtD0001001,

qHsaCtlD0001003,

qHsaCtlD0001002, respectively; PrimePCR™ arrays; Bio-Rad).
Amplification was carried out using a CFX384 Touch™ Real-Time PCR Detection System
(Bio-Rad) using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad) in all wells as
follows: initial incubation at 95°C for 2 min, followed by 40 cycles of 95°C for 5 s and
60°C for 30 s. The data was analyzed using the comparative Ct method with normalization
to the geometric mean of two stable housekeeping genes (RPS18 and UBC).

3.4.7 Protein expression analysis measured using multiplex assay
The expression of angiogenic factors was further investigated at the protein level using a
Luminex® multiplex assay for angiopoietin-1, CXCL12, HGF, and VEGFa, according to
the manufacturer’s instructions (R&D Systems). Scaffold lysates were produced by rinsing
the 8-day cell-assembled bead foams in PBS, snap freezing, and grinding them in liquid
nitrogen using a mortar and pestle. Proteins were extracted using a TNGT buffer (50 mM
Tris-HCl pH 7.4; 100 mM NaCl; 5% Glycerol; 1% Triton X), followed by a series of
centrifugation steps to remove ECM debris. The samples were analyzed on a Bio-Plex®
MAGPIX™ Multiplex Reader (Bio-Rad, Mississauga, ON), and the analyte levels were
normalized to the total protein content in the corresponding scaffolds measured using the
Pierce 660 nm protein assay (Thermo Fisher Scientific) with a CLARIOstar plate reader
(BMG Labtech).

3.4.8 Lentiviral transduction of ASCs and trilineage differentiation
studies
3.4.8.1 Lentiviral transduction of ASCs
To enable BLI and fluorescence tracking of the ASCs within the in vivo model, ASCs from
3 donors were transduced using lentiviral vectors co-expressing FLuc2 under the human
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elongation factor 1-alpha promoter for constitutive expression (pEF1-alpha-tdT-FLuc2
reporter) [270]. Vector production and lentiviral transductions were performed on ASCs at
passage 1 following previously published methods [270]. Briefly, integrating lentiviral
vectors with pEF1-alpha-tdT-FLuc2 reporters were generated by cotransfecting packaging,
envelope, and transfer plasmids into 293T cells. Vector supernatants were harvested 24
and 48 h after transfection and filtered through a 0.45 µm filter, aliquoted and frozen at 80°C until use. Functional viral titers were determined by transducing 1 x 105 H1299 cells
with various volumes of vector supernatants and using an LSR II/FACSCanto flow
cytometer (BD bioscience) for analysis. ASCs were then thawed, cultured 2-3 days, and
transduced using a viral multiplicity of infection (MOI) of 75 and 100 µg/mL of protamine
sulphate. ASC underwent a medium change 24 h post-transduction and were rinsed with
PBS three times 48 h post-transduction, prior to passaging. Quantification of the
percentage of transduced cells based on tdT expression was performed at passages 3 and 4
using a Guava easyCyte 8HT Benchtop flow cytometer (EMD Millipore, Billerica, MA,
USA). Three ASC populations were used for the trilineage differentiation studies (Section
3.4.8.2) and two populations were used for the in vivo experimentations (Section 3.4.9).

3.4.8.2 Trilineage differentiation studies
Trilineage differentiation studies were performed to confirm maintenance of the
multilineage differentiation capacity of the ASCs following transduction. Transduced and
non-transduced ASCs at passage 4 from three donors were included.
ASCs were differentiated towards the adipogenic lineage using an adipogenic
differentiation medium comprised of DMEM:Ham's F12 supplemented with 33 mM biotin,
17 mM pantothenate, 10 mg/mL transferrin, 100 nM hydrocortisone, 66 nM human insulin,
1 nM triiodothyronine, and 1% pen-strep, with 0.25 mM isobutylmethylxanthine (IBMX)
and 1 mg/mL troglitazone supplemented for the first 3 days. Non-induced controls were
also included by culturing the ASCs in proliferation media. After 14 days of culture,
perilipin immunofluorescence and oil red O staining were performed to visualize
intracellular lipid accumulation within the induced and non-induced groups (n = 3
wells/cell donor; N = 3 donors) following published methods [13]. In order to
quantitatively analyze the levels of intracellular lipid accumulation, dye extraction on the
oil red O-stained samples was performed after imaging. For extraction, the samples were
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rinsed with deionized water twice, and once with 70% ethanol (quickly, 1 well at a time)
to remove non-specific background, prior to the addition of 100% isopropanol to extract
the dye (15 min incubation, 150 rpm, room temperature). Supernatants were then
transferred from each replicate sample into triplicate wells of a 96-well plate, and
absorbance was read at 492 nm using a CLARIOstar® spectrophotometer (BMG LabTech,
Ortenberg, Germany). Data was expressed as a fold change relative to the non-transduced,
non-induced conditions.
Osteogenic differentiation was induced using an ostegenic differentiation medium
comprised of DMEM with 1 g/L of glucose supplemented with 10% FBS, 150 µM A2P,
10 mM β-glycerophosphate, 10 nM dexamethasone, 10 nM 1,25-dihydroxyvitamin D3,
and 1% pen-strep. In addition to the osteogenic induced group, a group cultured in DMEM
with 1 g/L of glucose supplemented with 10% FBS and 1% pen-strep was included as a
non-induced control. Media was changed every 2-3 days for all groups and the cells were
cultured for an additional 28 days. Osteogenic differentiation was assessed in terms of
matrix mineralization performed by von Kossa staining and Osteoimage® fluorescent
staining following published methods [135] and the manufacturer's instructions
respectively. An alkaline phosphatase (ALP) activity assay was also performed to quantify
the osteogenic differentiation response [135]. Cell lysate aliquots were combined with
nitrophenyl phosphate substrate within a 96-well plate. Following a 30 min incubation at
37°C quenched with 3 N sodium hydroxide, the absorbance of each well was measured at
405 nm using a CLARIOstar® spectrophotometer (BMG LABTECH Inc.). Quantification
of enzyme activity was performed using p-nitrophenol standards, and the data was
normalized to total protein content using the Pierce 660 nm protein assay (Thermo Fisher
Scientific).
Induction towards the chondrogenic lineage was performed in 3-D aggregate cultures of
the ASCs at a density of 250,000 ASCs/aggregate. To form the aggregates, the cells were
centrifuged at 300 xg for 5 min in 15 mL vented cap conical tubes and cultured for 48 h in
proliferation medium. The cells were then transferred into chondrogenic differentiation
medium comprised of DMEM:Ham's F12 supplemented with 10% FBS, 50 µg/mL
ascorbic acid, 6.25 mg/mL human insulin, 100 nM dexamethasone, 10 ng/mL transforming
growth factor β1 (TGF-β1) and 1% pen-strep for an additional 28 days. Non-induced
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aggregates cultured in proliferation media were included as a negative control.
Chondrogenic differentiation was assessed through immunohistochemical (IHC) staining
for collagen II. For this analysis, the cell aggregates were embedded in Tissue-Tek OCT
compound (Sakura Finetek), cryo-sectioned (7 µm sections), and stained with collagen II
anti-rabbit primary (1:200; cat. # ab34712; Abcam) following the methods described in
section 3.4.5.7. The samples were mounted in DAPI fluoroshield mounting medium and
imaged with an EVOS® FL Imaging microscope. No primary antibody controls were
included to confirm staining specificity.

3.4.9 Subcutaneous implantation of cell-assembled and preassembled DAT bead foams in an athymic mouse model
All studies followed the Canadian Council on Animal Care (CCAC) guidelines and were
reviewed and approved by the Animal Care Committee at The University of Western
Ontario (Protocol #2015-049).

3.4.9.1 DAT bead foam fabrication
Cell-assembled bead foams were fabricated as described in Sections 3.3.1 and 3.3.3.1,
using the transduced ASCs as described in section 3.3.8. To fabricate the pre-assembled
bead foams, DAT beads were produced as described in section 3.3.1 and allowed to thaw
immediately following electrospraying. Excess water was then removed, and the thawed
beads were gently transferred into cylindrical moulds (diameter = 8 mm, height = 5 mm),
frozen at -80°C, and lyophilized. The resulting pre-assembled bead foams were
decontaminated and gradually rehydrated through an ethanol series (100%, 90%, 75%,
50%, 25%, and 12.5% (v/v) diluted with sterile PBS), followed by three washes in sterile
PBS. The rehydrated scaffolds were stored at 4°C for up to 1 week. Prior to seeding, the
rehydrated bead foams were incubated overnight in complete proliferation media
(DMEM:F12 with 10% FBS, 100 U/mL penicillin and 0.1 mg/mL streptomycin). Each
DAT bead foam was seeded with 3x105 P4 transduced ASCs in 20 µL of complete medium,
to match the cell density within the cell-assembled bead foams. Following 1 h incubation,
the complete medium was topped up to 1.5 mL and the scaffolds were incubated for an
additional 24 h (2% O2 and 5% CO2, 37°C).
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To confirm that similar cell numbers were present on both types of scaffold prior to
implantation, scaffolds were rinsed in PBS (twice; 2 min), submerged into a solution of Dluciferin dissolved in PBS (1.2 mg/mL; Syd Labs Inc., Natick, MA, USA), and an IVIS
Lumina XRMS with optical-X-ray system (Perkin Elmer, Hopkinton, MA, USA) was used
to image Fluc2 enzymatic activity. BLI images were captured until a peak BLI signal was
obtained, up to 5 minutes after the start of the incubation and measured as an average
radiance (photons/second/cm2/steradian).

3.4.9.2 Subcutaneous implantation surgery
Cell-assembled and pre-assembled DAT bead foams were implanted subcutaneously in
female Crl:NU-Foxn1nu mice (nu/nu mice; Strain Code 088, Charles River, Wilmington,
MA, USA) as described in previous work [264]. Briefly, the mice were anaesthetised with
isoflurane and given subcutaneous injections of metacam (2 mg/kg loading dose; 1 mg/kg
follow up dose at 24 h; Boehhringer Ingelheim, Burlington, ON, Canada) and bupivacaine
(2 mg/kg; Aspen Pharmacare, Toronto, On, Canada). Bilateral paraspinal incisions (~1 cm)
were made on the dorsum and subcutaneous pockets were created on each flank, below the
panniculus carnosus. Two bioscaffolds were implanted per animal (one per flank;
positioning of experimental groups was randomized) and the incisions were closed with
surgical staples.

3.4.9.3 Cell tracking
BLI was performed using an IVIS Lumina XRMS In Vivo Imaging System (PerkinElmer,
Waltham, MA, USA). At postoperative days 0, 2, 4, 7, 14, 21, and 28, mice were
anesthetized with isoflurane and received a 100 µL intraperitoneal injection of D-luciferin
(30 mg/mL; Syd Labs Inc.). BLI images were captured for up to 90 minutes after injection,
measured as an average radiance and reported as a percentage normalized on data at day 0
(photons/second/cm2/steradian).

3.4.9.4 Immunohistochemical analysis of scaffold explants
The animals were sacrificed by CO2 overdose at 28 days post-implantation. The scaffolds
were carefully excised within their surrounding tissues and fixed in 10% buffered formalin
overnight at 4°C. The next morning, the explants were rinsed three times in PBS (20 min
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each) and then subjected to a sucrose gradient (10%, 20%, 30% sucrose in PBS; incubated
8 to 16 hours in each solution). Explants were then embedded in OCT and stored at -20°C
until cryo-sectioning (7 µm transverse sections).
After PBS incubation and blocking (10% goat serum and 0.2% tween diluted in TBS),
immunostaining was performed to identify murine endothelial cells (antigen: CD31,
ab28364, Abcam) in combination with localization of the transduced human ASCs using
the endogenous tdT signal. CD31 staining was performed overnight at 4°C (1:200 in
blocking solution, ab28364, Abcam). A secondary anti-rabbit antibody conjugated to
Alexa Fluor 650 (dilution 1:100, ab96902, Abcam) was used for detection and nuclei were
counter-stained using Fluoroshield mounting medium with DAPI (ab104139; Abcam).
Cross-sections at 3 different depths were imaged per sample using an EVOS FL Cell
Imaging System (Thermo Fisher Scientific). CD31 and tdT expression was quantitatively
assessed through positive pixel counting within the entire scaffold cross-section using
ImageJ, normalized to the total scaffold area (n = 2-3 scaffolds/trial, N = 2 trials with
different donors).

3.4.10

Statistical Analyses

All data were expressed as the mean ± standard deviation (SD) and analyzed by t-test or
two-way ANOVA with Tukey’s post-hoc comparison of the means. For the qPCR array
analysis, a multiple t-test analysis with a false discovery rate correction of 5% was
performed. Statistical analyses were performed using GraphPad Prism 7 (GraphPad, La
Jolla, CA, USA) and differences were considered statistically significant at P<0.05.

3.5 Results
3.5.1 DAT beads support attachment and survival of ASCs following
dynamic seeding
The electrospraying process generated beads of varying diameter, with an average diameter
of 819 ± 265 µm (Figure 3.1A). The beads were soft and compliant, with a Young’s
modulus of 0.35 ± 0.14 kPa (Figure 3.1B).
Using the established dynamic seeding regime in the spinner culture flasks, qualitative
confocal imaging showed that viable ASCs were well distributed on the surface of the DAT
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beads at 24 h after seeding (Figure 3.1C). The percentage of unadhered cells at 24 h was
low, with ~2% living and ~3% dead cells detected in the media based on the initial seeding
density (Fig. 3.1D).

Figure 3.1: Soft and compliant DAT beads supported the attachment and survival of
seeded human ASCs in a spinner culture flask system at 24 h after seeding. (A). Feret’s
diameter of the individual beads used to fabricate the foams prior to seeding (Pooled
results: n=25-28 beads/trial, N = 3 trials with different ECM suspensions). (B)
Representative force versus deformation curves for individual DAT beads prior to seeding.
Data from 3 cycles are shown with compression at a strain rate of 0.01 s-1. Young’s moduli
were calculated using nonlinear least squares curve fitting (n=6 beads/trial, N=3 trials with
different ECM suspensions). Modulus represented as mean ± SD. (C) Representative
Live/Dead® staining at 24 h after seeding showed living cells in green, with no dead cells
(red) visualized on the beads. Scale bars: 300 µm. (D) Percentage of unadhered cells at
24 h after seeding, based on the initial seeding density. (C-D) n=3 biological
replicates/trial, N=3 trials.

83

3.5.2 The use of a chemically-defined media allows for the production
of scaffolds with high cell viability
Following cell seeding, novel methods were established to synthesize robust and cohesive
cell-assembled DAT bead foams. More specifically, the process involved 3 days of static
culture within a mould, followed by 5 additional days of dynamic culture on an orbital
shaker using Prime-XV base media freshly supplemented with A2P (Prime-XV+A2P),
both with and without additional supplementation with recombinant human EGF, FGF-2,
and IGF-1 (+GF). Representative macroscopic images of the resulting cell-assembled bead
foams at day 8 are shown in Figure 3.2A. In general, the cell-assembled foams maintained
the geometry defined by the cylindrical moulds. Scaffolds produced in both media
formulations displayed excellent handling properties; however, the scaffolds generated in
the +GF condition were macroscopically more cohesive and uniform.
The number of ASCs initially seeded into the moulds (day 0) and in the final cell-assembled
bead foams (day 8) was estimated using a Picogreen® dsDNA assay (Figure 3.2B). In
general, there were significantly more cells present in the cell-assembled foams at day 8 as
compared to day 0, suggestive of cell proliferation. Further, there were significantly greater
numbers of cells in the +GF cell-assembled foams as compared to the basal PrimeXV+A2P condition. Complementary Ki-67 staining showed the presence of proliferative
cells within the constructs, with qualitatively higher densities of proliferative cells
visualized closer to the scaffold boundaries in both groups. Figure 3.2C shows the staining
patterns for the +GF condition at day 8, which was qualitatively similar to the basal PrimeXV+A2P media condition. While the cell density was qualitatively higher in the scaffold
periphery, DAPI+ cells were well-distributed throughout the cell-assembled foams.
The viable, apoptotic, and primary necrotic ASC populations within the cell-assembled
bead foams were quantified through flow cytometry analysis of annexin V and PI stained
cells isolated from the scaffolds (Figure 3.2D-E; controls available in supplemental Figure
3.1). The cells were more than 95% viable in both media formulations, and higher viability
in the basal media condition (Figure 3.2E). Although the expression of apoptotic and
primary necrotic cell markers was low under all conditions studied, the frequency of
apoptotic cell populations (as measured through positive annexin V staining) and primary
necrotic cell populations (as measured through single propidium iodide staining) quantified
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by flow cytometry was significantly higher in the +GF group, as compared to the basal
media condition (Figure 3.2E).

Figure 3.2: Cells were proliferating and were more than 95% viable within the cellassembled bead foams. (A) The cell-assembled DAT bead foams were cohesive,
structurally robust, and easy to handle, with geometries defined by the cylindrical moulds.
(B) Picogreen® dsDNA assay results showed increased cell numbers within the cellassembled bead foams from the + GF group at day 8 as compared to the basal PrimeXV+A2P medium condition at day 8 and the initial number of ASCs seeded into the moulds
at day 0. (C) Representative Ki-67 immunostaining (red) showed a qualitatively higher
distribution of proliferative cells close to the scaffold boundaries (white lines) after 8 days
of culture. Nuclei are counterstained with DAPI (blue). Scale bar: 150 µm. (D)
Representative flow cytometry plot following cell isolation and staining for annexin V and
propidium iodide at 7 days. (E) Analyzed flow cytometry results revealed high viability
(>95%) in both groups, with significantly higher viability in the basal Prime-XV+A2P
medium condition compared to the +GF group. (A-E) n=3 scaffold/trial, N=3 trials with
different cell donors; ANOVA (B) with Tukey’s post-hoc test or t-test (E); **P<0.01,
***P<0.001.
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3.5.3 The cell-assembled DAT bead foams remodel over the course
of the 8-day fabrication process
The macroscopically-enhanced stability in the cell-assembled foams fabricated in the +GF
conditions was consistent with the contraction data measurements (Figure 3.3A and B),
which showed that contraction was significantly higher in the +GF conditions as compared
to the basal Prime-XV+A2P medium. As expected, an inverse relationship was observed
between scaffold contraction and porosity, with significantly lower porosity in the +GF
condition (Figure 3.3C).
The physical differences observed between the two groups also suggested that the cell
culture conditions had an impact on scaffold remodelling. To further characterize this
remodelling, quantification of total sulphated GAG content revealed higher levels of GAG
in the cell-assembled bead foams at day 8 relative to the seeded and unseeded beads at day
0. Significant differences were also observed between the day 8 + GF and basal media
conditions, with significantly higher GAG levels in the + GF group (Figure 3.3D). Total
hydroxyproline content, indicative of the total collagen content, was similar in all of the
groups investigated (Figure 3.3E). Zymographic analysis of the proteolytic enzymatic
activity of gelatinases was also performed as an indicator of matrix remodelling (Figure
3.3F). When normalized to an MMP-2 standard, increased gelatin degradation and protease
activity was noted in the + GF condition at day 8 as compared to the basal media condition.
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Figure 3.3: The cell-assembled DAT bead foams remodelled over the course of the 8day fabrication process. (A) Representative macroscopic image of a contracted scaffold.
The green line represents the original area occupied by the beads in the mould at day 0,
while the yellow dotted line represents the contracted scaffolds after 8 days of culture. The
inner diameter of the silicone ring forming the mould measures 8 mm. (B) Contraction
measurements at day 8 showed enhanced contraction in the + GF culture condition (n=1518 replicates per donor, N=3 donor). (C) Porosity results obtained using a modified
Archimedes’ method showed a significant reduction in porosity in the day 8 + GF condition
compared to all other conditions (n=3 replicates per donor, N=3 donor). (D) DMMB assay
showing significantly higher levels of sulphated glycosaminoglycans in the day 8 + GF
condition as compared to all other groups. (E) Total hydroxyproline content as a measure
of the total collagen content showing no significant differences between the groups. (F)
Densitometry analysis of gelatinase enzymatic activity, relative to MMP-2 standards,
displayed increased activity in the day 8 +GF group. (B-F) n=3 scaffolds/trial, N=3 trials
with different cell donors; t-test (B-F) or ANOVA (C-D-E) with Tukey’s post-hoc test;
**P<0.01, ***P<0.001.
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3.5.4 The cell-assembly process is mediated by new ECM synthesis
To gain insight into the mechanisms of the cell-assembly process, immunohistochemical
staining for type I collagen and fibronectin were performed on scaffold cross-sections. As
shown in Figure 3.4, newly synthesized type I collagen and fibronectin (both in red; Figure
3.4) were localized in the cell-dense regions between the beads (blue, pre-labelled with
Alexa Fluor 350® succinimidyl ester; Figure 3.4), suggesting that the ASCs were actively
secreting ECM that functioned to fuse the beads together.

3.5.5 The culture conditions modulated ASC gene and protein
expression within the cell-assembled bead foams
An RT-qPCR array was performed to investigate the expression of genes associated with
ECM synthesis and remodelling, angiogenesis and inflammation in the human ASCs
within the cell-assembled bead foams after 8 days of culture (Figure 3.5). Consistent with
the previous results, the majority of the markers for ECM synthesis and remodelling
showed increased mRNA levels in the +GF condition as compared to the basal PrimeXV+A2P medium group. The levels of gene expression of the proteoglycans biglycan
(BGN), decorin (DCN), and versican (VCAN) were significantly upregulated in the +GF
samples, consistent with the enhanced total sulphated GAG content in this group (Figure
3.3). mRNA levels of the ECM synthesis and remodelling genes smooth muscle actin alpha
2 (ACTA2), collagen type I alpha 1 chain (COL1A1), collagen type III alpha 1 chain
(COL3A1), connective tissue growth factor (CTGF), and matrix metalloproteinase 1 and 2
(MMP1 and MMP2, respectively) were significantly increased in the +GF samples,
consistent with the enhanced MMP activity, enhanced scaffold contraction, and ECM
synthesis observed (Figures 3.3 and 3.4). The modulation of the angiogenic markers was
more complex, with increased levels of IGF1 and VEGFA, along with decreased levels of
FGF2 and SERPINE1, in the +GF group. Interestingly, a trend for enhanced expression of
genes associated with the immunodulatory functionality of ASCs was observed in the +GF
group, although the differences were only statistically significant for colony stimulating
factor 2 (CSF2), which could potentially be due to cell donor variability.
Expression of a selected set of pro-angiogenic factors at the protein level was also
investigated using a Luminex® magnetic bead assay to probe bead and bead foam lysates,
at day 0 and day 8 respectively. (Figure 3.6). For the four pro-angiogenic factors
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investigated, angiopoietin-1, CXCL12, HGF, and VEGF, the protein levels were increased
in both groups at day 8 when compared to freshly-seeded beads at day 0. Consistent with
the RT-qPCR array findings, varying patterns of expression were observed between the
two experimental groups at day 8. More specifically, a significant decrease in CXCL12
levels and a significant increase in VEGF levels were observed in the +GF group relative
to the basal media conditions, with no differences observed in the relative expression levels
of angiopoietin-1 (ANGPT1) or HGF between the groups. Overall, the findings suggest
that preconditioning with the growth factors did not substantially alter the expression of
the investigated pro-angiogenic factors in the ASCs within the cell-assembled bead foams.

3.5.6 Human ASCs co-expressing Fluc2 and tdT maintain their
trilineage differentiation capacity
To enable in vivo cell tracking, the scaffolds were prepared with human ASCs that had
been transduced with lentiviral vectors to constitutively express Fluc2 and tdT prior to in
vivo experimentation. To confirm that the transduction process did not alter the capacity of
the ASCs to differentiate towards the chondrogenic, adipogenic, and osteogenic lineages,
trilineage differentiation assays were performed. For all three lineages, the cells were
confirmed to retain their capacity to differentiate based on characteristic marker expression
(Supplementary Figure 3.2).
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Figure 3.4: Cell-assembly was mediated through ECM synthesis. (A) Representative
scaffold cross-section showed abundant expression of newly-synthesized collagen type I
and fibronectin in the cell dense region (nuclei shown in green) between two DAT beads
in the cell-assembled bead foams after 8 days of culture. The DAT beads were pre-labelled
with an Alexa Fluor 350® succinimidyl ester, to distinguish the newly-synthesized COL I
and FN (red) from the pre-existing ECM in the DAT (blue). (B) Picrosirius red staining
showed interconnected networks of collagen fibers of varying sizes in both groups. Scale
bar = 200 µm. Abbreviation: COL I = collagen type 1, FN = fibronectin.
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Figure 3.5: ECM-associated gene expression was modulated by growth factor
preconditioning in ASCs within the cell-assembled bead foams. Gene array results
represented as a Log2 of the fold change of +GF condition over the basal media condition,
where positive values represent higher mRNA levels in the + GF group and negative values
represent higher mRNA levels in the basal group. mRNA levels of most of the genes
associated with ECM synthesis and remodelling, including proteoglycans, were
significantly increased in the +GF condition. Four genes associated with angiogenesis were
also significantly modulated, with varying patterns between the experimental groups.
Globally, inflammatory gene markers appeared to increase in the +GF group, although the
difference was only significant for CSF2. n=3 scaffolds pooled/trial, N=3 trials with
different cell donors; multiple t-test analysis with a false discovery rate correction of 5%;
*P<0.05, **P<0.01, ***P<0.001.
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Figure 3.6: The cell-assembly fabrication process increased the expression of proangiogenic proteins by the ASCs, compared to freshly-seeded beads. Protein levels of
(A) ANGPT1, (B) CXCL12, (C) HGF, and (D) VEGF were quantified in bead and bead
foam lysates using a Luminex® magnetic bead assay at day 0 (24 hours after seeding) and
day 8. Results are reported relative to the total protein content. Significantly lower levels
of CXCL12 and higher levels of VEGF were observed in the day 8 +GF group compared
to the basal media condition. Abbreviations: ANGPT1= angiopoietin-1, CXCL12=
chemokine with C-X-C motif ligand 12, HGF= hepatocyte growth factor, VEGF= vascular
endothelial growth factor. n=3 scaffolds/trial, N=3 trials with different cell donors; oneway ANOVA with Tukey’s post-hoc test; *P<0.05.
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3.5.7 The cell-assembled bead foams show enhanced detection of
viable ASCs at early timepoints and greater murine CD31+ cell
recruitment at 28 days
The cell-assembled bead foams fabricated using the +GF condition were selected for
further analysis in vivo due to their improved stability and handling properties, as well their
enhanced cell density relative to the scaffolds fabricated in the basal Prime-XV+A2P media
conditions. In vivo ASC retention and murine CD31+ cell recruitment were compared
relative to ASCs statically seeded at the same density on our previously-established preassembled DAT bead foam platform [14, 264] in a subcutaneous implant model in athymic
nude mice. Transduced ASCs were used in this study to enable long-term in vivo cell
tracking through BLI imaging using a luciferase reporter, as well as ASC localization
within tissue cross-sections using the tdT reporter. Based on analysis of tdT expression by
flow cytometry, the average transduction efficiency was ~ 74.7 ± 5.2% at passage 3 and ~
75.5 ± 4.4% at passage 4 when seeded on scaffolds. BLI measurements of both type of
scaffold were performed in vitro and showed similar number of viable cells at day 0 prior
to implantation (Supplementary Figure 3.3A and B).
The BLI results showed an increase in signal in the cell-assembled bead foams at day 2
compared to day 0, suggesting there may be enhanced delivery of the luciferin or
potentially an increase in live cell numbers in this group in the early phase following
implantation (Figure 3.7A). When comparing the two scaffold groups together, the BLI
results indicated that the number of viable ASCs was significantly higher in the cellassembled bead foam group at day 2. While the trend for enhanced detection of viable
ASCs in the cell-assembled bead foams continued at days 4 and 7, variability was observed
and the difference between the groups was not statistically significant. Data from the later
timepoints suggested that both platforms contained similar numbers of viable ASCs, which
was corroborated by tdT+ cell counts within tissue cross-sections from the implants
collected at 28 days (Fig. 3.7B and C). Overall, both platforms were effective at supporting
the localization of viable ASCs within the implant site over the 4-week study.
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Figure 3.7: Early human ASC retention, as well as murine CD31+ cell recruitment at
28 days, was enhanced within the cell-assembled (CA) DAT bead foams as compared
to ASCs seeded and delivered on pre-assembled (PA) DAT bead foams. (A)
Representative macroscopic and bioluminescence images (superposed) from a mouse with
cell-assembled (left) and pre-assembled (right) implants at day 0, 2, 4, 7, and 28. Scale bars
= 1 cm. (B) Relative bioluminescence intensity levels, expressed as a percentage of the
levels at day 0, suggesting that early cell retention was enhanced in the cell-assembled bead
foams. (C) Representative CD31 immunostaining (green) and tdT endogenous signal (red)
in explanted scaffolds at day 28, showing qualitatively enhanced CD31+ cell infiltration in
the cell-assembled bead foams (top) compared to the pre-assembled bead foams (bottom)
at 28 days post-implantation. Nuclei were counter-stained with DAPI (blue), and the white
dotted lines denote the scaffold periphery. Scale bars = 400 µm. (D) Quantification of tdT+
structures on cryo-sections indicating both that both groups show similar human ASC
retention at day 28. (E) Quantification of CD31+ structures on cryo-sections suggesting that
angiogenesis was enhanced in the cell-assembled bead foam group at day 28.
Abbreviations: CA = cell-assembled bead foams, PA = pre-assembled bead foams. n=2-3
scaffolds/trial, N=2 trials with different cell donors; two-way ANOVA with Tukey’s posthoc test (B) or t-tests (D-E); **P<0.01.
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Macroscopic observation of the explants showed that all scaffold integrated within the host
tissues (Supplementary Figure 3.3C). Immunohistochemical analysis of the implants also
revealed the presence of murine CD31+ cells distributed heterogeneously at the scaffoldtissue interface in both groups, with CD31+ structure counts indicating that there were more
CD31+ cells in the cell-assembled bead foams (Figure 3.7B and D), suggesting there was
enhanced angiogenesis within this implant group.

3.6 Discussion
While DAT can be applied in its intact form as a 3-D cell-instructive scaffold for adipose
tissue engineering applications [104], DAT can also be further processed to incorporate the
complex ECM composition within alternative formats that may offer greater flexibility in
terms of other scaffold properties [13, 14, 119, 131, 134-136, 264]. Numerous studies have
reported on the pro-adipogenic effects of a wide variety of DAT-based bioscaffolds both
in vitro and in vivo [13, 14, 119, 131, 134-136, 264], which support the use of DAT as a
platform for soft tissue regeneration in plastic and reconstructive surgery. Of note, our
previous findings also indicate that our pre-assembled DAT bead foams promoted cell
survival and angiogenic marker expression in human dermal fibroblasts, which would be
favorable for enhancing implant integration and remodelling into host-derived soft tissues
[264]. In the current study, we sought to harness these benefits in the design of novel
scaffolds that were more structurally robust and compatible with maturation under dynamic
culture conditions [135], in order to achieve a high density of viable cells with proangiogenic functionality that were well distributed throughout the scaffolds.
The soft and compliant DAT beads, which had an average Young’s modulus in the range
of human skin (0.1 kPa to 10 kPa [251]), readily supported ASC attachment and survival
under the established seeding regime [135]. In developing the new cell-assembly process,
the culture conditions were selected to promote ASC expansion, as well as ECM synthesis
and remodelling. By using our novel approach, it was possible to fabricate robust ~3-mm
thick cell-assembled DAT bead foams containing an average of 3 x 105 ASCs within a total
culture period of 9 days. Despite the thickness of the scaffolds, ASC viability was high
(>95%) in all conditions. Notably, ASCs have been shown to be highly tolerant of hypoxic
and ischemic microenvironments in vitro and in vivo [175, 274], and have been reported to
adopt a more pronounced pro-angiogenic [215, 216] and pro-immunomodulatory
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phenotype [275] in environments with oxygen tension below 5%. This resilience and
adaptability to hypoxia, along with their ability to secrete pro-angiogenic molecules [276,
277], makes ASCs a highly promising cell source for promoting the vascularization of
biomaterial implants.
We selected the Prime-XV® MSC EXPANSION XSFM as our basal media, based on
previous observations in our lab that it promoted both ASC expansion and matrix
deposition. Further, the cell-assembly approach exploited the recognized ability of ASCs
to synthesize ECM upon stimulation with A2P in vitro [271, 272], with the cells forming
new ECM enriched in collagen type I [278], fibronectin [278], and sulphated
glycosaminoglycans [279] that functioned to fuse the beads together to create the cellassembled bead foams. Interestingly, supplementation with recombinant human EGF,
FGF-2, and IGF-1 was shown to be advantageous, resulting in an increased cell number
and improved scaffold cohesion. Results indicated that the modular assembly was mediated
by the presence of newly synthesized ECM, along with ECM remodelling, within the cellassembled bead foams. Overall, these findings are in line with previous studies
investigating the effects of these three growth factors. For example, all three growth factors
have been reported to have cytoprotective and proliferative effects on MSCs [218, 219,
224-226, 268]. In addition, EGF and IGF-1 treatments have both been previously shown
to increase the secretion of MMPs by ASCs [226, 268]. Further, EGF treatments were also
shown to stimulate the secretion of proteoglycans such as decorin and endocan, as well as
other proteins associated with ECM synthesis and remodelling including connective tissue
growth factor (CTGF) and tissue inhibitors of matrix metalloproteinases (TIMPs) [268].
Moreover, FGF-2 preconditioning has been indicated to stimulate a pro-fibrotic phenotype
in MSCs, which is consistent with the increased ECM secretion and remodelling observed
in the +GF group [218, 225].
The qualitatively enhanced integrity of the scaffolds fabricated in the +GF conditions was
consistent with the increased contraction and decreased porosity observed in this group
compared to the basal media conditions. These physical changes may have impeded the
diffusion of nutrients into, as well as the removal of waste from, the central regions of the
scaffolds, which could in turn explain the slightly reduced viability in the +GF condition.
However, accounting for these differences in viability, a significantly higher number of
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viable cells were present in the cell-assembled bead foams when the growth factor
preconditioning strategy was applied (~1.8-fold increase). Further, the in vivo results
support that the contracted scaffolds did not function as a barrier for cell migration, but
integrated well into the host tissues and supported the infiltration of host endothelial cells
required for implant vascularization.
The angiogenic gene and protein expression data supported that the ASCs secreted a range
of pro-angiogenic growth factors on the cell-assembled bead foams, regardless of whether
the scaffolds were fabricated in the +GF or basal media conditions. This data reveals that,
while there is variation in expression between the groups, there is no clear evidence that
the +GF preconditioning had a benefit in terms of modulating the expression of the proangiogenic factors that were assessed in the current study. Interestingly, there was a clear
trend towards the enhanced expression of immunomodulatory genes in the +GF conditions,
although the differences were only significant for the CSF2 gene, which could potentially
be due to cell donor variability. There is a growing body of evidence that
immunomodulation is an important mechanism of regeneration in ASC-based therapies
[126, 209, 275]. As such, it would be interesting to further probe these factors at both the
gene and protein levels in future studies incorporating a larger number of donors.
To date, the vast majority of studies evaluating biomaterial-based cell delivery strategies
in preclinical models have relied on endpoint histological evaluations to assess cell
retention. Popular approaches include the use of human-specific markers [249, 264] or cell
tracker dyes that necessitate pre-labelling prior to implantation [280]. Limitations of these
approaches include their inability to specifically identify viable cells, they do not allow for
longitudinal tracking, and they require a large number of animals to perform long-term
assessments [249, 264]. Further, they require the analysis of several cross-sections, which
can introduce substantial variability in the analysis due to variability of the cell distribution
across the depth of the scaffolds [249, 264]. Lipophilic membrane stains have been widely
used, but the signal diminishes as the cells divide and results can be confounded by
macrophage-mediated phagocytosis of the cells, as well as dye release and uptake by other
cell populations [280].
Addressing many of these limitations, non-invasive cell tracking technologies using
engineered cells represent an exciting alternative approach to enable long-term in vivo
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tracking of viable cell populations, and are therefore an extremely valuable tool in
comparing the efficacy of various biomaterial delivery platforms. In the present study,
human ASCs were transduced to co-express Fluc2 and tdT reporters in order to perform
longitudinal in vivo cell tracking studies using BLI imaging, as well as endpoint ASC
localization within tissue cross-sections [270]. Interestingly, data from the present study
suggests that the seeded ASCs remained within the bioscaffold area throughout the
duration of the study, based on both BLI cell tracking and endpoint histological analyses.
These results are in contrast with a previous study in which transduced human ASCs were
delivered subcutaneously within a fibrin gel, showing broad distribution after implantation
and up to 19 days post-procedure, with signals coming from the liver and, to a lesser extent,
the lungs [281]. Transduced human ASCs delivered intramuscularly in PBS into the
hindlimbs in BALB/c nude mice were also shown to have a small subset of cells migrating
out of the injection site and distributing throughout the body, with an estimated 10% of the
cells remaining 4 weeks after injection and stabilizing up to 32 weeks [282]. Other studies
where transduced human ASCs were delivered downstream of femoral artery excisions in
a hindlimb ischemia model [283] and in the peri-infarct region of a murine model of
myocardial infarction [284] revealed an estimated cell retention of 5% at day 28 and 40%
at 2 weeks, respectively. While varying models have been explored, the findings in the
current study suggest that the DAT-derived bead foams provide a cell-supportive platform
for localized ASC delivery within the subcutaneous space.
While providing interesting insights on the biodistribution of the ASCs over the course of
the study, it is important to note that there are challenges associated with the dependence
of BLI imaging on the delivery of the substrate and local oxygen concentration for imaging
[285]. Although these two variables can impact the BLI readings, it has been shown that
BLI can be applied effectively as an imaging modality in poorly vascularized areas, such
as downstream of a femoral artery ligation, where blood perfusion can be reduced to < 15%
of that in control limbs [283]. In the present study, the dependence on substrate and oxygen
delivery may have affected the cell numbers detected, particularly at the earlier time points,
due to the challenges in delivering the luciferin to the innermost portions of the implants,
particularly after the local vascular network may have been disrupted by the implantation
surgery. Regardless, BLI provides a useful tool to monitor the relative number of cells
detected within the implants over time and compare the values between our two platforms
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[285]. Further, it would be expected that this modulation in signal intensity would decrease
over time, as the implants became more vascularized and improved the delivery of the
substrate and oxygen.
The in vivo data showed an enhanced detection of viable ASCs in the cell-assembled bead
foams relative to the pre-assembled bead foams at early timepoints, but this difference
diminished over time. In addition, the IHC analysis of CD31+ structures as a marker of
murine endothelial cell infiltration within the implants suggested there was increased
angiogenesis in the cell-assembled bead foams. Knowing that the starting cell numbers
were similar in both groups, these findings suggest that differences in early cell retention
or alternatively in the composition and/or structure of the platforms may have impacted the
angiogenic response. For example, the high concentration of sulphated GAGs detected in
the cell-assembled bead foams may have contributed to the pro-angiogenic properties of
these scaffolds, as GAGs are known to bind and sequester growth factors, and can also
interact directly with endothelial cells through α5 and αv integrin interactions to modulate
cellular processes involved in blood vessel development [33, 256]. The differences
between the groups may also be attributed in part to the extended culture protocol
employed in synthesizing the cell-assembled bead foams, which may have modulated the
ASC phenotype and/or promoted the accumulation of beneficial paracrine factors within
the scaffolds. However, further studies comparing the cell-assembled versus pre-assembled
bead foams would be required to more fully assess the potential influence of these factors.
Regardless of the mechanisms, the data suggests that both platforms are favorable for
supporting the localized delivery and retention of viable ASCs over 28 days, with the cellassembled bead foams showing advantages in term of implant vascularization. The
development of a stable vascular network is particularly important in the context of soft
tissue engineering applications, where the need for new strategies to augment angiogenesis
is recognized [74, 79]. Research in this field aims to develop tissue-engineered constructs
with an intrinsic potential for therapeutic angiogenesis, as a means to avoid the failure of
constructs due to poor vascularization resulting in associated cell death [74, 79]. Overall,
the novel cell-assembled bead foams represent a promising bioscaffold format for ASC
delivery in strategies to promote localized angiogenesis and soft tissue regeneration.
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3.7 Conclusions
The cell-assembled DAT bead foams developed in the current study are a promising cell
delivery approach for applications in soft tissue regeneration. The scaffolds fabricated with
our novel methods were structurally robust and easy to handle, which would be favorable
for clinical applications. Detailed in vitro studies confirmed that the cell-assembly process
was mediated by the production of new ECM by the ASCs, enriched in collagen type I,
fibronectin, and sulphated GAGs, which functioned to fuse the DAT beads into a cohesive
3-D network that held the shape of the fabrication mould. Notably, despite the thickness
(~3 mm) of the constructs, cell viability remained high (>95%) after 8 days in culture, and
the cell-assembled bead foams were shown to contain a well-distributed population of
ASCs that secreted pro-regenerative paracrine factors. In vivo analysis confirmed the
capacity of the DAT bead foams to support long-term viable ASC retention following
subcutaneous implantation in a nu/nu mouse model, with an enhanced angiogenic response
observed within the implant region with the new cell-assembled bead foams relative to
when the ASCs were seeded and delivered on pre-assembled DAT foams. Overall, the cellassembled DAT bead foams represent a promising pro-angiogenic MSC delivery platform
for applications in soft tissue-engineering and therapeutic angiogenesis. Future work could
assess the pro-regenerative effects of the cell-assembled bead foams in preclinical models
of impaired wound healing or further explore the potential of these scaffolds for adipose
tissue engineering by analyzing the response at later time points. In addition, the novel cellassembly methods could be extended to other MSC populations and/or co-culture models,
and the effects of varying the ECM source could also be explored to generate a diverse
range of engineered tissues.
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Chapter 4

4

The effects of matrix composition on the adipogenic
differentiation of human adipose-derived stromal cells in
cell-assembled matrix-derived bead foams

4.1 Co-authorship statement
The work presented in Chapter 4 was conceptualized in collaboration with Dr. Lauren
Flynn. I personally designed and performed all of the experimental studies described in the
Chapter, with technical support from:
•

Ms. Courtney Brooks who helped to optimize the qPCR conditions (Figure 4.4C).

I analyzed all the data in collaboration with Dr. Flynn. I made all the figures. The
manuscript was written in collaboration with Dr. Lauren Flynn.
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4.2 Abstract
The extracellular matrix (ECM) of connective tissues is a three-dimensional environment
that plays critical roles in mediating cellular behavior and cell fate. As such, it has been
postulated that tissue-specific scaffolds derived from the ECM can mediate cell growth and
direct stem cell differentiation. However, many studies to date do not include derived from
non-tissue-specific ECM sources, making it challenging to interpret whether any observed
effects are in fact tissue-specific. Building from the work in the previous chapter, the novel
cell-assembly methods established with decellularized adipose tissue (DAT) were
extended to fabricate tissue-specific cell-assembled bead foams derived from other
compositionally distinct ECM sources. More specifically, decellularized trabecular bone
(DTB) and purified collagen type I (COL) were selected to show the versatility of the
approach with other decellularized tissues and commercially-sourced alternatives. The
DAT, DTB, and COL beads used to make the foams had similar structural and
biomechanical properties. Preliminary cell culture studies with human adipose-derived
stromal cells (ASCs) confirmed that stable foams could be generated with all ECM sources
using the cell-assembly approach. Analysis of adipogenic differentiation showed increased
glycerol-3-phosphate dehydrogenase enzyme activity and adipogenic gene expression in
the DAT- and COL-derived bead foams compared to the DTB-derived bead foams and
tissue culture polystyrene controls. In addition, visualization of intracellular lipid through
Bodipy® staining revealed differentiating adipocytes in the DAT- and COL-derived bead
foams, but not in the DTB-derived group, suggesting that the bone-derived ECM may have
inhibitory effects on ASC adipogenesis. Overall, the current study established that the cellassembly approach using human ASCs can be used to generate robust three-dimensional
scaffolds from a variety of ECM sources that may be useful as platforms for exploring the
effects of ECM composition on stem cell differentiation.
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4.3 Introduction
Comprised of a complex three-dimensional (3-D) network of proteins, glycoproteins, and
polysaccharides, the extracellular matrix (ECM) can mediate cell function through its
structural, biomechanical, and biochemical properties [16]. These properties vary from one
connective tissue to another, with physical properties ranging from soft and compliant
tissues, such as adipose tissue [113], to hard and stiff tissues, such as bone [286]. The
biochemical composition of the ECM is also specific to each tissue, with
immunohistological analysis showing that adipose tissue is an abundant source of collagen
types I, IV, V, and VI, fibronectin, and laminin [60, 61]. In contrast, similar analysis of the
organic phase of osseous tissue demonstrated that it is primarily comprised of collagen
types I, III, IV, V, and XII, as well as fibronectin, glycosaminoglycans (GAGs), and
specialized matricellular proteins, including osteocalcin (also known as bone gammacarboxyglutamic acid-containing protein; BGLAP), osteonectin (also known as secreted
protein acidic and rich in cysteine; SPARC), osteopontin (also known as secreted
phosphoprotein 1; SPP1), and bone sialoproteins [65, 68, 69].
Due to the critical role of the ECM in mediating cellular functions, there has been
increasing interest in the development of ECM-derived bioscaffolds for applications in
tissue engineering and regenerative medicine. By removing immunogenic components
from tissues (e.g. cells, intracellular organelles, and DNA), while preserving the structure
and composition of the native ECM as much as possible, decellularization techniques have
emerged as promising methods to obtain tissue-specific ECM [93, 94]. In recent proteomic
analyses using high throughput mass spectrometry-based approaches to compare the
composition of human decellularized adipose tissue (DAT) and human decellularized
trabecular bone (DTB), it was shown that DAT incorporated higher levels of factors
associated with adipogenesis, including fibroblast growth factors, chemokine (C-X-C
motif) ligand 14 (CXCL14), and Wnt-11 [62], while DTB was enriched in factors
associated with osteogenesis, including BMPs, insulin-like growth factor 2 (IGF-2), and
TGF-β [62].
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Based on these compositional differences, it has been widely postulated that tissue-specific
ECM can be harnessed to promote the lineage-specific differentiation of stem and
progenitor cell populations. For example, decellularized adipose tissue was shown to have
(i) “adipo-inductive” and (ii)“adipo-conductive” properties on human adipose-derived
stromal cells (ASCs), in both intact and further processed bioscaffold formats [14, 71, 104,
135]. These properties can be respectively described as (i) promoting adipogenesis in a
microenvironment not typically supportive of adipocyte differentiation, and (ii) enhancing
adipogenesis under adipogenic differentiation conditions. Similarly, DTB and DTBderived biomaterials have been shown to have “osteo-inductive” and “osteo-conductive”
effects on ASCs and other mesenchymal stromal cell (MSC) populations, such as bone
marrow-derived mesenchymal stromal cells (BMSCs) [287].
When studying the inductive and conductive effects of a novel biomaterial, it is often
difficult to identify the specific biomaterial properties that mediate cell fate and function.
Multiple characteristics of ECM-derived scaffolds can influence cellular responses,
including their structural, biomechanical, and biochemical properties. In particular,
biomechanical properties have frequently been reported to impact the adipogenic and
osteogenic cell differentiation balance in vitro [89, 90]. In studies with human MSCs and
dermal fibroblasts, stiffer substrates were shown to stimulate differentiation towards the
osteogenic lineages, while softer ones promoted differentiation towards the adipogenic
lineage [89, 90]. Studies exploring the role of ECM composition often rely on comparisons
to cell monolayers cultured on two-dimensional (2-D) surface coatings to draw their
conclusions. However, it is widely recognized that cell behavior varies substantially in 2D and 3-D systems [288] and these simplified 2-D models typically have highly different
characteristics as compared to the biomaterials under investigation, which can profoundly
impact the cellular response [87, 289].
With the goal of establishing robust platforms for exploring the effects of tissue-specific
ECM composition on ASC differentiation, the cell-assembly methods established with the
DAT in the previous chapter were extended to synthesize structurally-similar 3-D cellassembled bead foams from compositionally distinct ECM sources. Due to the inverse
relationship between adipogenesis and osteogenesis in MSCs [89, 90], DAT and DTB were
selected as the primary ECM sources of interest. An additional compositional control of
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purified collagen type I (COL) was included in the study to show the versatility of the
fabrication approach with a commercially-available matrix source, as well as to broaden
the analysis of the effects of the tissue-specific ECM composition. Following the validation
of the fabrication methods for the new ECM sources, preliminary studies were conducted
to probe the effects of ECM composition on the adipogenic differentiation of human ASCs
within the cell-assembled DAT-, DTB- and COL-derived bead foam platforms.

4.4 Materials and methods
4.4.1 Decellularization of human adipose tissue
Human subcutaneous adipose tissue was obtained and processed as described in section
3.4.1.

4.4.2 Decellularization of bovine trabecular bone
Decellularization of trabecular bone was conducted following a 3-day decellularization
protocol previously developed in the Flynn lab [290]. First, bovine trabecular bone was
obtained from fused intervertebral discs in the tail region of 30-month old cows obtained
from the Mount Brydges Abattoir, using a chisel and mallet, and cut into pieces (~ 2 mm
x 2 mm x 2 mm). All the subsequent steps were performed at a reagent versus tissue ratio
of 25 mL/g of tissue and all the decellularization solutions were supplemented with 1%
antibiotic-antimycotic solution (Gibco, Burlington, ON, Canada) and 1% PMSF, with the
exception of the enzymatic treatment steps where the PMSF was excluded. The bone
fragments were rinsed in PBS for 20 min to remove blood, and then transferred into a
hypotonic cell lysing solution (Solution A) comprised of 10 mM Tris and 5 mM EDTA.
The tissue was then subjected to 3 freeze-thaw cycles (from -80°C to 37°C), with
replacement of Solution A between each cycle. During the thawing step, the samples were
agitated at 200 rpm to facilitate perfusion of the solution within the tissue. Following the
freeze-thaw steps, decalcification of the tissue was performed by incubation in Formical
2000 (StatLab, Texas) at room temperature, 300 rpm, for 8 h. The processed bone was then
incubated in 100% isopropanol overnight (200 rpm, 37°C). The next day, tissues were
rinsed in Sorensen’s phosphate buffer rinse solution (SPB rinse solution; 8 g/L NaCl,
200 mg/L KCl, 1g/L Na2HPO4, and 200 mg/L KH2PO4 (pH 8.0)) three times, 30 min each,
at room temperature. Sorensen’s phosphate buffer digest solution (SPB digest solution;
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55 mM Na2HPO4, 17 mM KH2PO4, 4.9 mM MgSO4.7H2O) supplemented with 12.5 mg
RNase Type III (from bovine pancreas), 15,000 U DNase Type II (from bovine pancreas)
and 2,000 U Lipase type VI-S (from porcine pancreas) was then used to enzymatically
digest the tissues (200 rpm, 37°C, overnight). The last day, the DTB was obtained
following 3 additional rinses in the SPB rinse solution (30 min each, room temperature,
200 rpm), followed by two 30 min rinses in distilled H2O, freezing at -80°C, and
lyophilization.

4.4.3 Electrospraying of ECM suspensions
Lyophilized ECM samples, including type I bovine collagen (cat#5164, Advanced
Biomatrix, San Diego, CA, USA) were finely minced, suspended into 0.2 M acetic acid,
and homogenized (PowerGen Model 125 homogenizer, Fisher Scientific, Ottawa, ON,
Canada). The homogenized suspensions were diluted with deionized water to obtain a final
ECM concentration of 20 mg ECM/mL (dry weight). To increase the stability of the DTB
suspension, a small proportion of COL was added as a stabilizer, resulting in a final ECM
concentration of 20 mg ECM/mL (comprised of 17 mg/mL of DTB and 3 mg/mL of COL;
dry weight). Electrospraying was then conducted as described in section 3.3.1 for the DAT
and DTB suspensions, using of a 21G needle in place of a 25G needle for the DTB
suspension, to prevent clogging attributed to the presence of some larger ECM particles
that were more difficult to homogenize in this group. For the pure COL suspension, the
applied voltage used was increased to 18-19 kV (as compared to 16-18 kV), with a lower
extrusion speed of 30 mL/h (rather than 35 mL/h) to account for increased solution
viscosity.
Following synthesis, ECM-derived beads were decontaminated and rehydrated through an
ethanol series (100%, 99%, 98%, 95%, 90%, 80%, 70%, 50, 25%, and 12.5% (v/v) diluted
with sterile PBS), followed by three washes in sterile PBS. The rehydrated beads were
stored at 4°C before being used in the characterization and cell culture studies.

4.4.4 Human ASC isolation, expansion, and characterization
Collected human adipose tissue was processed within 2 h for ASC isolation following
published protocols [12]. Isolated ASCs were cultured on tissue culture polystyrene
(TCPS; Corning, NY, USA) at 37°C, 5% CO2 in proliferation medium comprised of
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DMEM:Ham’s F12 (Wisent Bio Products, Montreal, QC) supplemented with 10% fetal
bovine serum (FBS; Wisent Bio Products), 100 U/mL penicillin and 0.1 mg/mL
streptomycin (Wisent Bio Products). Media was changed every 2-3 days. Cells were frozen
at passage 0, stored in liquid nitrogen, and thawed when needed.

4.4.5 Physical and biochemical characterization of the individual
ECM-derived beads
4.4.5.1 Bead diameter
Hydrated DAT, COL, and DTB beads were imaged under a light microscope at low
magnification. The Feret’s diameter function on ImageJ (NIH, http://imagej.nih.gov/) was
then used to measure the largest diameter of the beads (N= 2-3 batch per conditions, n= 25
to 35 biological replicates per batch).

4.4.5.2 Mechanical Testing
The mechanical properties of individual ECM-derived beads were assessed using a
CellScale MicroTester system (Waterloo, ON, Canada). Testing of individual beads was
performed in a PBS bath at 37°C, using a 203 µm diameter cantilever attached to a square
platen (2 mm x 2 mm), and the beads were compressed to 50% deformation for 3
preconditioning cycles at a strain rate of 0.01 s-1 (1 cycle = 45 s compression, 1 s hold, 45
s recovery). The data was collected from 3 consecutive cycles and the Young's moduli were
calculated using nonlinear least squares curve fitting with a published extended mechanics
model for large elastic deformations of spherical microparticles [245] (N=2-3 batches per
condition; n=6 beads/batch).

4.4.5.1 Porosity measurement
Samples of the rehydrated beads were lyophilized and weighed. After recording their dry
mass, the scaffolds were immersed in 100% isopropanol overnight under light vacuum with
gentle agitation to minimize the formation of air bubbles. Excess isopropanol was then
removed through gentle blotting and the wet mass of the scaffold was recorded. Porosity
was calculated using a modified Archimedes’ method [246].
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4.4.5.2 Scanning electron microscopy (SEM)
The ultrastructure of the DAT, COL and DTB beads was visualized by scanning electron
microscopy (SEM) using published protocols [135]. Briefly, hydrated scaffolds were
lyophilized and coated with osmium prior to imaging with a LEO 1530 scanning electron
microscope at an accelerating voltage of 1 kV and working distance of 4 to 5 mm.

4.4.5.3 Picrosirius red staining
Following rehydration, the ECM-derived beads were embedded in OCT and sectioned into
7-µm thick cryo-sections. Picrosirius red staining was performed, and stained bead crosssections were visualized under circularly polarized light using a Nikon Optiphot
microscope (Nikon, Mississauga, ON, Canada). Images were captured with an Infinity 23 CCD camera (Lumenera, Ottawa, Canada).

4.4.6 Production of cell-assembled DAT, COL, and DTB bead foams
Rehydrated DAT, DTB or COL beads were seeded as described in section 3.4.3.1 and
scaffold assembly was performed as described in section 3.4.3.2.

4.4.7 In vitro adipogenic assessment
4.4.7.1 Adipogenic differentiation
Induction towards the adipogenic lineage was conducted following the 8-day cell-assembly
protocol using an adipogenic induction medium comprised of DMEM/F12 supplemented
with 33 mM biotin, 17 mM pantothenate, 10 mg/mL transferrin, 100 nM hydrocortisone,
66 nM human insulin, 1 nM triiodothyronine, and 1% pen-strep, with 0.25 mM
isobutylmethylxanthine (IBMX), and 1 mg/mL troglitazone supplemented for the first 3
days only. Characterization of ASC differentiation within each ECM-derived scaffold was
performed after 14 days of induction. Induced TCPS controls cultured in the differentiation
media for 14 days and non-induced TCPS controls cultured in proliferation media were
included in the studies.
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4.4.7.2 Adipogenic Gene Expression
Total cellular RNA was isolated from the various ECM-derived cell-assembled bead foams
and TCPS results at 0 and 14 days post-induction, as described in section 3.3.6. cDNA was
then synthesized from 1 µg of input RNA using the iScript™ Reverse Transcription
Supermix kit (Bio-Rad; Cat. # 1708840) according to the manufacturer's protocol.
Amplifications were carried out in a CFX384 Touch™ Real-Time PCR Detection System
(Bio-Rad) using SsoAdvanced Universal SYBR Green Supermix (Bio-Rad; 10 ng of
cDNA/well) as follows: initial incubation at 95°C for 2 min, followed by 40 cycles of 95°C
for 5 s and 58.5°C for 30 s. Three scaffolds from each cell line and each experimental group
was run in technical triplicates for all the targeted genes: peroxisome proliferator-activated
receptor γ (PPARG) and CCAAT enhancer-binding protein α (CEBPA). No template
controls and no RT controls were included in all trials. The data was analyzed using the
comparative Ct method with normalization to the geometric mean of two stable
housekeeping genes, GAPDH and IPO8.

4.4.7.3 Glycerol-3-phosphate dehydrogenase (GPDH) enzyme
activity assay
Intracellular GPDH enzyme activity was measured using a GPDH activity measurement
kit (Kamiya Biomedical Corporation, Cat. # KT-010, Seattle, WA, USA) at 14 days after
adipogenic induction. The data was normalized to total protein content using the Pierce
660 nm protein assay (Thermo Fisher Scientific, Oakville, ON, Canada).

4.4.7.4 Intracellular lipid staining
Intracellular lipid staining was performed using the lipophilic triglyceride-binding
Bodipy® 493/503 staining reagent (Thermo Fisher Scientific) at 14 days post-induction of
differentiation. Samples from the various ECM-derived bead foams and TCPS controls
were rinsed in PBS twice (5 min each, 25 rpm, 37°C), prior to incubation in the staining
solution (1:500 dye dilution in PBS+5% FBS, 1 h, at 37°C). Samples were then rinsed
twice in PBS (5 min each, 25 rpm, 37°C) before imaging using a Zeiss Multiphoton LSM
510 META confocal microscope.
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4.4.8 Statistical Analyses
All data were expressed as the mean ± standard deviation (SD) and analyzed by one-way
ANOVA with a Tukey’s post-hoc comparison of the means. Statistical analyses were
performed using GraphPad Prism 7 (GraphPad, La Jolla, CA, USA) and differences were
considered statistically significant at p < 0.05.

4.5 Results
4.5.1 Beads derived from the three ECM sources have similar
physical characteristics
Previously-established techniques for the fabrication of DAT-derived beads were adapted
for the fabrication of beads derived from DTB and COL. By refining the electrospraying
parameters tailored for each ECM suspension through systematically varying the voltage,
extrusion speed, and needle size, spherical subunits or beads were successfully fabricated
using the three ECM sources. The beads produced were characterized to confirm that
varying the ECM source did not substantially alter the physical properties of the subunits
used to fabricate the larger cell-assembled scaffolds.
SEM images revealed that DAT-, COL-, and DTB-derived beads were comprised of a
complex network of fibers with a rough and porous surface (Figure 4.1A, top panel).
Varying in texture and shape, the fibers from each group formed interconnected channels
and pores, both at the surface (Figure 4.1A, top panel) and interior (Figure 4.1A, bottom
panel) of the beads. Picrosirius red staining showed the presence of various sizes of
collagen fibers, heterogeneously distributed in all groups (Figure 4.1B). Overall,
qualitative assessments of the SEM and picrosirius red images did not show any obvious
differences between the groups.
Analysis of the hydrated bead diameter revealed similar average size ranges for the
electrosprayed beads, with an observed average Feret’s diameter of 820 ± 265 µm,
1163 ± 499 µm, and 955 ± 486 µm for the DAT, COL, and DTB beads respectively
(Figure 4.2A). However, the size distribution for the COL and DTB beads appeared to be
qualitatively broader as compared to the DAT beads, which may be related to the greater
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challenges that were encountered in electrospraying these suspensions due to their
increased viscosity and somewhat less homogeneous nature respectively. All three bead
types were highly porous, with average values >97%, based on a modified Archimedes’
test (Figure 4.2B). The three types of beads showed similar viscoelastic behaviour during
the mechanical testing under physiological conditions (37°C, in PBS; Figure 4.2C). There
was no significant difference in the Young’s modulus (DAT = 0.30 ± 0.16 kPa, COL =
0.25 ± 0.09 kPa, DTB = 0.39 ± 0.16 kPa) between the three ECM sources (Figure 4.2D).

Figure 4.1: Qualitative microscopic analysis of DAT, COL, and DTB beads showed
that the bead micro-architecture was similar across all ECM sources. (A).
Representative SEM images of whole beads (top row) and cryo-fractured beads (bottom
row), displaying the porous architecture of the ECM-derived beads. Scale bars: 100 µm
(Top row) and 10 µm (bottom row). (B) Picrosirius red staining showing the presence of
varying sizes of collagen fibers present in all groups. Scale bar = 200 µm.
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Figure 4.2: DAT, COL, and DTB beads had similar starting physical properties. (A)
Feret’s diameter of the individual beads used to fabricate the foams prior to cell-assembly
(Pooled results: n=20-30 beads/trial, N = 2-3 trials with different ECM suspensions). (B)
Porosity of the beads measured with a modified Archimedes’ method. Percentage of
porosity represented as mean ± SD (n = 3 bead foams/trial, N = 5 trials with different ECM
suspensions). (C) Representative force versus deformation curves for individual DAT,
COL, and DTB beads prior to seeding. Data from the 4th compression cycle are shown for
all beads, at a strain rate of 0.01 s-1. (D) Young’s modulus was calculated using nonlinear
least squares curve fitting. Modulus represented as mean ± SD (n=6 beads/trial, N=2-3
trials with different ECM suspensions).
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4.5.2 DAT-, COL-, and DTB-derived beads similarly support ASC
seeding and cell-assembled bead foam formation
Following the physical characterization, human ASCs were seeded on the DAT, COL, and
DTB beads using the developed 24 h seeding regimen. Corresponding confocal
Live/Dead® imaging of the ASC-seeded beads qualitatively showed comparable
attachment of viable ASCs on all of the groups, with a homogeneous distribution of the
cells across the surface of the beads derived from all three ECM sources (Figure 4.3A).
Using the previously developed 8-day cell-assembly method developed in Chapter 3,
robust cell-assembled bead foams were successfully produced from ASC-seeded DAT,
COL, and DTB beads (Figure 4.3B).

4.5.3 DAT and COL scaffolds are adipo-conductive, while DTB
scaffolds are adipo-repressive
Preliminary studies were then conducted to compare the adipogenic differentiation of the
human ASCs within the DAT, COL, and DTB cell-assembled bead foams over 14 days in
culture. To quantitatively assess the level of adipogenic differentiation, GPDH enzyme
activity was measured and normalized to total protein content (Figure 4.4A). GPDH
activity levels were increased in the DAT and COL bead foams relative to the DTB bead
foams and the TCPS induced and non-induced controls. Consistent with the GPDH enzyme
activity results, a qualitative increase in intracellular lipid accumulation was observed in
the DAT and COL groups relative to the other experimental conditions (Figure 4.4B).
These findings were also supported by RT-qPCR analysis of the early adipogenic markers,
PPARG and CEPBA, which showed higher mRNA levels in the DAT and COL groups,
compared to the DTB group and TCPS controls.
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Figure 4.3: Representative microscopic and macroscopic images of ECM-derived
beads and bead foams at 24 h post-seeding and 8-days post-moulding, respectively.
(A) Representative live/dead® staining, labelling living cells in green and dead cells in red,
showed that all ECM-derived sources promoted ASC attachment and survival 24 h after
seeding. The surface (top row) and 100-µm deep cross-section (bottom row) were imaged
using confocal microscopy. Scale bars: 300 µm. (B) Representative macroscopic images
after 8 days of transwell culture demonstrated that the production of cell-assembled bead
foams was possible with the three ECM sources. Scale bar: 5 mm.
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Figure 4.4: Preliminary results indicated that adipogenic differentiation appeared to
be enhanced in the DAT and COL bead foams, compared to the DTB bead foams and
TCPS controls, after 14 days of induction. (A) Normalized glycerol-3-phosphate
dehydrogenase (GPDH) enzyme activity levels showed enhanced adipogenic activity in
the DAT and COL bead foams, relative to the DTB bead foams and TCPS controls. (B)
Representative BODIPY® staining of intracellular lipid accumulation showed a
qualitatively increased presence of intracellular lipids in the DAT and COL bead foams,
relative to the other groups. Scale bar = 100 µm. (C) RT-qPCR analysis of the adipogenic
genes PPARG (left) and CEBPA (right) displayed increased expression in the DAT and
COL groups compared to the other groups. Tissue culture polystyrene (TCPS) induced and
non-induced (NON-ind.) were included for all assays. (A-C) n=3 bead foams/donor, N=1
donor; intra-donor variability measured using one-way ANOVA with Tukey’s post-hoc
test; **P<0.01.
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4.6 Discussion
The microenvironment plays a critical role in mediating cell fate and a growing body of
evidence has shown that tissue-specific ECM can direct cellular functions, including
growth and differentiation [16]. Research focusing on 2-D in vitro cell culture models, such
as coatings, has suggested that tissue-specific ECM derived from a range of decellularized
tissues (dermis, liver, skeletal and cardiac muscles, lung, endometrium, brain, and adipose
tissue) can direct stem and progenitor cell lineage commitment, when compared to nontissue-specific coating controls or purified collagen coatings [136, 289, 291, 292, 293 , 294,
295]. While convenient, these 2-D models fail to recapitulate the complex cell-ECM and
cell-cell interactions that occur within 3-D microenvironments [288]. However, the use of
bioscaffolds to study the effects of tissue-specific ECM in 3-D contexts isn’t without
challenges. For example, few studies include control scaffolds that have different
biochemical composition but similar physical properties, due to the difficulty of producing
tissue-specific and non-tissue-specific bioscaffolds with matching structural and
biomechanical characteristics. This lack of proper controls makes it difficult to interpret
the results of these studies, as cofounding variables may interact together to modulate the
effects mediated by the resulting scaffolds.
In the present study, we sought to produce physically similar cell-assembled bead foams
from three ECM sources to study the effects of ECM biochemical composition on the
adipogenic differentiation of human ASCs within 3-D bioscaffolds. As demonstrated
through several in vitro studies, a variety of external cues contribute to the delicate balance
of adipo-osteogenic differentiation in MSCs, including ECM-integrin interactions and
soluble factor-receptor binding [296]. Interestingly, studies have shown that adipogenic
induction factors inhibit osteogenesis, and conversely, osteogenic induction factors hinder
adipogenesis [89, 296]. Signal integration is mediated through several signaling cascades,
ultimately resulting in the activation or inhibition of the master adipogenic transcription
factors, PPARG and CEPBA [89, 296]. This inverse relationship between the adipogenic
and osteogenic cell commitment led to the selection of DAT as a tissue-specific proadipogenic ECM source [104], along with DTB as a non-tissue-specific and potentially
anti-adipogenic [297] ECM source. As collagen represents the main structural component
of both decellularized tissues, COL was also included as an additional ECM source control.
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Having different starting physical properties, DAT and DTB could not be used in their
intact forms and had to be processed into other scaffold formats to allow for the production
of scaffolds with matching physical properties. Due to the previous success in producing
the DAT-derived cell-assembled bead foams, this bioscaffold format was selected for the
present study. As a first step in the fabrication process, minced COL and DTB were
homogenized in acetic acid and electrosprayed into liquid nitrogen. However, several
challenges were encountered with the two new ECM suspensions having different
characteristics in comparison to the DAT suspensions. The COL suspension was much
more viscous than the DAT suspension and required fine-tuning of the electrospraying
parameters. More specifically, the voltage was increased from 16-18 kV to 18-19 kV and
the extrusion speed was reduced from 35 mL/h to 30 mL/h to compensate for the higher
viscosity. An opposite issue was encountered with the pure DTB suspension: the
suspension was thin and heterogenous, tending to separate into two phases. Small batches
of this pure DTB suspension were electrosprayed, but the resulting pure DTB beads were
found to be non-stable and disintegrated during the rehydration steps. Several strategies
were explored to resolve the issues, such as increasing the ECM concentration in the
suspension, greater homogenization and mixing time, and including an α-amylase
digestion step [298], without any success. To overcome this challenge, the DTB suspension
was supplemented with a small fraction of minced COL. Aiming to keep the total ECM
concentration constant across all groups (20 mg/mL), supplementing 17 mg/mL DTB with
3 mg/mL COL was found to be the minimum required to synthesize beads that remained
stable following rehydration (several DTB/COL ratios were tested; data not shown). Taken
together, the characterization data demonstrated that DAT, COL, and DTB-derived beads
with similar physical properties were produced, confirming the potential of the system for
comparing compositionally distinct ECM sources.
Overall, the production of reproducible cell-assembled bead foams was possible across all
conditions. It should be acknowledged that while the starting physical properties of the
ECM-derived beads were similar across all groups, the physical properties of the cellassembled bead foams were not characterized. It is therefore possible that the bead
properties may have changed over the cell-assembly process, through remodeling by the
cells; however, these potential differences between the groups could be attributed to the
innate differences in ECM composition mediating subtle cell behaviour differences
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between the groups. Motivated by technical considerations and tissue availability, COL
and DTB were obtained from xenogenic sources. While this might have impacted the
observed cell responses, the ECM is broadly conserved across species [253, 254], and
bovine osseous tissue are considered to have the most similar physiochemical and
structural resemblance to human osseous tissues compared to other sources [299]. In
addition, differences between the adipo-conductive properties of the human-derived DAT
and bovine-derived COL bead foams were not observed across all of the assays
investigated, suggesting that the ASCs responded well on the bovine-sourced materials.
Interestingly, DAT and COL cell-assembled bead foams induced a similar strong
adipogenic response that was greater compared to the DTB cell-assembled bead foam
group and the TCPS controls. This is in line with previous literature that has shown that 3D polycaprolactone (PCL) meshes coated with DAT, fibronectin, or laminin induced a
similar high level of adipogenic differentiation in human BMSCs when cultured for 21
days in differentiation media, which was enhanced compared to uncoated PCL mesh
controls [300]. These findings revealed that all ECM coatings had similar adipo-conductive
properties compared to the uncoated PCL mesh. However, the DAT-coated mesh displayed
the greatest adipo-inductive properties, as shown through a shorter two-day adipogenic
induction protocol followed by a three-week culture period in maintenance medium
including insulin but no other pro-adipogenic factors [300]. In this context, the highest
adipogenic response was consistently observed on the DAT-coated mesh, relative to the
other ECM-coated meshes [300]. As such, it would be interesting in future work to
compare the ASC response in the DAT and COL bead foams under conditions that were
less stimulatory towards the adipogenic pathway, to be able to discern more subtle
inductive effects that may be present in the DAT.
Notably, the absence of adipocytes in the DTB group at day 14 of differentiation compared
to the DAT and COL groups suggests that the DTB may have had inhibitory effects on
adipogenesis. This difference in cell fate may be due to the unique ECM composition of
the DTB bead foams. While little is known about the inhibitory effects of DTB on
adipogenesis, these preliminary findings are in line with existing results from osteogenicmimicking matrices [297, 301]. In this 2-D model, where matrices were derived from
decellularized osteogenically- and adipogenically-induced BMSC-derived cell sheets,
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PPARG gene expression was shown to be downregulated in BMSC-seeded osteogenicmimicking matrices, compared to BMSC-seeded adipogenic-mimicking matrices [297,
301]. Building on this data, it would be interesting to study the effects of ECM composition
on the osteogenic differentiation of ASCs using the cell-assembled DAT-, COL-, and DTBderived platforms in future work.

4.7 Conclusions
The findings from the present study demonstrate the potential of the novel cell-assembled
DAT and COL bead foams as a platform for adipose tissue engineering. In addition, we
established a new DTB-derived platform that may hold utility for applications in bone
regeneration. The approach generates robust 3-D scaffolds fabricated purely of cells and
ECM, which could potentially be applied as tissue substitutes or as 3-D culture models for
investigating the effects of ECM composition on the lineage-specific differentiation of the
ASCs. Results from the proof-of-concept study comparing the adipogenic response of the
ASCs within tissue-specific and non-tissue-specific cell-assembled bead foams, showed
that the bead foams derived from DAT and COL supported a high level of adipogenic
differentiation when induced in culture over 14 days. In contrast, the DTB bead foams were
shown to have inhibitory effects on the adipogenic differentiation of the ASCs. Taken
together, the study findings show that the newly developed cell-assembly platform is
versatile and can be used for the controlled comparison of biochemical properties between
various ECM sources. Future experiments could focus on further investigating the adipoconductive properties of the three ECM sources with a greater number of cell donors,
concomitant with studies focused on elucidating the temporal adipo-inductive properties
of the ECM sources in conditions that do not stimulate adipocyte differentiation. Further
experiments could also include a comparison of the osteo-inductive and osteo-conductive
effects of the DAT, COL, and DTB derived cell-assembled bead foams, to explore their
potential as cell delivery systems for bone regeneration.
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Chapter 5

5

General discussion and conclusions

5.1 General discussion
A growing body of work has identified biomaterials derived from the extracellular matrix
(ECM) as promising platforms that can be designed to mimic the biochemical, biophysical,
and biomechanical properties of the soft tissue milieu and be applied in strategies to
promote soft tissue regeneration [71]. These ECM-derived biomaterials can be versatile
modeling systems for studying the effects of ECM composition on various cellular
functions in vitro, such as survival and pro-angiogenic factor secretion, or can potentially
be applied as rationally-designed delivery systems for pro-regenerative cell populations in
vivo. Towards the development of tissue-specific strategies for soft tissue regeneration
applications, the combined use of decellularized adipose tissue (DAT) and adipose-derived
stromal cells (ASCs) has highlighted the cell-supportive effects of DAT-based biomaterials
to: (i) enable attachment, proliferation, migration, and differentiation of ASC in vitro [13,
14, 104, 119, 131, 134-136], and (ii) to direct pro-regenerative cascades in vivo, mediated
through cell infiltration, inflammation, angiogenesis, adipogenesis, and scaffold
remodeling following implantation [13, 14, 119, 126, 302].
When directly comparing DAT-derived materials, DAT scaffolds applied in their intact
form have shown great potential for volume retention and fat formation in vivo, while more
processed and porous formats such as DAT-derived bead foams have shown more rapid
scaffold remodeling and enhanced neo-vascularization [14]. As a result, these observations
provide a strong rationale for using DAT bead foams as a pro-regenerative bioscaffold for
soft tissue-engineering applications seeking to promote a pro-angiogenic response.
Building from this knowledge, the present thesis sought to provide further insight into the
design of modular DAT-derived bioscaffolds by studying the effects of ECM composition
on cell function and fate within modular bioscaffolds (Chapters 2 and 4). Further, a novel
method for fabricating robust, three-dimensional (3-D) cell-assembled ECM-derived
foams that incorporated a high density of viable cells that were well-distributed throughout
the scaffolds was developed and assessed for applications in soft tissue regeneration
(Chapter 3).
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Past research investigating the effects of ECM derived from decellularized tissues on cell
function has been largely performed using in vitro two-dimensional (2-D) systems, such as
ECM-derived coatings. When compared to non-tissue-specific decellularized tissue or
collagen coating controls, decellularized dermal [289], hepatic [289, 293], skeletal muscle
[289, 291], cardiac muscle [86, 291], pulmonary [292], brain [295], endometrial [294], and
adipose [136] tissues have been found to promote the growth, survival and lineage-specific
differentiation of tissue-matched cell types. While promising, these systems do not
accurately reflect the spatial arrangement of cells in 3-D microenvironments, nor the
complex nature of cell-ECM interactions [288]. To facilitate the investigation of tissuespecific effects between different ECM-derived biomaterials, studies from the present
thesis directly compared the effects of different types of ECM in 3-D naturally-derived
microenvironments. More specifically, the present studies are the first to compare the
effects of complex 3-D bioscaffolds derived from DAT with similar bioscaffolds derived
from purified collagen (Chapter 2 and 4) or non-tissue-specific sources, such as
decellularized trabecular bone (Chapter 4).
Consequently, the present thesis sought to generate and apply 3-D control platforms that
had similar structural and biomechanical properties to enable studies more specifically
focused on exploring the effects of starting composition within ECM-derived bioscaffolds.
In the first set of studies, pre-assembled DAT bead foams with similar physical
characteristics to pre-assembled COL bead foams were developed and used to explore the
effects of ECM composition on human wound edge dermal fibroblasts (weDFs). weDF
survival and secretion of pro-angiogenic soluble factors, including angiopoietin-1, C-X-C
motif chemokine 12 (CXCL12), hepatocyte growth factor (HGF), platelet-derived growth
factor (PDGF), and vascular endothelial growth factor (VEGF) were shown to be
significantly enhanced in the pre-assembled DAT bead foams, as compared to the preassembled COL bead foams. Consequently, it was found that the weDFs still possessed a
pro-regenerative potential that could be better harnessed using DAT as an ECM source
relative to COL. A study by Truong and collaborators compared different commerciallyavailable bioengineered wound dressings including purified collagen-based sources
(Dermagraft®, Integra®) and human decellularized dermis (Alloderm®, Dermalogen®,
and in-lab produced decellularized dermal matrix) in an acute full-thickness excision

121

wound model in nude mice [303]. Although the wound dressings were fabricated using
different processes, the human skin–derived products showed less wound contraction and
a histologically thicker neo-dermis as compared to the collagen-based products [303].
Taken together, results from Truong et al. and the present study provide evidence
supporting the use of complex ECM sources from soft decellularized connective tissues for
the design of pro-regenerative bioengineered wound dressings, as an alternative to purified
bovine collagen that is currently used in the clinical setting with mixed results [170, 171,
250].
Using histological analyses, the initial studies in the present work complemented previous
work investigating DAT composition published by Flynn (2010) [104] and Kuljanin et al.
(2017) [62]. Findings from the present work revealed that DAT-derived bead foams
contained contained higher levels of known pro-angiogenic ECM macromolecules
including sulphated glycosaminoglycans (GAGs), and collagen types IV, V, and VI,
relative to purified COL. Interestingly, heparan sulphate, a subtype of sulphated GAG, has
the innate ability to support angiogenesis through direct endothelial cell interactions
mediated by α5 and αV integrin binding, as well as through pro-angiogenic factor
sequestration, which can be released following tissue injury and ECM remodelling [256].
In addition, basement membrane collagens type IV [257] and VI [22] have been
demonstrated to stimulate angiogenesis by recruiting endothelial cells. Collagen type IV
has also been found to have dose-dependent effects on vessel elongation and stabilization
[258], and collagen type VI-deficient mice have been found to have impaired endothelial
cell survival and sprouting [22]. Additionally, collagen type V has also been implicated in
promoting newly developed blood vessels in granulation tissue [259], and its
haploinsufficiency has been associated with impaired wound healing outcomes in patients
suffering from Ehlers–Danlos Syndrome [21].
Along with biochemical composition, scaffold stability and cell distribution are other
important design considerations for ECM-derived cell delivery platforms [80, 81]. Even
though the weDFs on our previous pre-assembled DAT bead foams showed enhanced
survival and angiogenic marker expression (Chapter 2), the physical structure of the
scaffolds only allowed for static cell seeding and culture methods. Known to result in
limited cellular infiltration and distribution compared to dynamic approaches [304], these
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static methods were seen as a limitation of the biomaterial format and resulted in
heterogenously distributed cells that were predominantly localized in proximity to the
upper surface of the pre-assembled bead foams. As such, methods were developed to
produce our next-generation cell-assembled DAT bead foams, which contained a higher
density of viable ASCs that were more well distributed throughout the scaffolds. The
resulting novel cell-assembly approach harnessed the ASC ability to synthesize new ECM,
allowing for individual beads to fuse together to generate a stable construct without the use
of synthetic additives or chemical cross-linking, which may allow for enhanced
biocompatibility and bioactivity [85, 252]. Through the combined use of xenogenic-free
chemically defined media (XFCD), dynamic cell culture, L-ascorbic acid 2-phosphate
(A2P) stimulation, and growth factor preconditioning, the newly developed system allowed
for the development of thick (~3 mm thick) constructs with high cell viability (>95%) after
8 days in culture. Preconditioning using epidermal growth factor (EGF), basic fibroblast
growth factor (FGF-2), and insulin-like growth factor-1 (IGF-1) showed positive effects in
our unique system that were similar to previous studies exploring the impact of these three
growth factors on MSCs. In particular, EGF and IGF-1 treatments alone were found to
promote the secretion of MMPs by ASCs [226, 268], and EGF alone has been demonstrated
to promote the expression of ECM-related proteins, including proteoglycans, connective
tissue growth factor (CTGF) and tissue inhibitors of matrix metalloproteinases (TIMPs)
[268]. In addition, FGF-2 preconditioning induced a pro-fibrotic phenotype in MSCs, in
accordance with the data obtained in our study [218, 225]. Taken together, the
preconditioning treatments used in the fabrication process were beneficial for the
production of cohesive cell-assembled bead foams with a high cellularity and remodelling
potential.
For the second set of studies, human ASCs that were transduced to co-express firefly
luciferase (Fluc2) and tdTomato (tdT) reporters were employed to enable longitudinal in
vivo cell tracking studies using bioluminescence imaging (BLI), as well as endpoint
analyses of ASC distribution within tissue cross-sections using endogenous fluorescence.
This system was used to address limitations associated with classical cell identification
techniques often employed to evaluate donor cell retention within ECM-derived
biomaterials in pre-clinical models. For example, the use of immunohistological analyses
of human-specific markers does not allow for longitudinal tracking, and requires a large
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number of animals to perform long-term assessments [249, 264]. Further, there can be
substantial variability across the depth of the scaffolds that can result in inaccuracies when
trying to localize and quantify cell populations in thin sections taken from implants. The
use of cell tracker dyes to pre-stain cell populations prior to implantation, such as lipophilic
membrane dyes, has similar challenges associated with immunohistological analyses, in
addition to limitations associated with the loss of signal through cell division, as well as
dye release and uptake by other cell populations [280].
Measured using non-invasive BLI, the cell retention data from the current studies showed
enhanced detection of viable ASCs in the cell-assembled bead foams relative to the preassembled bead foams at an early timepoint, as well as the localized ASC distribution
within the implant region in both groups. The data obtained showed improved cell
localization to the implant, as compared to a similar study from Wolbank and colleagues,
which detected transduced human ASCs expressing luciferase throughout the body of nude
mice 19 days after subcutaneous implantation within a fibrin gel [281]. Other studies have
reported ASC retention to range from 5% to 10% of cells retained at the site of injection 4
weeks after intramuscular delivery into ischemic [283] or normal [282] himdlimbs, further
suggesting that the cell-assembled DAT-derived bead foams provide a supportive platform
for localized ASC delivery within the subcutaneous space.
In addition to the cell retention data, histological CD31+ structure counts indicated there
were more murine endothelial cells within the cell-assembled bead foams, suggestive of
augmented implant angiogenesis relative to the pre-assembled bead foams. Since the
number of cells seeded onto the beads foams were similar in the cell-assembled and preassembled groups, results from the in vivo studies suggest that early cell retention or
scaffold composition and/or structure may have increased the angiogenic response in the
cell-assembled bead foams. These differences in composition and structure could be
attributed to the distinct culture protocol utilized to produce the cell-assembled bead foams
as compared to the pre-assembled bead foams. More specifically, the extended culture
protocol in the cell-assembled bead foams may have modulated the ASC phenotype or
promoted the accumulation of beneficial paracrine factors. Further studies comparing both
scaffold platforms would be needed to more fully understand the specific mechanisms
involved in the enhanced pro-regenerative potential of the cell-assembled foams.
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In addition, it should be recognized that ASCs can exhibit donor-dependent behavior. This
inter-donor variability can be attributed to several factors such as age [305, 306], donor
health and disease status [305, 307], and the adipose depot used for sourcing [248]. More
specifically, aging alone has been shown to negatively impact ASC proliferation [306,
307], and in combination with the presence of systemic diseases, such as diabetes, it has
been attributed to impaired pro-angiogenic potential of the cells through decreased
paracrine activity [305, 306]. Further, aging and body mass index has also been correlated
with reduced ASC differentiation potential [307]. Consequently, matching ASCs for
known donor variables, including age, adipose tissue depot, and body mass index as
performed in Chapter 3 can help in minimizing inter-individual variability [248, 305-307].
However, donor-dependent behavior is inherent to the use of these primary cell population
and other unknown donor factors could also be contributors to increase donor variability.
For the last set of experiments, the methods used to generate the cell-assembled DAT bead
foams were extended to produce structurally-similar 3-D cell-assembled bead foams from
compositionally distinct ECM sources. With a special interest in evaluating the tissuespecific contribution of ECM composition on adipogenesis within the new constructs, DAT
and DTB were selected as the primary ECM sources due to the inverse relationship
between adipogenesis and osteogenesis in MSCs [89, 90]. Purified collagen type I (COL)
was included as an additional compositional control to highlight the versatility of the
fabrication approach by using a commercially available matrix source, as well as to
broaden the analysis of the effects of the tissue-specific ECM composition. When subjected
to 14 days of in vitro culture in adipogenic differentiation media, both the cell-assembled
DAT and COL bead foams induced an enhanced adipogenic response as compared to the
DTB cell-assembled bead foams and the tissue culture polystyrene (TCPS) controls. These
results were consistent with a study performed by Blum and collaborators in which 3-D
polycaprolactone (PCL) meshes coated with ECM derived from DAT, fibronectin, or
laminin showed similarly enhanced adipogenic differentiation in human bone marrowderived stromal cells (BMSCs) as compared to uncoated PCL mesh controls [300]. Using
a shorter two-day adipogenic induction protocol followed by a three-week culture period
in proliferation media including insulin but no other pro-adipogenic factors, this study also
showed that the BMSCs cultured on the DAT-coated meshes displayed enhanced
adipogenic lineage commitment relative to those cultured on the fibronectin and laminin
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coated groups [300]. These findings therefore demonstrated greater “adipo-inductive”
properties of the DAT-coated mesh compared to the other ECM groups [300]. In this
context, the highest adipogenic response was consistently observed on the DAT-coated
mesh, relative to the other ECM-coated meshes [300].
While the “adipo-conductive” properties of DAT as an ECM source were confirmed by
our preliminary study, our experimental design did not allow for the evaluation of the
“adipo-inductive” properties of the cell-assembled bead foams. However, the in vitro study
also revealed that the DTB group appeared to have inhibitory effects on adipogenesis, when
compared to the DAT and COL groups. Although there has been very limited research on
the effects of bone-derived ECM on adipogenesis, these findings are consistent with
previous results from 2-D BMSC-derived osteogenic matrices that revealed a
downregulation of PPARG gene expression in osteogenic matrices, compared to BMSCderived adipogenic matrices [297, 301]. These differences could be explained by the
distinct biochemical composition of the ECM specific to each tissue. Surrounding
adipocytes, fat lobules, blood vessels, and nerves, adipose tissue is rich in basement
membrane and its constituents including collagen type IV, type VI, laminin and nidogens
[60, 61]. The organic phase of osseous tissue was shown to be comprised of high levels of
collagen type I, but also contains smaller amounts of collagen type IX, X, and XII [308],
along with specialized matricellular proteins that include osteocalcin (also known as bone
gamma-carboxyglutamic acid-containing protein; BGLAP), osteonectin (also known as
secreted protein acidic and rich in cysteine; SPARC), osteopontin (also known as secreted
phosphoprotein 1; SPP1), and bone sialoproteins [65, 68, 69].

5.2 Future work
The body of work documented in my thesis provides strong evidence indicating that ECM
composition can impact cell behaviour and cell fate, as shown by alterations in weDF
phenotype on pre-assembled bead foams derived from DAT and COL and by adipogenic
lineage commitment in ASCs within cell-assembled bead foams derived from DAT, COL,
and DTB. Moreover, murine studies conducted with both pre-assembled and cellassembled bead foams showed the pro-regenerative potential of both biomaterial formats.
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More specifically, work presented in Chapter 2 showed that the survival and proangiogenic capacity of human weDFs were enhanced on the pre-assembled DAT bead
foams both in vitro and in vivo when compared to bead foams fabricated from COL. While
the pre-assembled foams have some limitations when applied as cell delivery vehicles, they
represent a useful platform for in vitro studies. Their high tunability and ease of production
supports future work focused on producing this bioscaffold format from other ECM
sources. For example, based on previous work by our team and others to decellularize
cardiac tissues [86, 128], pre-assembled cardiac-derived bead foams could be engineered
to culture cardiac progenitor cells under pathophysiological oxygen tensions and
inflammatory cytokines mimicking the infarct-heart microenvironment. Using this model,
cardiac progenitor proliferation, survival and function, such as their secretory profile, could
be investigated. Similar studies could be conducted with pro-regenerative cell populations,
such as BMSCs or circulatory endothelial progenitor cells, to better assess their survival
and functional capacities in conditions simulating stresses from the infarct-hear
microenvironment. Additionally, studies could focus on studying the effects of cell-free
pre-assembled DAT bead foams in an impaired wound healing model.
With regards to the work presented in Chapter 3, our findings revealed that the novel cellassembled DAT bead foams are a promising pro-regenerative cell delivery platform that
supports the localized in vivo retention of delivered ASCs with pro-angiogenic
functionality. Upcoming studies could further assess angiogenesis within the scaffold using
end-point 3-D x-ray micro-computed tomography angiography [309]. While these nextgeneration scaffolds showed great pro-angiogenic potential, the current study design did
not probe extensively for the inflammatory cell response, nor adipose tissue formation in
vivo. Consequently, further studies could aim to understand the leukocyte response to the
material, through immunohistological and/or flow cytometry analyses of cell-assembled
bead foams explanted at 1, 2, 4, and 8-weeks to assess for spatial distribution and
quantification, respectively. Leukocytes of interests could include neutrophils (neutrophil
elastase positive cells) [142] and macrophages (F4/80 positive cells; pan-macrophage
marker), and include analysis of macrophage subpopulations, e.g. activated towards the
more pro-inflammatory “M1” or pro-inflammatory “M2” axis of the M1-M2 spectrum
[143]. In this context, it would be interesting to quantify the relative levels of expression
of pro-inflammatory markers (e.g. CD80 and inducible nitric oxide synthase (iNOS)) and
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pro-regenerative markers (e.g. CD163, CD206 and arginase-1) [143]. Using similar time
points, investigation of adipogenesis within the scaffolds could also be performed by
staining whole-mount explants for perilipin, and imaging the stained explants using 3-D
confocal imaging combined with a previously published tissue clarification method [310].
In addition, suggested directions could also evaluate the pro-regenerative effects of the
scaffolds in other preclinical models, which could include murine impaired wound healing
or hindlimb ischemia models. Finally, next steps of this project could examine the
feasibility of producing cell-assembled bead foams using other cell populations, such as
BMSCs, or using co-culture methods that could include a combination of ASC-seeded
DAT beads with microvascular endothelial cell-seeded DAT beads. It would then be
interesting to assess the potential such pre-endothelialized cell-assembled bead foams to
anastomose in vivo with the existing murine vasculature.
In line with the results from Chapter 2 that demonstrated that the ECM composition within
the pre-assembled bead foams modulated the response of seeded cell populations in culture,
the preliminary data from Chapter 4 suggested that adipogenic differentiation was
enhanced in the cell-assembled bead foams fabricated from DAT and COL as compared to
DTB, supporting that the ECM composition within the platforms can modulate ASC
differentiation. Future experiments should focus on confirming the observed adipoconductive properties of the three ECM sources with a greater number of cell donors, along
with investigations aimed to elucidate the adipo-inductive properties of the ECM sources
in conditions that do not promote adipogenesis. These studies could broaden the panel of
genes used and include additional early-to-mid- (lipoprotein lipase, adiponectin, or leptin)
and late-stage (adipocyte-specific fatty acid binding protein, or perilipin) adipogenic
markers to more fully characterize the differentiation response [311]. Next directions could
also include a comparison of the osteo-inductive and osteo-conductive properties of the
cell-assembled bead foams derived from DAT, COL, and DTB, to explore their potential
as cell delivery systems for bone regeneration. Assays for assessing osteogenic
differentiation could include an enzymatic alkaline-phosphatase assay, a mineralization
assay using the fluorescent dye osteoimage® from Lonza, and gene expression analysis of
early (runt-related transcription factor 2 (RUNX2) and transcription factor Sp7, also called
osterix (OSX)) and mid-to-late (BGLAP, SPARC, SPP1) osteogenic markers to probe the
differentiation response over time [69, 312].
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5.3 Summary and significance
The body of work reported in my thesis demonstrated the potential of modular naturallyderived DAT biomaterials for soft tissue-engineering applications. When inoculated with
either weDFs or ASCs, DAT bioscaffolds promoted seeded cell survival, implant
vascularization, and constructive remodelling compared to controls in vivo. Moreover,
preliminary studies showed high levels of adipogenic differentiation in the ASCs cultured
within the cell-assembled DAT and COL bead foams.
The pre-assembled and cell-assembled bead foams were shown to be robust platforms
enabling the production of scaffolds with distinct tissue-specific ECM composition, while
having similar initial structural and biomechanical characteristics. Within the preassembled format, DAT was shown to be a clinically-relevant human matrix source for the
design of novel pro-angiogenic biomaterials for potential applications in wound healing.
Building from these findings, innovative cell-assembled DAT bead foams were developed
and were shown to have a greater pro-angiogenic potential than the previously-established
pre-assembled bead foams. These findings confirmed the potential of our novel modular
DAT-derived bead foam technology as an ASC delivery platform for applications in soft
tissue engineering, wound healing and therapeutic angiogenesis. To further evaluate the
effects of tissue-specific ECM composition on ASC differentiation, the cell-assembly
method was adapted to produce cell-assembled bead foams from distinct ECM sources,
namely DAT, COL, and DTB. Preliminary adipogenic differentiation data suggested the
DAT and COL were both highly adipo-conductive, while the DTB had inhibitory effects
on ASC adipogenesis. Overall, the work completed in this thesis supports the rationale that
DAT-derived bioscaffolds are promising pro-regenerative biomaterials and cell delivery
platforms for applications in soft connective tissue engineering, and that complex ECM
composition is an important factor in the design of biomaterials.
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Appendix A: Supplementary data
A.1

Supplementary data of Chapter 2

Supplementary Table 2.1: Cell donor information

60

Amputation
site
Below the knee

Wound
site
Toe

Female

87

Below the knee

Toe

Female

64

Below the knee

Toe

Donor Gender

Age

1

Male

2
3

Diagnosed risk factors (etiology)
Perivascular disease (non-diabetic
patient)
Perivascular disease and Type II
diabetes
Perivascular disease (non-diabetic
patient)

Supplementary Table 2.2: Immunophenotype of wound edge dermal fibroblasts
Marker
CD90
CD105
CD73
CD44
CD29
CD34
CD45
CD146
CD31

Mean ± Standard deviation (%)
(n=3, N=3)
99.2 ± 0.8
99.1 ± 0.8
96.2 ± 4.2
99.6 ± 0.4
99.0 ± 0.7
3.5 ± 1.0
1.5 ± 1.0
1.5 ± 1.0
1.4 ± 1.5
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Supplementary Figure 2.1: Positive controls for the immunofluorescence staining of
the ECM components. Mouse skin was used as a positive control for collagen type I (COL
I), collagen type IV (COL IV), fibronectin (FN), and laminin (LM) staining, while human
adipose tissue was used as a positive control for collagen type V (COL V) and VI (COL
VI) staining.
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Supplementary Figure 2.2: DAT and COL bead foams contain similar relative levels
of collagen type I and fibronectin, with no detectable laminin expression. (A)
Representative immunohistochemical staining for collagen type I, fibronectin (FN), and
laminin (LN) in cryo-sections of the DAT and COL bead foams. (B) Quantification of
relative collagen type I, fibronectin and laminin levels, with no statistical difference
between the groups (n=2-6 scaffolds/trial, N=3 trials with different ECM suspensions).
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Supplementary Figure 2.3: Pro-angiogenic gene expression for the individual cell
donors. Relative mRNA levels of the pro-angiogenic markers (A) VEGFA, (B) HGF, and
(C) CXCL12 at 9 days post-seeding showing the same trend for increased expression of
VEGFA and HGF in the weDF cultured on the DAT bead foams for all 3 cell donors, as
well as enhanced CXCL12 expression for donors 2 and 3. Gene expression levels were
normalized to the COL bead foam group for each cell donor, with 18S as the housekeeping
gene. (n=3 scaffolds/trial, N=3 cell donors).
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Supplementary Figure 2.4: Representative CD31 immunostaining (red) of seeded and
unseeded experimental groups showing qualitatively enhanced blood vessel
infiltration in the seeded DAT bead foams relative to the seeded COL bead foams and
unseeded controls at 14 days post-implantation. (A) Nuclei were counter-stained with
PicoGreen Reagent® (green) and the scaffolds were pre-labeled with an Alexa Fluor 350
succinimidyl ester (blue). White dotted lines denote the scaffold periphery. Scale bars =
100 µm. (B) Quantitative analysis of nuclear density within the bead foam implants,
showing no significant differences in total cell infiltration between the groups.
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A.2

Supplementary data of Chapter 3

Supplementary Table 3.1: Cell donor information
Donor

Gender

Age

Anatomical localization

Body mass index

1
2
3

Female
Female
Female

51
53
66

Subcutaneous abdominal adipose tissue
Subcutaneous abdominal adipose tissue
Subcutaneous breast adipose tissue

25.9
32.8
25.3

Supplementary Table 3.2: Genes from the custom-made qPCR arrays (Bio-Rad;
PrimePCR™ arrays)
Gene associated with

Gene symbol

Gene name

Proteoglycans

BGN
DCN
VCAN
ACTA2
COL1A1
COL3A1
COL4A1
CTGF
MMP1
MMP2
TGFB1
TIMP1
ANGPT1
FGF2
HGF
IGF1
SERPINE1
VEGFA
CCL2
CSF2
IL1B
TNF
CXCL10
RPS18
UBC

Biglycan
Decorin
Versican
Smooth muscle actin alpha 2
Collagen type I alpha 1 chain
Collagen type III alpha 1 chain
Collagen type IV alpha 1 chain
Connective tissue growth factor
Matrix metalloproteinase 1
Matrix metalloproteinase 1
Transforming growth factor beta 1
Tissue inhibitor of metalloproteinases 1
Angiopoietin 1
Fibroblast growth factor 2
Hepatocyte growth factor
Insulin like growth factor 1
Serpin Family E Member 1
Vascular endothelial growth factor A
C-C motif chemokine ligand 2
Colony stimulating factor 2
Interleukin 1 Beta
Tumor Necrosis Factor
C-X-C motif chemokine ligand 10
Ribosomal Protein S18
Ubiquitin C

ECM synthesis and
remodelling

Angiogenesis

Inflammation

Housekeeping genes
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Supplementary Figure 3.1: Immunophenotype of human ASCs and flow cytometry
controls for the viability studies. (A) The P4 ASCs used in the studies showed high
expression of mesenchymal markers (>98%; CD105, CD90, CD73, CD44, and CD29), low
expression of the progenitor cell marker CD34 (<5%), and negligible expression of
leukocyte, pericyte and endothelial markers (CD45, CD146, and CD31) (n = 3
samples/donors, N = 3 different donors). (B) Examples of the cell (left graph) and single
cell (middle graph) gating applied prior to the propidium iodide and annexin V doublestaining analyses (right graph; also presented in Figure 3.2D). (C-D) Propidium iodide and
annexin V double-stained ASCs cultured on tissue culture plastic (TCPS) used for the
gating. (C) TCPS cultured apoptotic control (treated with 1 µM staurosporine, 18 hours).
(D) TCPS viable control (non-treated).
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Supplementary Figure 3.2: The transduced ASCs co-expressing codon optimized
luciferase (Fluc2) and tdTomato (tdT) maintained their tri-lineage differentiation
capacity. (A) Expression cassette used in transduction of human ASCs. (B) Transduced
cells were qualitatively confirmed to differentiate towards the chondrogenic lineage, as
shown by the co-localization of the endogenous tdT signal (red) with staining for the
chondrogenic ECM marker collagen type II (green) in aggregate cultures at day 28. (C-D)
Transduced cells differentiated towards the adipogenic lineage, as shown by (C)
quantification of extracted Oil red O (ORO) dye at day 14, and confirmed by colocalization
of tdT+ cells (red) with (D; top panel) ORO-stained lipids (green) and (D; bottom panel)
perilipin (green). (E-F) Transduced cells differentiated towards the osteogenic lineage, as
shown by the (E) ALP enzyme activity assay, and (F; top panel) co-localization of the tdT
signal (red) with mineralized matrix identified with osteoimage® staining (green), and
confirmed by (F; bottom panel) von Kossa staining. Scale bars = 100 µm. (A-E) n=3
scaffolds/trial, N=3 trials with different cell donors; two-way ANOVA with Tukey’s posthoc test; ***P<0.001.
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Supplementary Figure 3.3: Cell-assembled (CA) and pre-assembled (PA) bead foams
had similar cell numbers at day 0, while explanted scaffolds at day 28 were shown to
be well integrated within the host tissues. (A) Representative macroscopic and
bioluminescence images (superposed) from a cell-assembled (top) and pre-assembled
(bottom) bead foam in vitro at day 0 (day of implantation in mice). The circle red area
represents the area quantified for each scaffold. Scale bars = 5 mm. (B) Relative
bioluminescence intensity levels showing similar cell numbers in both scaffold at day 0
(day of implantation in mice). (A-B) n=3-4 scaffolds/trial, N=2 trials with different cell
donors; t-test; N.S. = non-significant. (C) Representative macroscopic image of explanted
scaffold at day 28, showing integration within the host tissues. Scale bars = 1 cm. n=2-3
scaffolds/trial, N=2 trials with different cell donors.
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Appendix B: Research ethics board approval
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